



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/196,161	11/20/1998	YOKE MIN SIN	1459-005B	8822

22429 7590 09/08/2004

LOWE HAUPTMAN GILMAN AND BERNER, LLP
1700 DIAGONAL ROAD
SUITE 300 /310
ALEXANDRIA, VA 22314

EXAMINER

MINNIFIELD, NITA M

ART UNIT	PAPER NUMBER
----------	--------------

1645

DATE MAILED: 09/08/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No.		Applicant(s)	
	09/196,161		SIN ET AL.	
	Examiner		Art Unit	
	N. M. Minnifield		1645	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 20 May 2004.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-8 and 24-32 is/are pending in the application.
- 4a) Of the above claim(s) 25-32 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-8 and 24 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|---|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____ |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

1. Applicant's election of species SEQ ID NO: 1, claims 1-8 and 24, in the reply filed on May 20, 2004 is acknowledged. Because applicant did not distinctly and specifically point out the supposed errors in the restriction requirement, the election has been treated as an election without traverse (MPEP § 818.03(a)).
2. Claims 25-35 have been withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected species, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on May 20, 2004.
3. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.
4. It is noted that the prior art rejection of claims 1, 3, 4 and 6-8 rejected under 35 U.S.C. 102(b) as being anticipated by Lin et al (Dev. Biol. Stand. 1997, 90:461 Library of Congress stamped date is August 21, 1997) is withdrawn in view of the amendment to the claims filed September 4, 2003.
5. It is noted that the prior art rejection of claims 2 and 5 rejected under 35 U.S.C. 103(a) as being unpatentable over Lin et al (1997) as applied to claims 1, 3, 4 and 6-8 above, and further in view of Clark et al (PNAS, 1992, 89:6363-6367) and Smith et al (Gene, 1998, 67:31-40) is withdrawn in view of the amendment to the claims filed September 4, 2003.

6. Claims 1-8 and 24 are rejected under 35 U.S.C. 102(b) as being anticipated by Clark et al 1992 (PNAS USA, July, 1992, 89:6363-6367) or He et al 1997 (Aquaculture, 1997, 158:1-10).

The claims are directed to a vaccine for immunizing fish against ciliated ectoparasitic protozoans comprising an effective amount of a recombinant fusion protein (GST-iAgI) derived from an artificial DNA sequence for immobilization antigen, repeat I of *Ichthyophthiirus multifiliis* wherein said sequence is SEQ ID NO: 1 and a medium comprising at least one of buffers, adjuvants, immuno-stimulants or carriers. The vaccine, when injected into a fish, provides effective protection against white spot disease caused *Ichthyophthiirus multifiliis*. The fusion protein is produced using *E. coli*.

Clark et al discloses the expression of the immobilization antigen (i.e. iAgI); the cDNA encode a protein of 394 amino acids with a tandemly repeated structure characteristic of the i-antigen of other ciliated parasites (abstract). Clark et al discloses that the immobilization antigens of *I. multifiliis* are analogous to free-living ciliates and parasitic protozoa; and "...that transcript levels increase in parallel with the infectivity of the organism bears on the functional role in this system and is consistent with previous observations suggesting that the i-antigens of *Ich* are involved in the development of protective immunity in fish. (p. 6363, col. 2; see also p. 6367, col. 2). The materials and methods disclose how to obtain a recombinant immobilization antigen (p. 6363-6365). Clark et al discloses the entire amino acid sequence as set forth in SEQ ID NO: 1 (see figure 1). Clark et al discloses "on a more applied level, because the i-antigens of *Ich* interact with the immune system of fish, they have potential as protective immunogens and may

be of practical use in the treatment of a pathogen with major impact on aquaculture worldwide.” (p. 6367, col. 2).

It is noted that the prior art does not specifically recite a medium (buffer, adjuvant, immunostimulant, or carrier). However, it would be inherent that a vaccine composition would comprise a buffer, adjuvant or carrier of some kind, since the art discloses the use of the antigen in a vaccine for protection against disease.

Since the Patent Office does not have the facilities for examining and comparing applicants' vaccine with the vaccine of the prior art reference, the burden is upon applicants to show a distinction between the material structural and functional characteristics of the claimed vaccine and the vaccine of the prior art. See *In re Best*, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and *In re Fitzgerald et al.*, 205 USPQ 594.

7. Claims 1-8 and 24 are rejected under 35 U.S.C. 102(b) as being anticipated by He et al 1997 (Aquaculture, 1997, 158:1-10).

He et al discloses a potential antigenic epitope of the 48 kDa immobilization antigen of the *I. multifiliis* (i-AgI) that was cloned into a bacterial expression vector and the gene construct was introduced into *E. coli* and the glutathione S-transferase-iAgI (GST-iAgI) fusion protein was successfully expressed (abstract; materials and methods). He et al discloses that antisera against GST-iAgI fusion protein from catfish showed a positive reaction with a tomite protein of about 48 kDa, suggesting that the recombinant protein contains an antigenic epitope of i-AgI (abstract). He et al discloses that the recombinant GST-iAgI fusion protein can be used as a potential vaccine against the infection of *I. multifiliis* (abstract). He et al

discloses that *I. multifiliis* is a ciliated protozoan parasite and known to cause white spot disease (pp. 1-2). The cDNA encode a protein of 394 amino acids with a tandemly repeated structure characteristic of the i-antigen of other ciliated parasites (abstract). He et al discloses the same amino acid sequence of the iAgI as set forth in the claimed SEQ ID NO: 1 (see figure 1A). He et al discloses the antigen in buffer as well as mixed with adjuvant (see pp. 4-5). He et al discloses, “the immunogenicity of the GST-iAgI fusion protein was determined in goldfish immunized with the fusion protein. The results showed that the immunized fish had a significantly higher survival rate than that of the control fish after they were challenged with the infectious tomites of *I. multifiliis*. All these results indicated that the synthetic vaccine does share a similar antigenic determinant with a tomite’s protein of *I. multifiliis*.” (p. 8).

Since the Patent Office does not have the facilities for examining and comparing applicants' vaccine with the vaccine of the prior art reference, the burden is upon applicants to show a distinction between the material structural and functional characteristics of the claimed vaccine and the vaccine of the prior art. See *In re Best*, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and *In re Fitzgerald et al.*, 205 USPQ 594.

8. Claims 1-8 and 24 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. The claims are vague and indefinite in the recitation of “an artificial DNA sequence”. SEQ ID NO: 1 is an amino acid sequence only. The claim language should be consistent with the

sequence that is claimed. Further, does applicant intend the entire sequence of SEQ ID NO: 1 or a portion of it as indicated by the claim language?

9. No claims are allowed.


10. The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

11. The references cited or used as prior art in support of one or more rejections in the instant Office Action and not included on an attached form PTO-892 or form PTO-1449 have been previously cited and made of record in this application.

12. Any inquiry concerning this communication or earlier communications from the examiner should be directed to N. M. Minnifield whose telephone number is 571-272-0860. The examiner can normally be reached on M-F (8:00-5:30) Second Friday Off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette R.F. Smith can be reached on 571-272-0864. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


N. M. Minfield
Primary Examiner
Art Unit 1645

NMM

August 30, 2004

Notice of References Cited	Application/Control No. 09/196,161	Applicant(s)/Patent Under Reexamination SIN ET AL.	
	Examiner N. M. Minnifield	Art Unit 1645	Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-5,593,678	01-1997	Evans et al.	424/184.1
	B	US-2004/0143864	07-2004	Gong et al.	800/020
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N	WO 00/46373 A1	08-2000	WO	Clark et al	C12N 15/30
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Wang et al, Fish and Shellfish Immunology, Nov. 2002, 13/5:337-350 Abstract Only
	V	Clark et al, Annual Review of Fish Diseases, 1995, 5:113-131 Abstract Only
	W	Lin et al, Molecular and Biochemical Parasitology, 2002, 120:93-106
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 August 2000 (10.08.2000)

PCT

(10) International Publication Number
WO 00/46373 A1

(51) International Patent Classification⁷: C12N 15/30,
C07K 14/44, A61K 39/002, 48/00, C12N 15/62, C07K
19/00, C12N 1/11, C07K 16/20, C12Q 1/68

(74) Agent: SANDBERG, Victoria, A.; Mueing, Raasch
& Gebhardt, P.A., P.O. Box 581415, Minneapolis, MN
55458-1415 (US).

(21) International Application Number: PCT/US00/02962

(22) International Filing Date: 4 February 2000 (04.02.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/118,634 4 February 1999 (04.02.1999) US
60/122,372 2 March 1999 (02.03.1999) US
60/124,905 17 March 1999 (17.03.1999) US
60/131,121 27 April 1999 (27.04.1999) US

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SI, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(71) Applicants: UNIVERSITY OF GEORGIA RE-
SEARCH FOUNDATION, INC. [US/US]; 632 Boyd
Graduate Studies, Athens, GA 30602-7411 (US). COR-
NELL RESEARCH FOUNDATION, INC. [US/US];
Suite 105, 20 Thornwood Drive, Ithaca, NY 14850 (US).

(48) Date of publication of this corrected version:
25 April 2002

(72) Inventors: CLARK, Theodore, G.; 206 Fairmount Av-
enue, Ithaca, NY 14850 (US). DICKERSON, Harry, W.,
Jr.; 390 Hampton Court, Athens, GA 30605 (US). LIN,
Tian-Long; Wsi Road, Rongquiao #9, Fujhou, Fujian
350003 (CN).

(15) Information about Correction:
see PCT Gazette No. 17/2002 of 25 April 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSTIC AND PROTECTIVE ANTIGEN GENE SEQUENCES OF ICHTHYOPHTHIRIUS

(57) Abstract: An i-antigen protein from *Ichthyophthirius multifiliis* is effective to induce a protective immune response in fish. The invention includes antigenic and membrane-targeting sequences of i-antigen proteins, nucleic acid molecules that encode antigenic or membrane-targeting portions of i-antigen proteins, DNA and protein subunit vaccines, methods of inducing an immune response in fish and methods for detection and characterization of *I. multifiliis*.



WO 00/46373 A1

5 **DIAGNOSTIC AND PROTECTIVE ANTIGEN GENE SEQUENCES OF**
 ICHTHYOPHTHIRIUS

 This application claims the benefit of U.S. Provisional Application Serial
No. 60/131,121, filed April 27, 1999; U.S. Provisional Application 60/118,634,
10 filed February 4, 1999; U.S. Provisional Application 60/122,372, filed March 2,
1999; and U.S. Provisional Application 60/124,905, filed March 17, 1999, each
of which is incorporated herein by reference in its entirety.

Statement of Government Rights

15 This invention was made with government support under grants from the
United States Department of Agriculture (USDA) CSRS NRICGP, Grant No.
95-37204-2139. The U.S. government has certain rights in this invention.

Background of the Invention

20 *Ichthyophthirius multifiliis* is a holotrichous ciliated protozoan which is
an obligate parasite of freshwater fish. The life cycle of the parasite includes a
free-living infectious stage (the theront or tomite) and an obligate fish-associated
feeding stage (the trophont or trophozoite). The infective theront invades the
skin and the gill epithelia, resulting in disturbances in respiratory and excretory
25 functions. Once in epithelial tissue, the theront differentiates into the fish-
associated feeding form known as a trophont. When the trophont is mature, it is
released from the surface of the fish and secretes material forming a gelatinous
cyst. Within the cyst, the mature trophont undergoes multiple cell divisions to
produce hundreds of theronts, which are then released from the matrix to begin a
30 new cycle of infection.

Protection from Disease Caused by I. multifiliis

Ichthyophthiriasis, the disease caused by this parasite, is commonly referred to as "Ich" or "white spot disease." Under conditions of intensive aquaculture, Ich frequently has a high morbidity and mortality, resulting in significant financial losses to fish producers.

Treatments are available for Ich-infected fish. However, the chemical treatments are effective only against the free-living theronts; there is no known agent for eliminating trophonts associated with the host. Furthermore, some of the chemotherapeutic agents used to treat Ich are suspected to leave residues in treated fish and to be carcinogenic. As a result, certain of the available treatments, e.g., malachite green, are not permitted for fish raised for human consumption. In addition, chemical treatments result in physiological stress to the infected fish beyond that resulting directly from the infection.

Those fish which survive infection by *I. multifiliis* are generally immune to further infection by the live parasite. Early reports suggested that fish (mirror carp) were successfully immunized by exposure to sublethal doses of the parasite (Hines et al., J. Fish. Biol. 6:373-378 (1974)) and by exposure to the live parasite in conjunction with chemical treatment. There have also been reports of at least partial protective immunity in fish vaccinated using the killed parasite. For example, a substantial decrease in the number of infective parasites on the body surface of goldfish which had been previously injected with killed theronts was observed when the fish were challenged with a measured dose of live theronts (Parker, Studies on the Natural History of Ichthyophthirius multifiliis Fouquet 1876, an Ectoparasitic Ciliate of Fish, Ph.D. Dissertation, The University of Maryland, College Park, Maryland (1965)). Areerat ("The Immune Response of Channel Catfish, *Ictalurus punctatus* (Rafinesque), to *Ichthyophthirius multifiliis*", unpublished Master's thesis, Auburn University) reported that channel catfish injected with formalin-fixed trophonts were protected when challenged with a lethal dose of infective theronts. Goven et al. (J. Fish Biol. 17:311-316 (1980)) reported initial protection against lethal infection when fish were injected intraperitoneally with theront cilia. The experiment was

discontinued when all control fish had died and the fate of the vaccinated fish was not followed further.

More recently, however, Burkhardt et al. (J. Fish Dis. 13:401-410 (1990)) reported that neither immersion exposure nor intraperitoneal injection with killed
5 *I. multifiliis* theronts conferred protective immunity to challenge doses of live theronts, although there was a delay in mortality of the vaccinated fish was observed. Likewise, intraperitoneal injection with theront cilia preparations did not prevent mortality, only delayed it. Only intraperitoneal injection with live
10 theronts was effective in preventing mortality after challenge with infective parasites. Those fish which had been injected with live theronts remained protected against infection for an extended time, as evidenced by their resistance to challenge infections at 3 and 13 months after the original injection. Attempted immunization with formalin-fixed trophonts led to some delay in mortality but had an unclear effect on ultimate mortality.

15 The mucus coating of an immune fish participates in protection from Ich infection. Hines et al. (J. Fish. Biol. 6:373-378 (1974)) showed that both sera and mucus from immune fish was capable of immobilizing the infective form of *I. multifiliis*. These authors also noted that fish recovering from Ich had a different distribution of the parasite than did newly infected fish. Newly infected
20 fish exhibited parasites all over the body while a recovering fish exhibits parasites primarily at edges of the fish. These are the parts of the fish which are least well supplied with blood, and therefore, would be less well supplied with antibodies.

Clark et al. (Devel. Comp. Immun. 1-2:581-594 (1988)) studied the sera
25 of channel catfish that had been rendered immune to further Ich infection by exposure to sublethal surface infection and treated with chemotherapy. The sera of these immune catfish contain antibodies which specifically bind to *I. multifiliis* cilia; little cross-reactivity was observed for cilia prepared from the free-living ciliate *Tetrahymena thermophila*. Whole *I. multifiliis* cilia and a
30 ciliary membrane fraction gave similar reactions with the immune sera, but axoneme fractions showed little differential reaction in comparisons between

immune and preimmune sera. However, attempts to identify the ciliary proteins with which the antibodies reacted using blots from SDS gel electropherograms were not successful. Sera from immune fish also immobilize the parasite *in vitro*, with an apparent positive correlation between specific antibodies and immobilization of theronts *in vitro*.

There were early reports that fish vaccinated with *Tetrahymena pyriformis* and with *T. thermophila* or with cilia prepared from *Tetrahymena* were protected from Ich infection (e.g., U.S. Pat. No. 4,309,416, Dawe et al.). It had been proposed that the ciliary membrane antigens from *Tetrahymena* showed cross-reactivity with those of *I. multifiliis*. However, more recent reports showed that attempted vaccination of channel catfish with *T. thermophila* Lwoff cilia did not protect the fish from subsequent challenge with *I. multifiliis* (Burkhardt et al., *J. Fish Dis.* 13:401-410 (1990)). It has been postulated that the previous cross-reactivity was due to the conserved axoneme proteins, rather than due to serologically related ciliary membrane proteins.

I. multifiliis i-antigens

A novel mechanism of humoral immunity against *I. multifiliis* was recently described. Rather than being killed on the host, a majority of parasites are forced to exit fish prematurely in response to antibody binding (M. Cross, *J. Fish Dis.*, 15:497-505 (1992))(T. Clark et al., *Parasitol. Today*, 13:477-480 (1997)). While the precise mechanism underlying this phenomenon is unknown, the target antigens responsible for premature exit have been identified as a class of abundant surface membrane proteins known as immobilization antigens, or i-antigens (T. Clark et al., *Annu. Rev. Fish Dis.*, 5:113-131 (1995)). Antibodies against these proteins rapidly immobilize cells *in vitro*.

I-antigens are common to a variety of hymenostomatid ciliates and have been intensively studied in *Paramecium* and *Tetrahymena* where their expression undergoes marked variation in response to environmental stimuli (F. Caron et al., *Annu. Rev. Microbiol.*, 43:23-42 (1989); Smith et al., *J. Protozool.*, 39:420-428 (1992)). Antigenic switching in these cells results from the

differential expression of multiple i-antigen genes under defined sets of conditions and represents one of the most striking examples of antigenic shift in nature. To date, there is little evidence that this type of variation occurs in *Ichthyophthirius*; however, steady-state levels of i-antigen transcripts vary as much as 50 fold during transition from the host-associated trophont to the infective theront stage, and it is clear that the genes for these proteins are developmentally regulated through the parasite life cycle (T. Clark et al., Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992)). Furthermore, serotypic variants of the i-antigens have been described among geographic isolates of the parasite (H. Dickerson et al., J. Euk. Microbiol., 40:816-820 (1993)).

Although i-antigens have gained considerable attention with regard to their mode of expression, their biological function remains obscure. In *Paramecium* and *Tetrahymena*, i-antigens are linked to the plasma membrane through a glycosylphosphatidylinositol (GPI) anchor, and in some cases, form a thick layer that coats the plasma and ciliary membranes (F. Caron et al., Annu. Rev. Microbiol., 43:23-42 (1989)). This has led to speculation that their primary function is to shield the cell membrane from environmental insult; indeed, this fits a general model for the role of GPI-anchored proteins in lower eukaryotes. The fact that cross-linking of i-antigens at the surface of *Ichthyophthirius* elicits a physiological response in the parasite also suggests that these proteins may play a role in transmembrane signaling (T. Clark et al., Parasitol. Today, 13:477-480 (1997)). Consistent with this idea, i-antigen antibodies trigger mucocyst discharge in both *I. multifiliis* (T. Clark et al., J. Fish Biol., 31(A):203-208 (1987)) and *Tetrahymena thermophila* (J. Alexander, Trans. Amer. Microsc. Soc., 86:421-427 (1967)), as well as trichocyst discharge in *Paramecium* ssp.

The cDNA sequence associated with a 48 kD i-antigen from an isolate of *I. multifiliis* (G1 isolate, serotype A) was reported by Clark et al. (Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992)); serotyping was reported by Dickerson et al. (Annu. Rev. Fish Dis. 6:107-120 (1996)). A recombinant subunit vaccine derived from this cDNA sequence was reported by He et al. (Aquaculture 158: 1-10 (1997)). This subunit vaccine was engineered as a recombinant glutathione

sulfotransferase (GST) fusion with a 105 amino acid fragment of the protein that the researchers identified as a potential antigenic epitope, corresponding to one of several tandemly repetitive amino acid sequence domains identified by Clark et al. (Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992)). The nucleotide
5 sequence encoding the fusion construct was chemically synthesized and used for expression of the recombinant peptide in bacteria. Two amino acid substitutions relative to the native sequence were required in order to provide restriction sites in the corresponding DNA; moreover, protozoan glutamine codons TAA and TAG (which function as stop codons in *E. coli* and other conventional protein
10 expression systems) were replaced by the universal glutamine codons CAG or CAA in order to allow expression of the fusion construct in *E. coli*. The fusion vaccine gave weak protection against an undefined isolate of *I. multifiliis*; 50% of the vaccinated fish were heavily infected with *I. multifiliis* upon challenge with the live parasite, compared to 75% of control fish.

15 The 48 kD i-antigen protein has been isolated from cultures of *I. multifiliis* (Clark et al., Annu. Rev. Fish Dis. 5:113-131 (1995); Lin et al., J. Protozoology 39:457-463 (1992)). In addition, a 55 kD i-antigen protein has been isolated from cultures of *I. multifiliis* and affinity purified and used in studies on passive immunity (T. L. Lin et al., Inf. Immun. 64:4085-4090 (1996)).
20 Mouse monoclonal antibodies raised against this protein were effective to immobilize G5 isolates of *I. multifiliis*. However, a native i-antigen protein would be very difficult to obtain from *I. multifiliis* in large quantity because this obligate parasite cannot be easily cultured.

It is clear that an inexpensive and effective vaccine against Ich would be
25 of great benefit to the aquaculture industry.

Summary of the Invention

The present invention is directed to novel i-antigen polypeptides and nucleic acid molecules that encode them. Examples of novel i-antigen
30 polypeptides include polypeptides having SEQ ID NO:6 and SEQ ID NO:7 derived from *I. multifiliis*. The nucleic acid molecule provided by the invention

contains a polynucleotide fragment having a nucleotide sequence that encodes at least a portion of an i-antigen polypeptide, exemplified by nucleotide sequences SEQ ID NOs: 1, 3 and 5. In one embodiment, the polynucleotide fragment encodes at least a C-terminal portion of an i-antigen polypeptide having amino acid sequence SEQ ID NO:6; in another it encodes at least one terminal portion of an i-antigen polypeptide having amino acid sequence SEQ ID NO:7; in yet another it encodes at least an antigenic portion of an i-antigen polypeptide having amino acid sequence SEQ ID NO:7. The nucleic acid molecule of the invention can take the form of a vector that is capable of expression in an organism or in a cell, preferably a fish and/or in a conventional protein expression system, including bacteria, such as *E. coli*, yeast, mammalian cell culture or insect cells. The invention includes a host cell transformed with the vector of the invention, and further includes an organism, preferably a fish, comprising a nucleic acid molecule of the invention. Also included is an antibody capable of binding at least one of the i-antigen polypeptides of the invention.

The invention further includes a composition for inducing an immune response in a fish comprising a nucleic acid molecule that has a nucleotide sequence that encodes an antigenic portion of an i-antigen polypeptide of the invention. Likewise, the invention includes a composition for inducing an immune response in a fish comprising an antigenic i-antigen polypeptide of the invention. The invention further includes a method for causing an immune response in the fish by administering an immunogenic composition as described, for example as a prophylactic or therapeutic vaccine. The composition preferably prevents or controls *I. multifiliis* infection in fish.

Also included in the invention is a method for detecting *Ichthyophthirius* in an aquaculture. A sample containing nucleic acid is obtained from an aquaculture fish or from water present in the aquaculture, then at least one primer oligonucleotide having a sequence complementary to at least a portion of SEQ ID NO:6 or SEQ ID NO:7 is added to the nucleic acid sample. A polymerase chain reaction amplification is conducted, and the amplified product is analyzed for the presence of a product amplified by the at least one

oligonucleotide primer. Advantageously, the amplified product can then be used to formulate or customize a vaccine effective to treat or prevent *Ichthyophthirius* infection. The method thus optionally includes making a polynucleotide vaccine that contains at least a portion of the amplified product, or a protein subunit vaccine that includes an antigenic polypeptide encoded by the portion of the amplified product; and administering the vaccine to treat or prevent *Ichthyophthirius* infection in a fish or fish population.

Further, the invention provides a method for identifying an *I. multifiliis* serotype. A sample containing *I. multifiliis* nucleic acid is combined with at least one primer oligonucleotide that has a sequence complementary to a region of an *I. multifiliis* nucleotide sequence encoding an i-antigen that is unique to and selective for that serotype, then a polymerase chain reaction amplification is conducted. The reaction mixture is analyzed for the presence of a product amplified by the serotype-selective oligonucleotide primer.

Brief Description of the Figures

Figure 1 shows the nucleotide sequence (SEQ ID NO:2) and the deduced amino acid sequence (SEQ ID NO:6) of the 48 kD i-antigen gene (*LAG48[G1]*); a guanine (G) nucleotide that marks the start of the 1.2 kb cDNA is indicated by the arrow; the adenosine (A) nucleotide in the gene's putative ATG start codon for the 48 kD i-antigen is assigned the number +1; a stretch of 14 mostly hydrophobic amino acids at the C-terminus of the deduced protein is boxed; the 3 small amino acids (Cys-Ala-Ser, denoted with asterisks) may represent the site at which cleavage and GPI-anchor addition occurs.

Figure 2 shows nucleotide sequences for (a) the native G5 55 kD i-antigen coding region including stop codons (SEQ ID NO:44); and (b) a synthetic 55 kD i-antigen coding region, including stop codons (SEQ ID NO:102), useful as a DNA vaccine and in conventional protein expression systems.

Figure 3 shows (a) an alignment of the deduced amino acid sequences of the genomic 48 kD (upper line) (SEQ ID NO:6) and 55 kD (lower line) (SEQ ID

NO:7) i-antigens of *I. multifiliis*; where asterisks indicate identities between the two deduced protein sequences, double dots indicate highly homologous amino acids, and single dots indicate moderately homologous amino acids; boxes indicate conserved regions; and (b) an alignment of the nucleotide sequences of the coding regions of the *LAG48 [G1]* gene (upper line) (SEQ ID NO:1) and the *LAG55 [G5]* gene (lower line) (SEQ ID NO:3) of *I. multifiliis*, where asterisks indicate identities between the two nucleotide sequences.

Figure 4 shows the deduced amino acid sequence of the 55 kD i-antigen encoded by the *LAG55 [G5]* coding region in Fig. 2(a).

Figure 5 shows an amino acid sequence alignment of five homologous tandemly repeated amino acid sequence domains of (a) the deduced 48 kD i-antigen genomic coding region and (b) the deduced 55 kD i-antigen coding region; amino acids that are shared by three or more repeats are boxed; asterisks denote cysteine residues conserved in all repeats.

Figure 6 is a restriction map of the cloned genomic DNA fragment encoding the 48 kD i-antigen; *Swa* I, (S); *Eco*R I, (E); *Nsi*, (N); and *Hind* III, (H); the filled portion indicates the coding region of the i-antigen gene.

Figure 7 shows a comparison between the *LAG48 [G1]* gene sequence and 1.2 kb cDNA sequence. Panel (A) is a schematic illustrating the basic differences between the gene and cDNA sequences (boxed); the filled regions of the gene sequence are not present in the 1.2 kb cDNA sequence; ATG, start codon; TGA, stop codon; nt, nucleotides; inverted triangle indicates the site of the observed C/T transversion. Panel (B) diagrams equivalent regions of the 1.2 kb cDNA (nucleotides 1-1172) and *LAG48 [G1]* gene (nucleotides 56-1227); the C/T transversion is indicated at nucleotide 897 (cDNA) and 952 (genomic DNA). Panel (C) shows the nucleotide sequences specified by the 3' ends of the 1.2 kb cDNA (SEQ ID NO:64), the *LAG48 [G1]* gene (SEQ ID NO:66), the ICH5/EPB 3' RACE product (SEQ ID NO:67), and two additional cDNAs designated 1-3 (SEQ ID NO: 68) and 1-1 (SEQ ID NO:69); also shown are the corresponding deduced amino acid sequences of the 1.2 kb cDNA (SEQ ID NO:63) and the *LAG48 [G1]* gene (SEQ ID NO:65); a point mutation in the

RACE product is boxed and is most likely attributable to the use of a low fidelity thermostable DNA polymerase during synthesis; the bracket covering nucleotides +1409 through +1413 in the *LAG48[G1]* transcript indicates a putative polyadenylation site.

5 Figure 8 shows an amino acid sequence alignment of *I. multifiliis* and *Giardia* surface proteins; the *LAG48[G1]* (amino acids 20-428) (SEQ ID NO:61) and *Giardia lamblia* vspA6-S1 (amino acids 61-459) (SEQ ID NO:62) gene products were compared using CLUSTALW multiple sequence alignment software; common cysteine residues are boxed; the segment of the *Giardia* VSP
10 shown here (accession no. Q24970) comprises 67% of the predicted protein.

Figure 9 is a schematic illustrating the method used to isolate the 1 kb cDNA encoding a portion of the G5 55 kD i-antigen sequence.

Figure 10 is a schematic illustrating a method utilizing inverse PCR that was used to obtain the nucleotide sequences flanking the 1 kb cDNA sequence in
15 the gene encoding the G5 55 kD i-antigen.

Figure 11 shows an SDS-PAGE gel and a Western blot of solubilized and GPI-phospholipase C treated membrane proteins from *I. multifiliis* (strain G5).

Figure 12 lists oligonucleotide primers used for DNA shuffling-based synthesis of a G5 synthetic i-antigen gene.

20 Figure 13 shows the nucleotide sequence encoding the synthetic G5 proline mutant i-antigen protein (L6P) (SEQ ID NO:53); the arrow indicates the mutation position.

Figure 14 shows the amino acid sequence of a synthetic G5 proline mutant i-antigen protein (L6P) (SEQ ID NO:54); the arrow indicates the position
25 of the mutation.

Figure 15 is a Western blot showing expression of a recombinant synthetic 55 kD i-antigen protein in *E. coli*.

Figure 16 shows survival and days to death of channel catfish vaccinated with purified 55 kD i-antigen subunit protein.

30 Figure 17 is a Western blot showing expression and secretion from a transformed *Tetrahymena* of a G1 i-antigen with C-terminal truncation.

Figure 18 shows Western blotting analysis of sera from fish vaccinated with the 55 kD plasmid vaccines.

Figure 19 shows ELISA results for fish vaccinated with *Tetrahymena* expressing (a) membrane associated G1 i-antigen and (b) secretory form of G1 i-antigen.

Figure 20 is a 10X magnification of serotype A *I. multifiliis* an immobilization test conducted using sera (1:20 dilution) from (a) fish vaccinated with live *Tetrahymena* expressing *neo* ("anti-live Tneo," the negative control) and (b) fish vaccinated with live *Tetrahymena* expressing the full-length 48 kD i-antigen protein from a G1 *I. multifiliis* isolate ("anti-live TG1).

Figure 21 is a gel showing the use of universal primers P2 and P4 to amplify nucleotide sequences in several different *I. multifiliis* serotypes.

Detailed Description of the Invention

The present invention provides a nucleic acid molecule comprising a polynucleotide fragment having a nucleotide sequence that encodes at least a portion of an i-antigen protein.

In one aspect of the invention, the nucleotide sequence of the polynucleotide fragment encoding the i-antigen protein is derived from *I. multifiliis* (G1 isolate), and encodes a putative i-antigen having a molecular weight of about 48 kD. In a preferred embodiment of this aspect of the invention, the polynucleotide fragment is at least about 20 nucleotides in length and has at least a 3' terminal portion of a nucleotide sequence as shown in Fig. 1, nucleotides 1 through 1326 (SEQ ID NO:1), wherein nucleotides 1 through 1326 represent the coding region of the *LAG48[G1]* gene of *I. multifiliis*. In a particularly preferred embodiment, the polynucleotide fragment is SEQ ID NO:1. The term "3' terminal portion" of SEQ ID NO:1 includes at least one nucleotide contiguous to and located 3' of nucleotide 1226, exemplified by nucleotides 1227 through 1326 (SEQ ID NO:4) in SEQ ID NO:1. A "coding region" is a linear string of nucleotides that encodes a polypeptide, usually via mRNA, when placed under the control of appropriate regulatory sequences. The boundaries of a

coding region are generally determined by a translation start codon at its 5' end and a translation stop codon at its 3' end. Optionally, the polynucleotide fragment of the invention includes one or more flanking nucleotides on one or both of the 5' and 3' ends of the coding region, representing untranslated regions (UTRs) as shown in Fig. 1. A polynucleotide fragment of the invention can, for example, have a nucleotide sequence represented by nucleotides -432 through 2054, as shown in Fig. 1 (SEQ ID NO:2).

In another aspect of the invention, the nucleotide sequence of the polynucleotide fragment encoding an i-antigen protein is derived from *I. multifiliis* (G5 isolate), and encodes an i-antigen having a molecular weight of about 55 kD. In a preferred embodiment of this aspect of the invention, the polynucleotide fragment is at least about 20 nucleotides in length and has at least one terminal portion of a nucleotide sequence as shown in Fig. 2(a), nucleotides 1 through 1404 (SEQ ID NO:3), wherein nucleotides 1 through 1404 represent the coding region of the *LAG55[G5]* gene of *I. multifiliis*. A terminal portion of SEQ ID NO:3 can be a 5' terminal portion or a 3' terminal portion of SEQ ID NO:3. A 5' terminal portion of SEQ ID NO:3 includes at least one nucleotide contiguous to and located 5' of nucleotide 61, exemplified by nucleotides 1 through 60 (SEQ ID NO:19) in Fig. 2(a). Likewise, a 3' terminal portion of SEQ ID NO:3 includes at least one nucleotide contiguous to and located 3' of nucleotide 1344, exemplified by nucleotides 1345 through 1404 (SEQ ID NO:20) in Fig. 2(a). In a particularly preferred embodiment, the polynucleotide fragment is SEQ ID NO:3. Optionally, the polynucleotide fragment of the invention includes one or more flanking nucleotides on one or both of the 5' and 3' ends of the coding region.

The invention further includes a nucleic acid molecule comprising a polynucleotide fragment having a nucleotide sequence selected from the class of nucleotide sequences that encodes a polypeptide having at least a C-terminal portion of SEQ ID NO:6 (Fig. 1). Preferably, the polynucleotide is at least about 20 nucleotides in length. The term "polypeptide" as used herein refers to a polymer of amino acids and does not refer to a specific length of a polymer of

amino acids. Thus, for example, the terms peptide, oligopeptide, and protein are included within the definition of polypeptide. A "C-terminal portion" of SEQ ID NO:6 includes at least one amino acid contiguous to and located to the C-terminal side of amino acid 409 (Ala409) in SEQ ID NO:6, and is exemplified by amino acids 410 (Lys410) through 442 (Leu442) (SEQ ID NO:18) (Figs. 1 and 3(a)). Preferably, a C-terminal portion of SEQ ID NO:6 includes at least about 6 contiguous amino acids from SEQ ID NO:18, more preferably at least about 14, even more preferably at least about 20. In a particularly preferred embodiment of this aspect of the invention, a C-terminal portion of SEQ ID NO:6 includes the last 14 amino acids of SEQ ID NO:6 (-Phe-Leu-Ser-Ile-Ser-Leu-Leu-Phe-Ile-Ser-Phe-Tyr-Leu-Leu, SEQ ID NO:13), which represents a novel hydrophobic signaling sequence for targeting to a ciliate membrane; even more preferably the C-terminal portion includes the last 23 amino acids of SEQ ID NO:6 (-Gln-Cys-Ala-Ser-Thr-Thr-Phe-Ala-Lys-Phe-Leu-Ser-Ile-Ser-Leu-Leu-Phe-Ile-Ser-Phe-Tyr-Leu-Leu, SEQ ID NO:14). Most preferably, the polynucleotide fragment of this aspect of the invention has a nucleotide sequence selected from the class of nucleotide sequences that encodes a polypeptide having SEQ ID NO:6.

It is envisioned that the C-terminal membrane targeting sequence of SEQ ID NO:6, exemplified by SEQ ID NOs:13 and 14, can be fused to other proteins and use to direct membrane surface display of the fused proteins in other ciliates known to utilize GPI anchors, such as *Tetrahymena* and *Paramecium*. Conservative substitutions of hydrophobic residues, discussed in more detail below, such as substitutions of leucine, isoleucine, and phenylalanine with each other, are expected to be well tolerated within these signal sequences, and nucleotide sequence encoding SEQ ID NOs: 13 and 14 that have been modified with one or more of these conservative substitutions are also included in the invention.

One example of the class of nucleotide sequences that encodes a polypeptide having amino acid SEQ ID NO:6 is SEQ ID NO:1. This class of nucleotide sequences is large but finite, and the nucleotide sequence of each

member of the class can be readily determined by one skilled in the art by reference to the standard genetic code, as used in *E. coli*. Additional members of this class of nucleotide sequences, for use in ciliate expression systems, can be determined using the modified genetic code for ciliates, as described herein.

- 5 Likewise, the invention includes a nucleic acid molecule comprising a polynucleotide fragment having a nucleotide sequence selected from the class of nucleotide sequences that encodes a polypeptide having at least a terminal portion of amino acid sequence SEQ ID NO:7. Preferably, the polynucleotide is at least about 20 nucleotides in length. A terminal portion of SEQ ID NO:7 can be an N-terminal portion or a C-terminal portion. An "N-terminal portion" of SEQ ID NO:7 includes at least one amino acid that is contiguous to, and located to the N-terminal side of, amino acid 21 (Ala21) in SEQ ID NO:7, and is exemplified by amino acids 1 (Met1) through 20 (Ser20) (SEQ ID NO:15). Preferably, an N-terminal portion of SEQ ID NO:7 includes at least about 6 contiguous amino acids from SEQ ID NO:15, more preferably at least about 10, even more preferably at least about 15. In a particularly preferred embodiment of this aspect of the invention, an N-terminal portion of SEQ ID NO:7 includes the first 20 amino acids of SEQ ID NO:7 (Met-Lys-Asn-Asn-Ile-Leu-Val-Ile-Leu-Ile-Ile-Ser-Leu-Phe-Ile-Asn-Gln-Ile-Lys-Ser, SEQ ID NO:15), which constitutes a novel membrane targeting sequence. A "C-terminal portion" of SEQ ID NO:7 includes at least one amino acid that is contiguous to, and located to the C-terminal side of amino acid 448 (Ile448) in SEQ ID NO:7, and is exemplified by amino acids 449 (Gln449) through 468 (Leu468) (SEQ ID NO:17). Preferably, a C-terminal portion of SEQ ID NO:7 includes at least about 6 contiguous amino acids from SEQ ID NO:17, more preferably at least about 14, even more preferably at least about 20. In a particularly preferred embodiment of this aspect of the invention, a C-terminal portion of SEQ ID NO:7 includes the last 14 amino acids of SEQ ID NO:7 (Phe-Leu-Ser-Ile-Ser-Leu-Leu-Leu-Ile-Ser-Tyr-Tyr-Leu-Leu, SEQ ID NO:16), which represents a novel hydrophobic signaling sequence for targeting to a ciliate membrane; more preferably the C-terminal portion includes the last 20 amino acids of SEQ ID
- 10
- 15
- 20
- 25
- 30

NO:7 (Gln-Cys-Asp-Phe-Ala-Asn-Phe-Leu-Ser-Ile-Ser-Leu-Leu-Leu-Ile-Ser-Tyr-Tyr-Leu-Leu, SEQ ID NO:17).

It is envisioned the N-terminal and C-terminal membrane targeting sequences of SEQ ID NO:7, exemplified by SEQ ID NOs:15-17, can be fused to other proteins and used to direct secretion or membrane surface display of the proteins in other ciliates known to utilize GPI anchors, such as *Tetrahymena* and *Paramecium*. Additionally, the N-terminal membrane targeting sequence may be more generally applicable to other protein expression systems. Conservative substitutions of hydrophobic residues, such as substitutions of leucine, isoleucine, and phenylalanine with each other, are expected to be well tolerated within these signal sequences, and nucleotide sequence encoding SEQ ID Nos:15-17 that have been modified with one or more of these conservative substitutions are also included in the invention.

Examples of the class of nucleotide sequences that encode a polypeptide having amino acid SEQ ID NO:7 are SEQ ID NOs:3 and 5. This class of nucleotide sequences is likewise large but finite, and the nucleotide sequence of each member of the class can also be readily determined by reference to the standard genetic code, as used in *E. coli*. Additional members of this class of nucleotide sequences, for use in ciliate expression systems, can be determined using the modified genetic code for ciliates, as described herein.

The nucleic acid molecule of the invention can be DNA, RNA, or a combination thereof, and can include any combination of naturally occurring, chemically modified or enzymatically modified nucleotides. The nucleic acid molecule can be equivalent to the polynucleotide fragment encoding an i-antigen protein, or it can include said polynucleotide fragment in addition to one or more additional nucleotides or polynucleotides. For example, the nucleic acid molecule of the invention can be a vector, such as an expression or cloning vector. A vector useful in the present invention can be circular or linear, single-stranded or double stranded, and can include DNA, RNA, or any modification or combination thereof. The vector can be a plasmid, a cosmid, or a viral vector, such as baculovirus. Preferably, the nucleic acid molecule of the invention takes

the form of an expression vector that is capable of expression in an organism or in a cell of the organism, in culture or in vivo. An organism or cell in which the coding sequence of the vector can be expressed can be eukaryotic or prokaryotic, and can be, without limitation, a bacterium, a yeast, an insect, a protozoan, preferably a ciliate such as *Tetrahymena*, or animal, such as a fish or a mammal. Preferably, the vector is expressible in a fish and/or in a conventional protein expression system, including bacteria, such as *E. coli*, yeast, such as *Pischia pastoris*, mammalian cell culture or insect cells.

When the vector is intended for use in bacterial, yeast, mammalian or insect expression systems, the coding sequences of the vector are preferably engineered to utilize the conventional genetic code rather than the ciliate genetic code that is employed in the native *I. multifiliis* coding sequences. Thus, in preferred embodiments of these aspects of the invention, the nucleotide sequence of the polynucleotide fragment that encodes an i-antigen protein is altered such that each ciliate glutamine codon TAA and TAG in the nucleotide sequence derived from the *I. multifiliis* isolate is replaced with a universal glutamine codons, either CAG or CAA. Accordingly, a particularly preferred embodiment of the nucleic acid molecule of the invention includes a polynucleotide fragment having SEQ ID NO:5.

It should be understood that the nucleic acid molecule of the invention can be single-stranded or double-stranded, and further that a single-stranded nucleic acid molecule of the invention includes a polynucleotide fragment having a nucleotide sequence that is complementary to a nucleotide sequence that encodes an i-antigen protein or portion thereof according to the invention. As used herein, the term "complementary" refers to the ability of two single stranded polynucleotide fragments to base pair with each other, in which an adenine on one nucleic acid fragment will base pair to a thymine on the other, and a cytosine on one nucleic acid fragment will base pair to a guanine on the other. Two polynucleotide fragments are complementary to each other when a nucleotide sequence in one nucleic acid fragment can base pair with a nucleotide

sequence in a second nucleic acid fragment. For instance, 5'-ATGC and 5'-GCAT are fully complementary, as are 5'-ATGC and 5'-GCAT.

Further, the single-stranded nucleic acid molecule of the invention also includes a polynucleotide fragment having a nucleotide sequence that is

5 substantially complementary to a nucleotide sequence that encodes an i-antigen protein or portion thereof according to the invention, or to the complement of the nucleotide sequence that encodes an i-antigen or portion thereof. Substantially complementary polynucleotide fragments can include at least one base pair mismatch, such that at least one nucleotide present on a first polynucleotide

10 fragment will not base pair to at least one nucleotide present on a second polynucleotide fragment, however the two polynucleotide fragments will still have the capacity to hybridize. For instance the middle nucleotide of each of the two DNA fragments 5'-AGCAAATAT and 5'-ATATATGCT will not base pair, but these two nucleic acid fragments are nonetheless substantially

15 complementary as defined herein. Two polynucleotide fragments are substantially complementary if they hybridize under hybridization conditions exemplified by 2X SSC (SSC: 150 mM NaCl, 15 mM trisodium citrate, pH 7.6) at 55°C. Substantially complementary polynucleotide fragments for purposes of the present invention preferably share at least one region of at least about 50

20 nucleotides in length, which shared region has at least about 85% nucleotide identity, preferably at least about 90% nucleotide identity. More preferably, substantially complementary polynucleotide fragments share a plurality of regions of between about 50 nucleotides and about 150 nucleotides in length, which shared regions have at least about 85% nucleotide identity, preferably at

25 least about 90% nucleotide identity. In a particularly preferred embodiment, the substantially complementary nucleotide sequence encodes at least one of SEQ ID NOs:90-100 as shown on Fig. 3(a). Locations and levels of nucleotide sequence identity between two nucleotide sequences can be readily determined using

CLUSTALW multiple sequence alignment software.

30 The invention further includes a nucleic acid molecule comprising a polynucleotide fragment that hybridizes to at least a portion of the complement

of either or both of SEQ ID NO:1 or SEQ ID NO:3, under standard hybridization conditions, provided that the polynucleotide fragment encodes a polypeptide comprising at least a membrane targeting portion or an antigenic portion of an i-antigen protein. A membrane targeting portion of an i-antigen protein is one that targets the polypeptide to either the endoplasmic reticulum (e.g., an N-terminal signal sequence) or to the plasma membrane (e.g., a GPI anchor sequence). Standard hybridization conditions are exemplified by 2X SSC (SSC: 150 mM NaCl, 15 mM trisodium citrate, pH 7.6) at 55°C.

The invention further includes a nucleotide molecule comprising a polynucleotide fragment encoding an antigenic analog or modification of a polypeptide represented by SEQ ID NO:6, or an antigenic fragment thereof that includes at least a C-terminal portion of SEQ ID NO:6; further, the invention includes a nucleotide molecule comprising a polynucleotide fragment encoding an antigenic analog, fragment, or modification of a polypeptide represented by SEQ ID NO:7, as described in more detail below.

Also provided by the invention is a novel i-antigen protein. In a further aspect of the invention, therefore, the i-antigen protein is encoded by a nucleotide sequence derived from *I. multifiliis* (G1 isolate), and has a molecular weight of about 48 kD. In a particularly preferred embodiment of this aspect of the invention, the i-antigen protein is encoded by the nucleotide sequence as shown in Fig. 3(b), nucleotides 1 through 1326 (SEQ ID NO:1), representing the coding region of the *LAG48[G1]* gene of *I. multifiliis*, and has the amino acid sequence SEQ ID NO:6 (Fig. 1). In another aspect of the invention, the i-antigen protein is encoded by a nucleotide sequence derived from *I. multifiliis* (G5 isolate), and has a molecular weight of about 55 kD. In a particularly preferred embodiment of this aspect of the invention, the i-antigen is encoded by the nucleotide sequence as shown in Fig. 2(a), nucleotides 1 through 1404 (SEQ ID NO:3), representing the coding region of the *LAG55[G5]* gene, and has the amino acid sequence SEQ ID NO:7 (Fig. 4).

The i-antigen polypeptide of the invention includes an i-antigen polypeptide having SEQ ID NO:6; an i-antigen polypeptide having SEQ ID

NO:7; an analog or modification of an i-antigen polypeptide having SEQ ID NO:6; a fragment of an i-antigen polypeptide having SEQ ID NO:6 having at least a C-terminal portion of SEQ ID NO:6; an antigenic analog, fragment, or modification of an i-antigen polypeptide having SEQ ID NO:7; and an analog, fragment, or modification of an i-antigen polypeptide having SEQ ID NO:7 wherein said analog, fragment or modification has at least one terminal portion of SEQ ID NO:7.

An antigenic analog, fragment, or modification of a polypeptide having SEQ ID NOs:6 or 7 is one that generates an immune response in fish against *I. multifiliis*. Antigenicity of an polypeptide can be evaluated *in vitro* by performing a Western blot on the purified polypeptide (for example, an affinity purified polypeptide) using polyclonal antisera from a rabbit that was vaccinated with at least an antigenic portion of a native *I. multifiliis* i-antigen protein, preferably with a complete *I. multifiliis* i-antigen protein (e.g., SEQ ID NO:6 or SEQ ID NO:7).

Antigenic analogs of polypeptide having SEQ ID NO:6, SEQ ID NO:7 include i-antigen polypeptides having amino acid substitutions that do not eliminate polypeptide antigenicity in fish. Substitutes for an amino acid may be selected from other members of the class to which the amino acid belongs. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and tyrosine. Polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine and glutamine. The positively charged (basic) amino acids include arginine, lysine and histidine. The negatively charged (acidic) amino acids include aspartic acid and glutamic acid. Examples of preferred conservative substitutions include Lys for Arg and *vice versa* to maintain a positive charge; Glu for Asp and *vice versa* to maintain a negative charge; Ser for Thr so that a free -OH is maintained; and Gln for Asn to maintain a free NH₂. Fragments of an i-antigen polypeptide of the invention include i-antigen polypeptides containing deletions or additions of one or more contiguous or noncontiguous amino acids that do not eliminate the antigenicity of the i-antigen in fish are also contemplated. Fragments of an i-

antigen polypeptide contain at least about six amino acids, preferably at least about 10 amino acids, more preferably at least about 60 amino acids. Modified i-antigens include i-antigens that are chemically and enzymatically derivatized at one or more constituent amino acid, including side chain modifications, backbone modifications, and N- and C- terminal modifications including acetylation, hydroxylation, methylation, amidation, and the attachment of carbohydrate or lipid moieties, cofactors, and the like.

The invention further includes an antigenic polypeptide that shares a significant level of primary structure with either or both of SEQ ID NO:6 or SEQ ID NO:7. Preferably, the antigenic polypeptide of this aspect of the invention is a synthetic polypeptide. A synthetic polypeptide is one that does not have the amino acid sequence of a polypeptide that is isolated from an organism; i.e., it is not a naturally occurring polypeptide. An antigenic polypeptide shares a significant level of primary structure with either or both of SEQ ID NO:6 or SEQ ID NO:7 if it has a plurality of amino acid sequence domains, each domain having about 60 to about 100 amino acids, of which six are cysteines that fall into register when the sequence domains are aligned with the amino acid sequence domains of SEQ ID NOs:6 or 7, as exemplified in Fig. 5. The predominant primary structure motif in an antigenic polypeptide of the invention is -Cys-Xaa_{2,3}-Cys- (SEQ ID NOs:31, 32), where Xaa is any amino acid, and where Xaa_{2,3} means Xaa₂ or Xaa₃, that is, where pairs of cysteines are separated by two or three amino acids. Preferably, the antigenic polypeptide of the invention has larger scale repeating motifs characterized by -Cys-Xaa₂-Cys-Xaa_m-Cys-Xaa₃-Cys-Xaa_n-Cys-Xaa₂-Cys- where m = 15 - 25, preferably 20-22, and n = 15-25, preferably 19-20 (e.g., SEQ ID NO:33 where m = 20, n = 20). More preferably, the larger scale repeating motifs are characterized by -Cys-Xaa₂-Cys-Xaa_m-Cys-Xaa₃-Cys-Pro-Xaa_p-Cys-Xaa₂-Cys- where m = 15-25, preferably 20-22 and p = 14-24, preferably 18-19 (e.g., SEQ ID NO:88 where m = 20, p = 18). In a particularly preferred embodiment, the larger scale repeating motifs are characterized by -Cys-Xaa₂-Cys-Xaa_q-Gln-Cys-Xaa₃-Cys-Pro-Xaa-Gly-Thr-Xaa_r-Cys-Xaa₂-Cys-, where q = 14-24, preferably 19-21, and r = 11-21,

preferably 15-16 (e.g., SEQ ID NO:89 where $q = 20$, $r = 20$). In a particularly preferred embodiment of the invention, each amino acid sequence domain of an antigenic polypeptide of the invention has at least 90% amino acid identity with at least one of SEQ ID NOs:8-12 (Fig. 5(a)) and 55-60 (Fig. 5(b)); most
5 preferably, each amino acid sequence domain of an antigenic polypeptide of the invention has at least 95% amino acid identity with at least one of SEQ ID NOs:8-12 and 55-60 (Fig. 5).

The location and level of amino acid sequence identity between two amino acid sequences can be readily determined using CLUSTALW multiple
10 sequence alignment software. Alternatively, the two amino acid sequences (i.e., the amino acid sequence of the candidate domain sequence of the antigenic polypeptide and the reference amino acid sequence selected from SEQ ID NOs:8-12 and 55-60) are aligned such that the cysteines are in register, then further aligned to maximize the number of amino acids that they have in
15 common along the lengths of their sequences; gaps in either or both sequences are permitted in making the alignment in order to place the cysteines in register and to maximize the number of shared amino acids, although the amino acids in each sequence must nonetheless remain in their proper order. The percentage amino acid identity is the higher of the following two numbers: (a) the number of
20 amino acids that the two sequences have in common within the alignment, divided by the number of amino acids in the reference sequence, multiplied by 100; or (b) the number of amino acids that the two sequences have in common within the alignment, divided by the number of amino acids in the candidate polypeptide, multiplied by 100.

25 The invention further includes a polypeptide having a membrane targeting sequence selected from a C-terminal portion of SEQ ID NO:6, an N-terminal portion of SEQ ID NO:7, and a C-terminal portion of SEQ ID NO:7, as described above.

30 The present invention further provides a vaccine for use in preventing or controlling disease in fish caused by *I. multifiliis*. The polynucleotide vaccine comprises a polynucleotide fragment, preferably a DNA fragment, having a

nucleotide sequence encoding an antigenic polypeptide comprising at least an antigenic portion of an i-antigen protein derived from *I. multifiliis*. The polynucleotide vaccine optionally further comprises a promoter, preferably the CMV promoter, operably linked to the coding sequence for the i-antigen polypeptide (e.g., U.S. Pat. No. 5,708,448, Davis). There are numerous plasmids known to those of ordinary skill in the art useful for the production of polynucleotide vaccines. A specific embodiment employs constructs using the plasmid pcDNA3.1 as the vector (InVitrogen Corporation, Carlsbad, CA). In addition, the vector construct can contain immunostimulatory sequences (ISS), such as unmethylated dCpG motifs, that stimulate the animal's immune system. Other possible additions to the polynucleotide vaccine constructs include nucleotide sequences encoding cytokines, such as granulocyte macrophage colony stimulating factor (GM-CSF), interleukin-12 (IL-12) and co-stimulatory molecules such B7-1, B7-2, CD40. The cytokines can be used in various combinations to fine-tune the response of the animal's immune system, including both antibody and cytotoxic T lymphocyte responses, to bring out the specific level of response needed to affect the animal's reproductive system. The polynucleotide vaccine can also encode a fusion product containing the antigenic polypeptide and a molecule, such as CTLA-4, that directs the fusion product to antigen-presenting cells inside the host. Plasmid DNA can also be delivered using attenuated bacteria as delivery system, a method that is suitable for DNA vaccines that are administered orally. Bacteria are transformed with an independently replicating plasmid, which becomes released into the host cell cytoplasm following the death of the attenuated bacterium in the host cell. An alternative approach to delivering the polynucleotide to an animal involves the use of a viral or bacterial vector. Examples of suitable viral vectors include adenovirus, polio virus, pox viruses such as vaccinia, canary pox, and fowl pox, herpes viruses, including catfish herpes virus, adenovirus-associated vector, and retroviruses. Exemplary bacterial vectors include attenuated forms of *Salmonella*, *Shigella*, *Edwardsiella ictaluri*, and *Yersinia ruckerii*. Preferably,

the polynucleotide is a vector, such as a plasmid, that is capable of autologous expression of the nucleotide sequence encoding an i-antigen.

In a particularly preferred embodiment, the vaccine is a DNA vaccine comprising a DNA fragment having a nucleotide sequence that encodes a polypeptide having amino acid sequence SEQ ID NO:6 or SEQ ID NO:7, an antigenic analog, fragment, or modification of a polypeptide having SEQ ID NO:7, an antigenic analog or modification of a polypeptide having SEQ ID NO:6, or an antigenic fragment of a polypeptide having SEQ ID NO:6 provided that the fragment includes at least a C-terminal portion of SEQ ID NO:6. An antigenic analog, fragment, or modification of an i-antigen polypeptide is one that generates an immune response in fish against *I. multifiliis*. For example, a preferred DNA vaccine comprises a DNA fragment having a nucleotide sequence encoding an amino acid sequence selected from the group consisting of SEQ ID NOS:8-12 and 55-60; these eleven amino acid sequences represent tandemly repeated amino acid sequence domains found in the deduced amino acid sequence SEQ ID NO:6 and are expected to be antigenic. More preferably, the DNA vaccine comprises all or a portion of nucleotide sequence SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5, provided that the portion of SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5 encodes an antigenic polypeptide and further provided that, in SEQ ID NO:1 and SEQ ID NO:3 codons TAA and TAG that code for glutamine in *I. multifiliis* are changed to CAG or CAA. Most preferably, the DNA vaccine includes a synthetic DNA fragment having a nucleotide sequence that encodes a polypeptide SEQ ID NOS:6 or 7 using codons that are biased in favor of the host's codon usage.

Polynucleotide-based immunization induces an immune response to an antigen expressed *in vivo* from a heterologous polynucleotide fragment introduced into the fish. This method can be advantageous over other methods because heterologous nucleic acid expression may continue for a length of time sufficient to induce a relatively strong and sustained immune response without the need for subsequent "booster" vaccinations, as is common when portions of the protein antigen itself have been injected into the animal. A polynucleotide

vaccine comprising a polynucleotide fragment having a nucleotide sequence encoding an i-antigen protein can be administered to a fish using biolistic bombardment, bath immersion, ingestion or direct injection, as described in U.S. Pat. No. 5,780,448 (Davis), preferably intraperitoneal or intramuscular injection.

- 5 A preferred method of administration is biolistic bombardment, as with a "gene gun." A polynucleotide vaccine formulated for oral administration preferably contains DNA encapsulated in a biodegradable polymer. Examples of a suitable biodegradable polymer include chitosan and homo- or co-polymers of polylactic acid and polyglycolic acid. The invention thus further provides a method for
- 10 immunizing freshwater fish against *I. multifiliis* by administering to the fish a polynucleotide vaccine of the invention, preferably a DNA vaccine.

- The amount of polynucleotide vaccine to be administered to an animal depends on the type and size of animal, the condition being treated, and the nature of the polynucleotide, and can be readily determined by one of skill in the
- 15 art. In fish, for example, if the polynucleotide vaccine is to be injected, the amount per injection is preferably at least about 10 ng; at most it is preferably about 50 µg, more preferably it is less than about 1 µg. If the polynucleotide vaccine is to be administered using a gene gun, the amount per dose is preferably at least about 1 ng; at most it is preferably about 10 µg, more preferably it is less
- 20 than about 1 µg. For administration by immersion, the concentration of the polynucleotide in the aquatic medium is preferably at least about 10 ng/mL; at most it is preferably about 50 µg/mL, preferably it is less than about 1 µg/mL. For oral administration the amount per dose is preferably at least about 10 ng; at most it is preferably about 10 µg, preferably less than about 1 µg. In some
- 25 applications, one or more booster administrations of the vaccine at time periods subsequent to the initial administration are useful to create a higher level of immune response in the animal.

- In another aspect, the vaccine of the invention comprises an i-antigen polypeptide having amino acid sequence SEQ ID NO:6 or SEQ ID NO:7, an
- 30 antigenic analog, fragment, or modification of a polypeptide having SEQ ID NO:7, an antigenic analog or modification of a polypeptide having SEQ ID

NO:6, or an antigenic fragment of a polypeptide having SEQ ID NO:6 provided that the fragment includes at least a C-terminal portion of SEQ ID NO:6. This type of vaccine is referred to herein as a "protein subunit vaccine" even if it contains the entire i-antigen sequence. The i-antigen or antigenic analog, fragment, or modification thereof for use in the protein subunit vaccine of the invention can be naturally occurring (i.e., isolated from *I. multifiliis*) or recombinant. A protein subunit vaccine of the invention are conveniently administered to fish using bath immersion, ingestion, topical administration, or direct injection, preferably intraperitoneal or intramuscular injection. A protein subunit vaccine formulated for oral administration preferably contains polypeptide encapsulated in a biodegradable polymer as described above in connection with the polynucleotide vaccine of the invention. In addition, the protein subunit vaccine can be administered to an animal via a live vector, such as recombinant *Tetrahymena*. *Tetrahymena* can be transformed such that it expresses the i-antigen or antigenic analog, fragment, or modification thereof, either in the cytosol, as a transmembrane protein, as a GPI-anchored protein or as a secreted protein. Recombinant *Tetrahymena* can be injected into the animal or, in the case of an aquatic animal such as a fish, can be administered via immersion. Oral administration of *Tetrahymena* if also envisioned. The invention thus further provides a method for immunizing freshwater fish against *I. multifiliis* by administering to the fish a protein subunit vaccine of the invention.

The amount of protein subunit vaccine to be administered to an animal depends on the type and size of animal, the condition being treated, and the nature of the protein, and can be readily determined by one of skill in the art. In fish, for example, if the protein subunit vaccine is to be injected, the amount per injection is preferably between about 0.1 μg and about 1000 μg per 10g fish; more preferably it is between about 1 μg and about 100 μg per 10 g of fish. For administration by immersion, the concentration of the protein in the aquatic medium is preferably at least about 10 ng/mL; at most it is preferably about 50 $\mu\text{g/mL}$, preferably it is less than about 1 $\mu\text{g/mL}$. For oral administration the

amount per dose is preferably between about 0.1 µg and about 100 µg per 10g fish; more preferably it is between about 1 µg and about 10 µg per 10 g of fish. Preferably, the protein subunit vaccine also includes an adjuvant. Further, one or more boosters are preferably administered at time periods subsequent to the
5 initial administration to create a higher level of immune response in the animal.

In yet another aspect, the vaccine of the invention comprises a fusion protein comprising a carrier polypeptide and an i-antigen polypeptide of the invention or an analog, fragment, or modification thereof. An i-antigen analog, fragment, or modified i-antigen for use in this aspect of the invention can itself
10 be antigenic or nonantigenic; in embodiments wherein the i-antigen analog, fragment or modified i-antigen is nonantigenic, the carrier polypeptide provides the necessary antigenicity by stimulating the fish's immune system to react to the fusion protein thereby generating an immune response in fish against *I. multifiliis*. A nonantigenic analog, fragment, or modification of the i-antigen
15 thus function as a hapten. An example of an antigenic carrier polypeptide is KLH. Conventional fusion constructs between carriers such as glutathione sulfotransferase (GST) and i-antigens of the invention or antigenic analog, fragment, or modifications thereof are also included as protein subunit vaccines according to the invention, as are fusions of the i-antigen and an affinity tag such
20 as a polyhistidine sequence. A fusion construct may be preferred for use as a protein subunit vaccine when the antigenic i-antigen analog, fragment, or modification thereof is small. The invention further provides a method for immunizing freshwater fish against *I. multifiliis* by administering to the fish a fusion protein vaccine of the invention.

25 Monoclonal antibodies that recognize immobilizing epitopes on i-antigens are protective in passive immunization experiments, but their activity is serotype-specific. On the other hand, fish that are actively immune following exposure to one serotype are cross-protected against heterologous strains. Thus, in one embodiment, the vaccine of the invention (whether in the form of a
30 protein vaccine or a polynucleotide vaccine) is monovalent in that it is derived from a particular i-antigen from a particular serotype of *I. multifiliis* and effective

to treat or prevent infection of the vaccinated animal by that serotype.

Preferably, the monovalent vaccine contains at least one antigenic determinant that is shared by i-antigens of different serotypes, such that it also prevents infection by other *I. multifiliis* of other serotypes, thus offering broad protection.

- 5 In another embodiment, the vaccine of the invention (whether in the form of a protein vaccine or a polynucleotide vaccine) is a combined vaccine or a multivalent vaccine that prevents infection by other *I. multifiliis* of more than one serotype. The combined or multivalent vaccine can contain or encode, for example, a plurality of serotype-specific i-antigen polypeptides or antigenic
10 portions thereof, derived from multiple serotypes of *I. multifiliis*, or can contain or encode a synthetic or fusion i-antigen polypeptide containing multiple antigenic determinants that together generate an immune response against multiple serotypes of *I. multifiliis*.

- In a preferred embodiment of the vaccine of the invention, i-antigen or an
15 antigenic portion thereof is linked at its carboxy-terminus to at least two molecules of the C3d component of complement, using molecular cloning techniques. Preferably, the i-antigen or antigenic portion thereof is linked to about three molecules of the C3d component of complement. The C3d molecule can be either homologous or heterologous with respect to the species to be
20 vaccinated. Complement genes have been cloned and characterized in salmonids (J. Lambris et al., J. Immunol. 151:6123 (1993); J. Sunyer et al., Proc. Natl. Acad. Sci USA 93:8546 (1996)). For vaccinations of fish, the i-antigen or antigenic portion thereof is preferably linked to a salmonid C3d, such as trout C3d or catfish C3d. In the case of a protein subunit vaccine, the recombinant
25 protein is conveniently expressed in bacteria, then administered to fish. This technique has been shown to generate an increase in the immune response in mice (P. Dempsey et al., Science 271:48 (1996)). The receptor for C3d, namely CD21, is expressed primarily on B cells and the follicular dendritic cells of lymphoid tissues. In the case of a polynucleotide vaccine, a plasmid encoding a
30 fusion protein that incorporates an i-antigen or antigenic portion thereof, linked

at its carboxy-terminus to at least two molecules of the C3d component, is administered to the fish.

The active immune-stimulating ingredients are optionally mixed with excipients or diluents that are pharmaceutically acceptable as carriers and compatible with the active ingredient. The term "pharmaceutically acceptable carrier" refers to a carrier(s) that is "acceptable" in the sense of being compatible with the other ingredients of a composition and not deleterious to the recipient thereof. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the immune-stimulating composition (including vaccine) may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, and/or adjuvants which enhance the effectiveness of the immune-stimulating composition.

Fish that can be vaccinated against Ich infection include freshwater teleosts, preferably fish that are widely farmed in aquaculture including channel catfish, trout, salmon, tilapia and eels. The goal of vaccination against Ich infection is to elicit a population of lymphocytes, which upon subsequent exposure to the parasite proliferate and produce antibodies and/or effector cells specific to the parasite, resulting in protection against lethal infections. A vaccine effective for the prevention of Ich infection in freshwater fish is thus one which elicits the production of protective antibodies in a fish exposed to said vaccine. Those protective antibodies will prevent lethal infection of the vaccinated fish upon challenge with *I. multifiliis*. In the present invention, protective antibodies generated in the fish are specific for *I. multifiliis* i-antigens. Fish that can be immunized include ornamental and food fish.

The present invention further includes monoclonal or polyclonal antibodies, whether derived from fish, rodents, mammals, avians, or other organisms, that bind to the i-antigen proteins described herein, including antigenic analogs, fragments and modifications thereof. Production and isolation of monoclonal and polyclonal antibodies to a selected polypeptide sequence is routine in the art.

Sera from immune fish is known to confer passive immunity against both viral and bacterial pathogens when injected into non-immune fish (Hedrick et al. Trans. Amer. Fish Soc. 116:277 (1987); Viele et al. J. Fish Biol. 17:379 (1980)). We have carried out similar experiments in which mouse monoclonal antibodies specific for Ich i-antigen(s) of the A and D serotypes were transferred into non-immune 10-15 g catfish fingerlings. Monoclonal antibodies which have the ability to immobilize these serotypes *in vitro* conferred passive protection against the parasite *in vivo*. Fish weighing 10-15 g were injected intraperitoneally with 20 -200 µg of purified mouse monoclonal antibody (MAb) and challenged with infective theronts after 24 hours. A serotype (G1-specific) MAb included 10H3, 3H12, 8E11, 6A11 and 5A8; D serotype (G5 and G3-specific) MAb included G3-27 and G3-61. Animals injected with immobilizing MAb survived lethal infection while controls were completely overwhelmed. The passive protection achieved in the channel catfish model supports the use of i-antigen protein(s) as vaccines for eliciting active immunity (Lin et al., Inf. Immun. 4085-4090 (1996); see also He et al. (Aquaculture 158:1-10 (1997)).

Comparison of newly discovered amino acid sequences SEQ ID NO:6 (the G1 *I. multifiliis* isolate) and SEQ ID NO:7 (the G5 *I. multifiliis* isolate) shows regions of amino acid identity that were heretofore unknown and unpredictable, because the sequence of only one *I. multifiliis* i-antigen (i.e., the sequence encoded by the cDNA for the 48 kD protein, Clark et al. (Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992) was known. Fig. 3(a) shows regions of identity or high homology, which are boxed. It is expected that an oligonucleotide probe or primer having a sequence that encodes a conserved region of the i-antigens as identified herein will be useful for identifying additional i-antigens in *I. multifiliis* having other serotypes; molecular methods for constructing these probes and primers and using them to screen genomic libraries are routine in the art. For example, amino acid sequences at the N and C- termini are highly conserved (see Fig. 3(a)). The corresponding regions of the genes would likely serve as sites for the design of diagnostic PCR primers that could be used to amplify i-antigen sequences from any parasite isolate.

Moreover, using mouse monoclonal antibodies against the i-antigens, we have been able to define differences between parasite isolates, and have shown that protection following passive antibody transfer is strain (i.e., isolate) specific. Thus, the identification of additional i-antigens using nucleotide probes and
5 primers derived from conserved regions as described herein will likely provide amino acid and nucleotide sequence information that allows the production of additional serotype-specific i-antigen DNA and protein subunit vaccines.

Accordingly, the invention further provides for an oligonucleotide probe or primer (including its complement) having a nucleotide sequence encoding at
10 least a portion of an i-antigen conserved region as shown in Fig. 3(a) (boxed regions). Preferably, the oligonucleotide probes or primers are represented by nucleotide sequences that encode conserved *I. multifiliis* i-antigen regions of at least about eight amino acids in length, which conserved regions are selected from portions of SEQ ID NOs:90-100 (Fig. 3(a)) that contain at least about eight
15 amino acids. More preferably, the oligonucleotide probes or primers are represented by the sequences MKYNILLT (SEQ ID NO:36), FLSISLLF (SEQ ID NO:38), GTALDDGV (SEQ ID NO:46), AGTDTCT (SEQ ID NO:48), CTKKLTSGA (SEQ ID NO:50) and FAKFLSISL (SEQ ID NO:52). Further, the invention provides a method for identifying i-antigens in *I. multifiliis* by
20 using the oligonucleotide probe or primer of the invention to identify and isolate novel nucleotide sequences encoding other i-antigens, for example by probing a genomic DNA or cDNA library of an isolate of *I. multifiliis* or by conducting polymerase chain reaction. Vaccines that utilize the nucleotide and amino acid sequences of the i-antigens so discovered, which as a result are effective against
25 other serotypic variants of *I. multifiliis*, are also provided.

Knowledge of the i-antigen nucleotide and amino acid sequences set forth herein also opens up new possibilities for detecting, diagnosing and characterizing *Ichthyophthirius* in fish populations. For example, an oligonucleotide probe or primer based on a conserved region of the i-antigen
30 protein can be used to detect the presence of *Ichthyophthirius* in a fish or in water, and an oligonucleotide probe or primer based on a less conserved region

can be used to identify a specific *Ichthyophthirius* serotype. The invention therefore includes methods for detecting and characterizing *Ichthyophthirius*, for example in aquaculture facilities.

5 *Recombinant Expression of I-antigens*

As already noted, the principal difficulty associated with making a vaccine against *I. multifiliis* is the fact that this obligate parasite cannot be easily cultured. Thus, production of i-antigen in a recombinant system is highly desirable. Ciliated protozoans, however, including *Ichthyophthirius*, utilize
10 TAA and TAG as codons for the amino acid glutamine, while most other organisms recognize those as termination codons. Therefore, according to the invention, either the native nucleotide sequence is expressed in a ciliated protozoan, or the native nucleotide sequence is altered to use a universal glutamine codon (either CAG or CAA) in place of any TAA and TAG triplets
15 used in the native sequence.

Bacterial expression systems. Selection of a vector or plasmid backbone depends upon a variety of desired characteristics in the resulting construct, such as a selection marker, plasmid reproduction rate, and the like. Suitable plasmids for expression in *E. coli*, for example, include pUC(X), pKK223-3, pKK233-2,
20 pTrc99A, and pET-(X) wherein (X) denotes a vector family in which numerous constructs are available. pUC(X) vectors can be obtained from Pharmacia Biotech (Piscataway, NH) or Sigma Chemical Co. (St. Louis, MO). pKK223-3, pKK233-2 and pTrc99A can be obtained from Pharmacia Biotech. pET-(X) vectors can be obtained from Promega (Madison, WI) Stratagene (La Jolla, CA)
25 and Novagen (Madison, WI). To facilitate replication inside a host cell, the vector preferably includes an origin of replication (known as an "ori") or replicon. For example, ColE1 and P15A replicons are commonly used in plasmids that are to be propagated in *E. coli*.

The expression vector optionally includes a promoter sequence operably
30 linked to the nucleotide sequence encoding i-antigen protein. A promoter is a DNA fragment which causes transcription of genetic material. Transcription is

the formation of an RNA chain in accordance with the genetic information contained in the DNA. The invention is not limited by the use of any particular promoter, and a wide variety are known. Promoters act as regulatory signals that bind RNA polymerase in a cell to initiate transcription of a downstream (3'
5 direction) coding sequence. A promoter is "operably linked" to a nucleic acid sequence if it is does, or can be used to, control or regulate transcription of that nucleic acid sequence. The promoter used in the invention can be a constitutive or an inducible promoter. It can be, but need not be, heterologous with respect to the host cell. Preferred promoters for bacterial transformation include *lac*,
10 *lacUV5*, *tac*, *trc*, T7, SP6 and *ara*.

The nucleotide sequence encoding the i-antigen protein can advantageously be fused, at either the 5' or 3' end, to a nucleotide sequence encoding an affinity tag, such as a polyhistidine amino acid sequence. The resulting fusion construct can be conveniently purified using the affinity tag for
15 subsequent use. Affinity tags and methods for protein purification using affinity tags are well-known in the art. Optionally, a cleavage site, such as a Factor X cleavage site, can be introduced between the affinity tag and the amino acid sequence of the i-antigen to facilitate large-scale preparation of the i-antigen protein free of the carrier polypeptide.

20 The expression vector optionally includes a Shine Dalgarno site (i.e., a ribosome binding site), and a start site (e.g., the codon ATG) to initiate translation of the transcribed message to produce the enzyme. It can also include a termination sequence to end translation. A termination sequence is typically a codon for which there exists no corresponding aminoacyl-tRNA, thus ending
25 polypeptide synthesis. The nucleic acid fragment used to transform the host cell can optionally further include a transcription termination sequence. The *rrnB* terminators, which is a stretch of DNA that contains two terminators, T1 and T2, is the most commonly used terminator that is incorporated into bacterial expression systems (J. Brosius et al., *J. Mol. Biol.* 148:107-127 (1981)).

30 The TAA and TAG codons in the native coding sequence of the i-antigen can be substituted with conventional glutamine codons either by site-directed

mutagenesis (see e.g., Sambrook et al. (1989) Molecular Cloning, Second Edition, Cold Spring Harbor Laboratory Press, Plainview, NY) or by creating a synthetic coding sequence using chemical synthesis of the desired coding sequence. Manual DNA synthetic techniques are well known (see, e.g.,
5 Caruthers (1983) in Methodology of DNA and RNA Sequencing, Weissman (ed.), Praeger Publishers, New York, Chapter 1), as is automated DNA synthesis using any of several commercially available systems.

An alternative strategy is to express the i-antigen coding sequence with the UAA and UAG glutamine codons in a suppressor strain of *E. coli*. Cohen et
10 al. (J. Molec. Biol. 216:189-194 (1990)) has reported a plasmid vector (pAD205) which provides an inducible suppressor tRNA which recognizes UAA and UAG codons and which is charged with glutamic acid. The plasmid pAD205 contains the gene encoding the artificial suppressor tRNA^{glu} su oc205, previously described by Raftery et al. (EMBO J. 6:1499-1506 (1987)) which gene is
15 expressed in pAD205 under the regulatory control of an isopropyl- β -D-thiogalactopyranoside (IPTG)-inducible tac promoter. IPTG induces the expression of the tRNAs and thus allows the readthrough of UAG and UAA stop codons. Basal levels of the suppressor tRNAs are kept low by the presence of a leaky transcription termination signal between the promoter and the tRNA gene
20 to minimize potentially lethal effects on the cells. J. Cohen et al. (J. Mol. Biol. 216:189 (1990)) reported the expression of a *Paramecium* tubulin gene in *E. coli* using this vector.

Eukaryotic expression systems. The insect baculovirus vector, *Autographa californica*, is capable of high level expression of foreign gene
25 inserts and posttranslational modifications (see, e.g., International Patent Publication WO 90/14428). In terms of qualitative considerations, posttranslational modifications, including glycosylation, may be crucial in stimulating appropriate antigenic responses in vaccinated animals. In this regard yeast vectors can be useful since both glycosylation and secretion of foreign
30 proteins are possible (Innis et al., Science 228:21 (1985)). A commercially available system (Immunex Corp., Seattle, WA) which is advantageous from

both qualitative and quantitative standpoints has recently been described (Hopp et al., Biotechnology 6:1204 (1988)). This system allows both the detection and simplified purification of fusion proteins from yeast supernatants or *E. coli* extracts.

5 Protozoan expression systems. *Tetrahymena* is a ciliated protozoan which is taxonomically related to *I. multifiliis*. *T. thermophila* recognizes UAA and UAG codons as glutamine codons as does *I. multifiliis*. In addition, posttranslational modifications, particularly glycosylation, are expected to occur more normally in organisms related to *Ichthyophthirius* (for example,
10 *Tetrahymena*) than in procaryotes such as *E. coli*, or more distantly related eucaryotes. Because such modifications can play a critical role in immune recognition, *Tetrahymena* can have an advantage on this level as well. Vectors for and gene expression in *Tetrahymena thermophila* have been reported. For example, *T. thermophila* has been successfully transformed using self-
15 replicating palindromic ribosomal DNA (rDNA) purified from macronuclei (Brunk et al., Exp. Cell Res. 162:390 (1988)); Lovlie et al., Proc. Natl. Acad. Sci. USA 85:5156 (1988); Tondravi et al., Proc. Natl. Acad. Sci. USA 83:4369 (1986)). A selectable paromomycin resistance marker has been isolated and characterized; the resistant phenotype is due to a point mutation in the 17S
20 rRNA gene. Resistance to hydromycin is conferred by this mutation as well (Sprangler et al., J. Biol. Chem. 260:6334 (1985)). Subsequently shuttle vectors capable of autonomously replicating as plasmids in *Tetrahymena* as well as in *E. coli* have been developed (Yu et al., Proc. Natl. Acad. Sci. USA 86:8487 (1989)); Yu et al., Proc. Natl. Acad. Sci. USA 85:5151 (1988)). Such plasmids have
25 been stably maintained at high copy number for more than 65 generations, and there has been at least one homologous gene expressed from a *Tetrahymena* shuttle vector.

Successful expression of an Ich gene in *T. thermophila* allows the production of relatively large amounts of antigen in a purified form, at relatively
30 low cost. In addition to its use in the production of purified antigens, transformed *T. thermophila* can also be used as a live vector in the animal host,

as described above. This second approach provides the most efficient means of exposing fish to *I. multifiliis* surface antigens (short of infecting them with the live parasite itself). Up to 500,000 *T. thermophila* cells can be injected into the peritoneal cavity of 15 g channel catfish, where they survive for several days without causing adverse effects.

EXAMPLES

The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

Example 1

Isolation and Characterization of the *I. multifiliis* (G1 Isolate) Gene Encoding the 48 kD I-antigen

Parasite culture. *Ichthyophthirius multifiliis* (isolate G1) was maintained on juvenile channel catfish (*Ictalurus punctatus*) as previously described (H. Dickerson et al., *J. Euk. Microbiol.*, 40:816-820(1993)). Briefly, the infection is passaged on fingerling channel catfish by incubation of one infected fish with five uninfected fish in a 10 gallon aquarium. Fish were gently rubbed and host-associated trophonts that were released from the skin were allowed to adhere to the sides of collecting dishes. Cells were then washed once in carbon-filtered tap water and permitted to divide to form infective theronts (18-24 hours at 23°C). After filtration through 0.0015 inch wire mesh (Fisher Scientific, Pittsburgh, PA) cells were used for DNA isolation.

Genomic DNA isolation. Total DNA was obtained using a modification of procedures described by Kavenoff et al. (*Chromosoma*, 41:1-27 (1973)). Theronts were harvested by centrifugation at 1,000 X g for 2 minutes and the resulting cell pellet lysed in 2 volumes HET buffer (0.5 M EDTA, 0.01 M

Tris-HCl, pH 9.5) containing 1% SDS at 65°C. After 30 minutes, samples were cooled to 50°C and additional HET containing pronase (2 mg/ml) was added to bring the final volume to 4 times that of the original cell pellet. Lysates were incubated 4-6 hours, diluted with 0.5 vol 0.1 X SSC (0.1X SSC: 15 mM NaCl/1.5 mM sodium citrate, pH 7.0) and then extracted with an equal volume of phenol:chloroform:isoamyl alcohol (25:24:1). After separation from the aqueous layer, the organic phase was back-extracted with 0.5 volume of 10 mM Tris-HCl, 1 mM EDTA, pH 8.0 (TE) and the aqueous layers combined. Samples were re-extracted with phenol:chloroform:isoamyl alcohol (25:24:1) and chloroform:isoamyl alcohol (24:1), and nucleic acids were precipitated by addition of 2 volumes ethanol. The precipitate was collected by centrifugation at 10,000 x g for 15 minutes (4°C), washed in cold 70% ethanol and air dried. The pellet was dissolved in 2 X SSC containing 1 mM EDTA, and contaminating RNA was removed by digestion with 100 µg/ml RNase A (Promega) at 37°C for 1 hour. DNA was precipitated by addition of 2 volumes ethanol and collected by centrifugation as above. The pellet was washed for several hours in cold 70% ethanol and the DNA dissolved in TE to a final concentration of 50-250 µg/ml.

Genomic library construction. Total DNA (20 µg) was digested overnight at 37°C with the restriction endonuclease *Swa* I (4.2 units enzyme/µg DNA) (Boehringer-Mannheim Biochemicals, Indianapolis, IN). This enzyme has an 8 base pair recognition sequence containing all As and Ts. Because the non-coding regions of ciliate DNA are extremely A-T rich, *Swa* I cuts preferentially and relatively often in intergenic regions yielding roughly gene-sized pieces of DNA. After phenol extraction, restriction fragments were ethanol precipitated and dissolved in TE (10 mM Tris/1 mM EDTA pH 8.0. Potential staggered ends were repaired by incubation with T4 DNA polymerase (0.2 unit/µl for 30 minutes at 37°C) (Promega, Madison, WI), and small fragments (<271 base pairs (bp)) removed by chromatography on Sephacryl 400 (Amersham Pharmacia Biochemical, Piscataway NJ). Genomic DNA (average size ~ 1.5-3 kb) was combined with a 20-fold molar excess of 10_{mer} *Eco*R I

adaptors (e.g., Cat. No. C-1291, Promega) and the mixture incubated for 18 hours at 15°C in the presence of T4 DNA ligase (0.25 unit/μl) (Promega). T4 polynucleotide kinase (to 0.25 unit/μl; Promega) and ATP (to 10 nM) were added and the reactions incubated an additional 30 minutes at 37°C to phosphorylate adaptor ends. Fragments were phenol extracted and ethanol precipitated as above, and again fractionated on Sephacryl 400 to remove excess adaptors. Resulting DNA was then ligated with λZAP II arms (Stratagene, La Jolla, CA) which had been *EcoR* I digested and dephosphorylated. Ratios of insert to vector DNA were varied according to the recommendations of the manufacturer. Individual ligation reactions were packaged using Gigapack II packaging extracts (Stratagene) and libraries titered on *E. coli* XL1-Blue MRF' in the presence of X-gal and IPTG. A library containing 4 X 10⁵ phage plaques (> 90% white) was amplified and used for gene isolation.

Library Screening. The amplified library was plated at 5 X 10⁴ plaques/150 mm plate and the resulting phage particles lifted onto nylon filters (Micron Separations Inc., Westborough, MA) as described by Sambrook et al., 1989. A total of 8 filters were hybridized under conditions of high stringency (5X SSC at 68C overnight in 2% blocking reagent (Boehringer Mannheim Biochemicals, Indianapolis, IN), followed by two 5 minute washes in 2X SSC, 0.1% SDS, followed by two 15 minute washes in 0.5X SSC, 0.1% SDS at 68C) with a 1.2 kb cDNA probe against the 48 kD i-antigen (Clark et al. Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992)) labeled with digoxigenin (Genius System; Boehringer-Mannheim Biochemicals). This probe was previously shown to encode most of the 48 kD i-antigen of parasite isolate G1. Filters were reacted with an alkaline phosphatase-tagged anti-digoxigenin antibody (Boehringer-Mannheim Biochemicals) and developed with CSPD chemiluminescent substrate (Tropix). Twelve positive clones were isolated and subjected to two rounds of plaque purification, wherein a positive clone is selected, diluted, replated and rescreened. Inserts were then subcloned into pBluescript SK(-) by *in vivo* excision in the presence R408 helper phage (Stratagene). Plasmid DNA was purified from bacterial cultures by alkaline

lysis and anion-exchange chromatography using modified silicagel resins (Qiagen, Valencia, CA). Cloned inserts were mapped by digestion with appropriate restriction enzymes using techniques known to one of skill in the art (see, for instance, Sambrook et al., 1989). All positive recombinants contained a
5 3.3 kb *Swa* I fragment. A restriction map of the cloned insert from one recombinant (GL3-8) is shown in Fig. 6. Both strands of the region extending from the left end through the distal *Eco*R I site of the insert were subjected to nucleotide sequencing. DNA sequencing was performed with a Perkin Elmer/Applied Biosystems Division 377 automated DNA sequencer using dye
10 terminator chemistry and AmpliTaq-FS DNA polymerase (Perkin Elmer, Norwalk, CT). Sequence analysis showed that the insert encoded the entire 48 kD i-antigen.

Transcript Mapping. The 5' end of i-antigen transcripts were mapped by primer-extension analysis. Briefly, 10 pM of antisense primer H4
15 (AGCAGCACCTACATCAGTCAATCC, SEQ ID NO:21) complimentary to a sequence near the putative ATG start codon of the 48 kD i-antigen gene (nucleotides +94-117), was end-labeled with $\gamma^{32}\text{P}$ (Amersham, Arlington Heights, IL) in the presence of T4 polynucleotide kinase (10 units; Promega) (Sambrook et al., 1989). The labeled primer (2 pM) was hybridized with 10 μg
20 total RNA from *I. multifiliis* theronts (G1 isolate) and extended at 42° for 1.5 hours in the presence of AMV reverse transcriptase (26 Units; Boehringer-Mannheim). Mussel glycogen was added as a carrier (200 $\mu\text{g}/\text{ml}$; Boehringer-Mannheim) and the extension product was precipitated by addition of 0.5 volume 7.5 M ammonium acetate and 2.5 volumes ethanol. Following
25 centrifugation (14,000 X g for 10 minutes), the pellet was air dried and dissolved in H_2O . The size of primer extension products was determined relative to a ^{32}P -labeled sequencing ladder run on parallel lanes of a 6% polyacrylamide/urea sequencing gel. The ladder was prepared in a dideoxy sequencing reaction (Sequenase kit; United States Biochemicals) using single-stranded M13mp18
30 DNA as a template, and M13 universal primer GTAAAACGACGGCCAGT (SEQ ID NO:22) labeled with ^{32}P . After electrophoresis, gels were fixed, dried

and autoradiographed for visualization of labeled DNA fragments (Sambrook et al., 1989).

The 3' ends of i-antigen transcripts were mapped using the RACE (rapid amplification of cDNA ends) protocol (M. Frohman, In RACE: Rapid amplification of cDNA ends. In: PCR Protocols: A Guide to Methods and Applications, Innis, M. A., et al., (eds.) Academic Press, San Diego, pp. 28-38 (1990)). Total RNA was prepared from *I. multifiliis* (G1) theronts by lysis in guanidine thiocyanate, and poly(A)⁺ mRNA was purified by two rounds of chromatography on oligo(dT)-cellulose (Clark et al. Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992)). First-strand cDNA was then prepared from 1 µg poly(A)⁺ RNA, using 25 pmol of primer EPBdT₁₈ (GCGAATTCTGCAGGATCCAACT₁₈, SEQ ID NO:23); kindly provided by Dr. Royal McGraw, University of Georgia), and AMV reverse transcriptase (0.25 unit/µl; Boehringer-Mannheim) (Sambrook et al., 1989). Following incubation at 42°C for 2 hours, a fraction of the first-strand product was used as template in a second-round PCR reaction containing either of two forward primers, namely, ICH5 (GTGTCGACAGCAGGTACTGATACATG, SEQ ID NO:24) or H5 (CGAAAACAGTGGTGGTAGTACCTT, SEQ ID NO:25) in combination with the reverse primer, EPB (GCGAATTCTGCAGGATCCAAAC, SEQ ID NO:26). The ICH5 primer corresponded to a region of the gene that lay proximal to the breakpoint between the gene and 1.2 kb cDNA sequence, while H5 corresponded to a region of the 1.2 kb cDNA that lay distal to that site. PCR was carried out under standard conditions using 20 pmol primer/100 µl reaction and 5 U *Taq* DNA polymerase (Promega) (1 minute at 94°C, 1 minute at 52°C, 1 minute at 72°C; 30 cycles). The ICH5/EPB product was electrophoresed on a 1.4% agarose gel and ran as a broad band of ~295-375 bp. DNA was eluted from the gel, digested with *Sal* I and *Eco*R I, and then directionally cloned into pBluescript SK(-) for subsequent sequence analysis.

cDNA Clones. A λZAP II cDNA library prepared from *I. multifiliis* trophont RNA was screened with a ³²P-labeled 24_{mer} oligonucleotide (5'-

AGCAGCACCA ACATCAGTCA AACC, SEQ ID NO:27) encoding eight amino acids near the N-terminus of the 48 kD i-antigen, as previously described (Clark et al. Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992)). In addition to a clone that provided the 1.2 kb i-antigen cDNA (designated 2-3), the library
5 screen yielded several additional positive recombinants. Two such clones (designated 1-1 and 1-3) were chosen for sequence analysis. cDNA inserts were subcloned into pBluescript SK(-), and plasmid DNA sequenced on the positive strand using the ICH5 primer.

Southern blotting analysis. 5' and 3'-specific probes were generated
10 using the polymerase chain reaction. The 5'-specific probe was a 475 bp fragment spanning nucleotides +188-662 of the gene and was amplified using the 1.2 kb cDNA as a template in conjunction with the forward and reverse primers, ATGGTAATTAACCTTTCGCAGCAAATAA (SEQ ID NO:28) and GGTCTGCATTTAACACATAA (SEQ ID NO:29), respectively. The 3'-
15 specific probe was a 495 bp fragment amplified from genomic DNA using H5 as the forward primer, and the reverse primer AGATACATCAGTATACGAAA (SEQ ID NO:30). The later sequence was derived from the H5/EPB RACE product. Probes were purified by agarose gel electrophoresis, and labeled using random oligonucleotide synthesis (High Prime DNA labelling kit™;
20 Boehringer-Mannheim) in the presence of $\alpha^{32}\text{P}$ -dCTP (Amersham). Genomic DNA (5 μg) from *I. multifiliis* theronts (G1 isolate) was digested with either *EcoR* I, *Hind* III or *Swa* I, fractionated on a 0.7% agarose gel and transferred to nylon. The filter was then hybridized with probes specific for either the 5' or 3' ends of the 1.2 kb cDNA in separate reactions. The probes were radiolabeled to
25 10^9 cpm/ μg and used at 10^6 cpm/mL. Hybridization was carried out under conditions of high stringency (washed overnight in 6X SSC, 10X Denhardt's reagent, 0.1% SDS, 10 $\mu\text{g}/\text{mL}$ denatured herring sperm DNA at 65C; followed by one 15 minute wash at room temperature in 2X SSC, 0.1% SDS, followed by one 15 minute wash at 65C in 2X SSC, 0.1% SDS, followed by one 15 minute
30 wash at 65C in 0.5X SSC, 0.1% SDS, followed by one 15 minute wash at 65C

in 0.2X SSC, 0.1% SDS) as previously described (Clark et al. Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992)).

Comparisons between gene and cDNA sequences. Results of nucleotide sequencing reactions were compiled and analyzed using *DNASIS* software (version 2.0; Hitachi Software Engineering, Yokohama, Japan). When the nucleotide sequence of the 1.2 kb cDNA used as a probe in this study was compared with the coding region of the 48 kD i-antigen gene, a number of differences were observed. These included two single-base substitutions (nucleotides +781 and 952), as well as complete divergence in the region distal to nucleotide +1227 (nucleotide 1172 of the cDNA). To determine whether these differences were real, the 1.2 kb i-antigen cDNA was resequenced and found an error at position +781 (position 726 of the cDNA should read A rather than C as originally reported) (GenBank accession no. M92907 updated). The transversion at nucleotide 952, and the divergent sequence at the 3' end of the cDNA were, nevertheless, confirmed.

As indicated in Fig. 7, these differences would result in an amino acid substitution at position 318 (phenylalanine for leucine), and an entirely different sequence at the carboxy-terminus of the gene product. Specifically, the cDNA product would lack the C-terminal hydrophobic amino acid residues specified by the gene. Hydrophobic domains at the C-termini of GPI-anchored proteins are necessary for covalent attachment of glycosylphosphatidylinositol moieties (P. Englund, Annu. Rev. Biochem., 62:121-138 (1993)), and the deletion of relevant coding sequences from transgenes that encode such proteins usually results in secretion rather than membrane binding. Furthermore, there are a number of instances in which alternative splicing of endogenous mRNAs gives rise to transcripts that either specify, or fail to encode hydrophobic C-terminal peptides (I. Caras et al., Nature, 325:545-548 (1987); H. Gower et al., Cell, 55:955-964(1988)). In the first case, such products are retained at the plasma membrane (as GPI-anchored proteins), while in the second, they are exported from the cell. Both secreted and membrane bound forms of a 48 kDa i-antigen have been described in *I. multifiliis* (C. Xu et al., J. Euk. Microbiol., 42:558-564 (1995)).

It should also be noted that the parasite isolate designated G1 contains a second i-antigen gene believed to encode an antigenically related 60 kDa protein (T. Clark et al., Annu. Rev. Fish Dis., 5:113-131 (1995)); this gene is recognized by the 5'-specific probe used in this study and appears as a 5 kb fragment in the
5 *Swa* I digest as discussed below. The 3'-specific probe fails to recognize this fragment indicating that the 1.2 kb cDNA is not a product of this gene.

Interestingly, when the 3'-end of i-antigen transcripts were mapped by RACE using a sense primer upstream of nucleotide +1227 (primer ICH5), the resulting PCR product had essentially the same sequence as the gene (Fig. 6).

10 Consistent with this observation, two independent i-antigen cDNAs were isolated from the same library used to prepare the 1.2 kb probe and found that these contained the same sequence as the gene at their 3' ends (Fig. 6). By contrast, when a sense primer corresponding to the 1.2 kb cDNA downstream of nucleotide 1172 (primer H5; see herein) was used, the RACE product that was
15 generated was much larger than expected (~600 bp) and had a sequence entirely different from that of the gene. Furthermore, it was not possible to generate PCR products with genomic DNA as a template in standard reactions using sense and antisense primer pairs that flanked nucleotide 1172 of the 1.2 kb cDNA.

20 Since this suggested that the sequences on either side of nucleotide 1172 were discontinuous within the genome, Southern hybridization analysis was carried out using probes described above corresponding to 5' and 3' regions of the 1.2 cDNA. The restriction fragments recognized by the two probes were different. A 3.3 kb band recognized by the 5'-specific probe in the *Swa* I digest
25 corresponded to the genomic DNA fragment described herein. A larger (5 kb) band was also observed, which may represent the gene for a related 60 kD i-antigen expressed by the G1 isolate (Clark et al., Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992); T.Clark et al., Annu. Rev. Fish Dis., 5:113-131 (1995)).

Example 2**Identification of the Open Reading Frame
and Analysis of the Deduced 48 kD I-antigen Sequence from *I. multifiliis*
(G1 Isolate)**

5

Computer-based sequence analysis. Homology searches were performed at the ISREC World Wide Web server (Swiss Institute for Experimental Cancer Research) using the BLAST network service (BLAST, basic local alignment search tool; WU-BLAST server version 2.0a13) and the

10 SwissProt+Trembl+TrUpdates peptide sequence databases. Predictions of potential signal peptides and their cleavage sites were made using the Signalp World Wide Web server (<http://www.cbs.dtu.dk/services/SignalP/>) version 1.0. Peptide mass was determined using the PEPTIDE MASS tool accessed through the ExPASy molecular biology World Wide Web server of the Swiss Institute of
15 Bioinformatics (<http://expasy.hcuge.ch/sprot/peptide-mass.html>). Amino acid sequence alignment was carried out using the CLUSTALW (1.74) multiple sequence alignment program accessed through the ExPASy web server.

Identification of the open reading frame. The cDNA used to screen the genomic library in Example 1 begins with a 5'-terminal G that lies several
20 nucleotides upstream of a valine codon (GTT) marking the N-terminus of the mature 48 kD i-antigen (Clark et al., Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992)). This G residue corresponds to nucleotide +56 of the genomic DNA sequence shown in Fig. 1. Translating downstream from this nucleotide (and in-frame with the original cDNA), the gene was found to contain a single,
25 uninterrupted reading frame extending through nucleotide +1326, followed by two adjacent TGA stop codons. *I. multifiliis*, along with other hymenostomatid ciliates, utilize TGA as the only stop codon; the standard TAA and TAG triplets specify glutamine instead.

Translating in the opposite direction, the region immediately upstream of
30 the 5'-terminus of the cDNA was found to encode a methionine (predicted by the ATG triplet at nucleotides +1-3), followed by a stretch of 19 mostly

hydrophobic amino acids. The hydrophobic nature of these amino acids (along with the fact that the i-antigens are membrane polypeptides) would suggest that this region specifies a signal peptide that targets the protein to the plasma membrane. To investigate this further, neural network algorithms trained on
5 signal peptides and their cleavage sites (H. Nielsen et al., Prot. Engin., 10:1-6 (1997)) were used to examine the first 50 amino acids of the deduced protein sequence beginning with the methionine residue cited above. Such algorithms identified the first 20 amino acids as a signal peptide (S mean = 0.839), and predicted a cleavage site between the alanine and valine residues (amino acids
10 20 and 21, respectively) of the deduced amino acid sequence. The N-terminal amino acid of the 48 kD antigen protein corresponds to the valine residue predicted above (Clark et al., Proc. Nat. Acad. Sci. USA, 89:6363-6367 (1992)). Taken together, these observations argue strongly that amino acids 1-20 of the deduced protein constitute a signal peptide.

15 Assignment of the methionine residue (amino acid position 1) as the start site of the 48 kD protein is also supported by the results of primer extension analysis on polyA⁺ RNA from the infective theronts. I-antigen transcripts appear to initiate at two sites located -33 and -34 nucleotides upstream of the A nucleotide of the methionine codon. Because no other ATG triplets are
20 predicted within this region, the methionine residue at position 1 almost certainly represents the translational start site of the protein itself. Based on these considerations, the coding region of the gene extends 1326 nucleotides and specifies a protein precursor of 442 amino acids having a theoretical MW_r (molecular mass) of 45,025 daltons. The gene is designated *LAG48[G1]*. A
25 total of 23 UAA and UAG triplets (encoding glutamine in *I. multifiliis* but functioning as stop codons in most other eukaryotes and prokaryotes) are present within *LAG48[G1]*.

Curiously, the third position of the codons shared a strong preference for either A or T (84.9%). While the significance of this is not understood, such
30 bias appears to be a common feature of i-antigen genes (D. Martindale, J. Protozool., 36:29-34 (1989); J. Deak et al., Gene, 164:163-166 (1995)) and may

reflect important constraints on RNA structure. The polyA tract at the 3' end of the RACE product, shown in Fig. 7, most likely represents the site at which polyadenylation of *LAG48[G1]* mRNA occurs. Based on this (and assuming an average length of 100-200 nt for the polyA tail), the predicted size of RNA transcripts from this gene would be in the range of 1,543-1643 nt.

Amino acid sequence motifs. Analysis of the deduced protein sequence of the gene revealed a minor discrepancy between the predicted mass of the preprocessed protein (45 kDa), and the size of the mature i-antigen based on SDS-PAGE (48 kDa) (T. Clark et al., Annu. Rev. Fish Dis., 5:113-131 (1995)). Potential secondary modifications could appreciably alter the electrophoretic mobility of the processed protein. Furthermore, structural anomalies associated with repetitive sequence motifs could lead to incorrect estimates of size based on SDS-PAGE.

This aside, the most interesting structural features of the deduced protein are hydrophobic regions at the N- and C- terminus, a consensus P-loop domain, and tandemly repetitive cysteine-rich motifs. A stretch of 14 mostly hydrophobic amino acids separated from a short spacer from three small amino acids (-Cys-Ala-Ser-) was predicted at the extreme carboxy-terminus of the protein (Fig. 1). This type of sequence is highly characteristic of an addition site for a glycosylphosphatidylinositol (GPI) anchor (P. Englund, Annu. Rev. Biochem., 62:121-138 (1993)). Other evidence shows that the 48 kD i-antigen is, in fact, GPI-anchored. The hydrophobic region at the amino-terminus of the protein is consistent with i-antigens being membrane associated proteins; presumably, the N-terminus targets the protein to the endoplasmic reticulum. The P-loop domain at position 316-323 [Gly-[Xaa₄]-Gly-Lys-Ser] (SEQ ID NO:34) may or may not be significant. While this type of structure is generally associated with proteins that bind ATP or GTP, the presence of such motifs does not insure a role in nucleotide binding (M. Saraste et al., Trends Biochem. Sci., 15:430-434 (1990)). Indeed, proteins with closest similarity to the 48 kDa i-antigen in terms of primary structure (i.e., the *Lembadion* L-factor, *Tetrahymena* SerH, and *Giardia* VSP surface antigens) all lack a consensus phosphate-binding

loop. Instead, these proteins, like the deduced 48 kD i-antigen, have numerous Cys-Xaa_{2,3}-Cys (SEQ ID NO:31, 32) motifs embedded within higher order tandemly repeated amino acid sequence domains.

Repetitive sequence domains. Beginning with a cysteine residue at position 23, five homologous segments with an average of 80 amino acids each were identified within the deduced 48 kD i-antigen protein sequence (Fig. 5(a)). Adjacent repeats had the greatest degree of homology, with the second and third being ~ 90% identical. As shown in Fig. 5(a) and (b), the repeats are characterized by 6 invariant cysteines that fall into register when the segments are aligned. The predominant spacing between cysteines has the order Cys-Xaa_{2,3}-Cys (SEQ ID NO:31, 32). There are 14 such motifs in the 48 kD i-antigen protein sequence, as well as 4 larger elements having the order, Cys-Xaa₂-Cys-Xaa₂₀-Cys-Xaa₃-Cys-Xaa₂₀-Cys-Xaa₂-Cys (SEQ ID NO:34). The spacing between the last cysteine of each repeat, and the first cysteine of the next repeat is Cys-Xaa₃-Cys (SEQ ID NO:32).

Cysteine motifs with the order Cys-Xaa_{2,3}-Cys (SEQ ID NO:31, 32) are common to a large and diverse family of proteins that bind zinc and other metal ions (J. Berg et al., *Science*, 271:1081-1085 (1996)). A search of the SWISS-PROT/TrEMBL database showed similarities (smallest sum probability level 2.8e-06) between the 48 kD i-antigen and several other entries, five of which were protozoan membrane proteins. These included the SerH immobilization antigen of the free-living ciliate *Tetrahymena thermophila* (accession no. Q27197), a putative membrane protein (L-factor) from the predatory ciliate *Lembadion bullinum* (accession no. Q94589), and three variant-specific surface proteins (VSPs) of the mammalian gut parasite, *Giardia lamblia* (accession nos. Q24977; Q24970; P21849). Homologies with two additional entries (an antifreeze protein from Arctic cod [accession no. Q13028], and the product of an unidentified gene from *Caenorhabditis elegans* [accession no. Q17084]) were considered less significant because of unusual bias in the amino acid composition of these proteins. With regard to the protozoan membrane proteins, all contained numerous Cys-Xaa_{2,3}-Cys (SEQ ID NO:31, 32) motifs. The

product of the *Giardia* vspA6-S1 gene (accession no. Q24970) showed the greatest similarity to the 48 kD i-antigen in terms of the overall spacing of these motifs, with 29 of a possible 30 cysteine residues in the *I. multifiliis* protein overlapping with the identical amino acid in the vspA6-S1 gene product (Fig. 8).

- 5 This region has eight Cys-Xaa_{2,3}-Cys (SEQ ID NO:31, 32) motifs that do not align with similar domains in the *I. multifiliis* polypeptide.

Example 3

10 Identification of an *I. multifiliis* (G5 Isolate) Gene Encoding a 55 kD I-antigen

Construction of G5 cDNA library. A G5 cDNA library was made as follows. First-strand cDNA synthesis was primed with a 20-fold molar excess of oligodT₁₈ in a reaction containing 5 µg of polyA⁺ RNA from *I. multifiliis* theronts (strain G5) and AMV reverse transcriptase as described by Krug et al. (Meth. Enzymol.152:316-325 (1987)). Second-strand synthesis was carried out in the presence of DNA polymerase I and Rnase H, followed by hairpin loop cleavage with mung bean nuclease as described by Gubler (Meth. Enzymol.152:330-335 (1987)). The second-strand product was size-fractionated and adaptors were added as in construction of the G1 genomic DNA library (Example 1). After removal of excess adaptors, material > 500 bp was cloned into the lambda phage vector λZAPIITM as for G1 genomic DNA.

20 Screening of the G5 cDNA library. The G5 cDNA library was first screened under conditions of reduced stringency with a digoxigenin-labelled probe corresponding to the coding region of the 48 kD i-antigen gene of parasite isolate G1. No positive clones were identified. Previous attempts to screen a custom-made genomic DNA library from another parasite isolate (G1.1) with the same probe had also resulted on no positive clones.

30 Degenerate PCR primers were then produced against the 5' and 3' ends of the 48 kD i-antigen gene. These primers, designated #35 and #37, corresponded to the 5' and 3' regions of the coding sequence of *LAG48[G1]*, and the primer

sequences were as follows: #35: ATGAAATA(C/T)AA(C/T)ATTTTATTAATT (SEQ ID NO:35), which is a 4-fold degenerate sense primer corresponding to all or part of the amino acid sequence MKYNILLT (SEQ ID NO:36) at the N-terminus of the *LAG48[G1]* gene product; and #37:

- 5 AAATAATAA(G / A)GAAAT(A / C)GATAAAAA (SEQ ID NO:37), which is a 4-fold degenerate antisense primer corresponding to all or part of the amino acid sequence FLSISLLF (SEQ ID NO:38) at the C-terminus of the *LAG48[G1]* gene product. PCR conditions were 30 cycles of 94° C for 1 minute, 52° C for 1 minute, 72° C, for 1 minute. A single band corresponding to an amplified i-
10 antigen coding region (55 kD) was expected. However, this reaction yielded several bands on agarose gels visible by ethidium staining, none of which had the expected size of a product from a gene encoding a 55 kD protein (Fig. 9).

- To determine which band, if any, corresponded to an amplified i-antigen coding region, the amplification products were Southern blotted and probed
15 under conditions of reduced stringency with a radiolabelled cDNA probe corresponding to the 48 kD i-antigen of isolate, i.e., radiolabelled *LAG48[G1]*. Hybridization conditions were 6X SSC (Denhardt's, SDS, herring sperm DNA) at 55° C overnight. Blots were washed in 2X SSC at RT (2 X 15 minutes), followed by 2X SSC at 55° C (2 X 15 minutes). The *LAG48[G1]* probe revealed
20 a band of about 1.1 kb on the blot.

- The amplification products were again resolved by agarose gel electrophoresis, the region of the gel corresponding to DNA fragments of approximately 1.1 kb was excised, and the fragment was labeled with ³²P-dCTP. The radiolabelled fragment was used to probe the G5 cDNA library under high
25 stringency conditions as for the G1 genomic DNA library (Example 1). A single positive clone containing a 1 kb cDNA insert was identified. On sequencing, this cDNA predicted a protein with all the hallmarks of an i-antigen, viz. tandemly repetitive amino acid sequence domains (approximately 80 amino acids each) containing 6 periodic cysteine residues (C-X_{2,3}-C motifs), in addition
30 to a stretch of hydrophobic amino acids at the C-terminus virtually identical to those predicted by the gene for the 48 kD antigen. The 1 kb cDNA was

nevertheless truncated and lacked the region coding for the N-terminal part of the protein.

RACE (Rapid Amplification of cDNA Ends) was carried out in an attempt to determine the missing 5' sequence. An antisense primer designated
 5 G5-11 (TGCTCGAGAATCTGTTGCTCCACCTG, SEQ ID NO:39) was used for first-strand cDNA synthesis, then a polyG tail was added and the resulting cDNA was amplified with the forward and reverse primers Q₀.

(CCAGTGAGCAGAGTGACGAGGACTCGAGCTCAAGCCCCCCCCCCCC
 CCCCC, SEQ ID NO:40) and, G5-11

10 (TGCTCGAGAATCTGTTGCTCCACCTG, (SEQ ID NO:39) respectively (PCR conditions: 1 cycle of 94° C for 3 minutes, 30° C for 2 minutes, 72° C for 40 minutes, then 30 cycles of 94° C for 45 seconds, 53° C for 45 seconds, 72° C for 90 seconds (e.g., Frohman, Meth. Enzymol. 218:340-356 (1993)). This was followed by a second round of (nested) PCR using the forward and reverse
 15 primers Q₁ (GAGGACTCGAGCTCAAGC, SEQ ID NO:41) and G5-12 (AACTCGAGTACCAGCAGGGCATTAAAC, SEQ ID NO:42), respectively (PCR conditions: 30 cycles of 94° C for 45 seconds, 53° C for 45 seconds, 72° C for 2 minutes). This produced a RACE product that approached the extreme 5' end of the coding region of the G5 gene (*LAG55(G5)*), but still failed to reach it;
 20 no ATG start codon was observed.

We then resorted to a procedure referred to as inverse PCR (see Fig. 10). Based on the known sequence of the 1 kb cDNA (the shaded bar in Fig. 10), two oppositely oriented primers, G5-11 (SEQ ID NO:39) and G5-4

(CACACCTTGTCCGGCAATTAAAC, SEQ ID NO:43) were designed and

25 used to amplify the regions flanking the 5'- and 3'-ends of the 1 kb cDNA.

Genomic DNA (1 µg) from the G5 parasite isolate was incubated with a variety of different restriction enzymes (including Afl II and Sma I) in separate 20 µl reactions for 6 hours. DNA fragments were brought to a volume of 200 µl in 1X DNA ligation buffer (Gibco-BRL Life Technologies, Gaithersburg, MD), then
 30 chloroform extracted and allowed to self-anneal at 22° C for 12 hours in the presence of T4 DNA ligase (40U) (Gibco-BRL). DNA was ethanol precipitated

and amplified using the forward and reverse primer pair G5-11 and G5-4 under the following conditions: 10 cycles of 94° C for 10 seconds, 60° C for 30 seconds, 68° C for 4 minutes, followed by 20 cycles of 94° C for 10 seconds, 60° C for 30 seconds, 68° C for 4 minutes (+ 20 seconds for each cycle). DNA
5 fragments of about 1.6 and about 1.9 kb were produced in the samples generated by the restriction enzymes Afl II and Swa I, respectively. The amplified products were cloned into the pCR-Script™ plasmid vector (Stratagene) and sequenced. Both clones contained the 5' end of the coding sequence of the 55 kDa i-antigen gene, along with additional sequences flanking the 5' and 3' ends
10 of the coding regions.

New forward and reverse primers were constructed based upon nucleotide sequences of the 5' and 3' regions flanking the 55 kD coding region, and these primers were used to amplify the entire coding region of the gene using G5 genomic DNA as a template. A comparison between the deduced
15 amino acid sequence encoded by the 48 kD i-antigen gene and the deduced amino acid sequence encoded by the 55 kD i-antigen gene, and of the coding regions of the two genes, is shown in Fig. 3.

Example 4

20 Glycolipid Anchoring of *I. multifiliis* (G5 Isolate) 55 kD I-antigen Protein

Membrane proteins from *I. multifiliis* (strain G5) were extracted with the non-ionic detergent Triton X-114. Following Triton extraction, detergent micelles (containing amphipathic proteins) were treated with a recombinant
25 GPI-phospholipase C (GPI-PLC) from African trypanosomes which cleaves the lipid anchor from GPI-linked membrane proteins. Fig 11, left panel, shows a Coomassie blue stained gel of the membrane proteins fractionated by SDS-PAGE. Lane (A) contains total detergent soluble membrane proteins. The prominent band at 55 kD represents the i-antigens of the G5 strain. Lane (B)
30 shows the detergent soluble membrane protein fraction after cleavage with GPI-PLC. Lane (C) contains proteins liberated into the aqueous phase after enzyme

treatment. Note the transfer of the 55 kD band from the detergent to the aqueous phase. Fig. 11, right panel, shows a Western Blot of fractions (A) and (C) reacted with an antibody conjugate that recognizes a cross-reacting determinant on the cleaved portion of the GPI-anchor that becomes exposed following enzyme treatment. Positive staining of a 55 kD band in lane (C) (but not A) argues strongly for GPI-linkage of *Ichthyophthirius* i-antigens with the plasma membrane.

Example 5

Recombinant Production of a 55 kD I-antigen Protein in *E. coli*

Synthesis of a synthetic gene. A synthetic G5 i-antigen gene sequence (SEQ ID NO:102, Fig. 2(b)) was constructed using a method known as DNA shuffling essentially as described by Stemmer, et al. (*Gene* 164:49-53 (1995)). Eighteen overlapping primers (primers 3201-3218, Fig. 12) spanning the entire length of the G5 i-antigen coding sequence were combined in a single tube at a final concentration of 5 μ M and allowed to assemble in a cycling reaction carried out 30 times at 94° C for 15 seconds, 52° C for 30 seconds and 70° C for 30 seconds (plus 10 additional seconds in each cycle). Following the assembly reaction, 2.5 μ l of the product was amplified with the original flanking primers (3201 and 3218) to produce a full-length synthetic gene. The resulting product was cloned and sequenced. Mutations arising from error-prone synthesis PCR were corrected by site-directed mutagenesis (Transformer Site-Directed Mutagenesis kit, Clontech Laboratories, Inc., Palo Alto, CA).

Synthesis of modified versions of the synthetic gene. Based on its deduced sequence, the 55 kD protein contains hydrophobic sequences at its N- and C-terminus that are presumed to target the protein to the plasma membrane (the N-terminal sequence acting as a signal peptide for ER localization, and the C-terminal sequence acting as a GPI-anchor cleavage and addition site). To determine whether different gene products might be processed differentially by the immune system following their expression in fish, we made two modified

versions of the gene, one lacking the GPI-anchor addition sequence and the other lacking the N-terminal signal peptide. Specifically, we wanted to determine whether the product of the C-terminal deletion might give rise to a stronger humoral immune response since it was expected be secreted from cells rather than be bound to the plasma membrane through a glycolipid anchor. Therefore, having made the synthetic gene for the 55 kD protein, we used PCR to construct the modified versions of the full-length gene. The first lacked the coding region for the signal peptide at the N-terminus (residues 1-20), and the second lacked the hydrophobic stretch at the extreme C-terminus of the protein (amino acids 453-468).

I-antigen protein production in *E. coli*. A recombinant version of the 55 kD *I. multifiliis* i-antigen protein of parasite isolate G5 (SEQ ID NO:7) was produced in *E. coli* strain XL-1 Blue using the plasmid expression vector pProEX™-1 (Gibco-BRL LifeSciences) into which a version (SEQ ID NO:53) of the synthetic gene (SEQ ID NO:5) had been inserted. This version (SEQ ID NO:53) was identical to SEQ ID NO:5 except that it contained a point mutation at nucleotide position 17 in the coding sequence (Fig.13), resulting in the substitution of a proline for a leucine at amino acid position 6 in the i-antigen protein sequence (L6P) (SEQ ID NO:54) (Fig. 14). Logarithmic cultures were incubated in IPTG to induce expression of the 55 kD antigen fused to a 6x-histidine tag and rTEV protease cleavage signal. Fig. 15 shows a Western blot of a 10% SDS-polyacrylamide gel on which equivalent amounts of bacterial protein from cells taken before (1) and above (2) induction with IPTG were run. The blot was reacted with monospecific rabbit antibodies against the 55 kD i-antigen of the G5 strain followed by goat anti-rabbit IgG couples to alkaline phosphatase. Color substrates were NBT and BCIP. Note the strong band at about 55 kD in the induced sample.

The modified versions of the synthetic gene that lacked membrane targeting sequences at their 5'- or 3'- ends were cloned into several procaryotic expression vectors containing IPTG-inducible promoters (pProEX-1 (Gibco), pET22b(+) (Novagen), pQE-16 (Qiagen) and pGEX-4P- I (Pharmacia)).

Recombinant proteins of the expected size that reacted strongly on Western blots with monospecific polyclonal antibodies against the 55 kDa antigen were produced in all bacterial transformants following the addition of IPTG.

5

Example 6

Immune Response of Catfish to Vaccination with *I. multifiliis* (G5 Isolate) 55 kD I-antigen Protein

It is known that naive fish are completely protected against infection by *I. multifiliis* following passive transfer of immobilizing murine monoclonal antibodies (mAbs). To test whether *I. multifiliis* i-antigens themselves can elicit protective immunity, vaccination trials were carried out with channel catfish (*Ictalurus punctatus*) immunized with 55 kD i-antigen purified by mAb affinity chromatography from *I. multifiliis* serotype D. Fifty channel catfish (each weighing 10-15 g) were immunized by two intraperitoneal (i.p.) injections (two weeks apart) consisting of 10 µg of purified 55 kD i-antigen of the *I. multifiliis* G5 isolate (i-Ag) in Freund's complete or incomplete adjuvant. The same number of negative control animals were immunized similarly with either an irrelevant 14 kDa *I. multifiliis* G5 protein (14kD) or bovine serum albumin (BSA). A fourth group of positive control fish was vaccinated by two i.p. injections of 8000 and 10,000 live G5 parasites (live *Ich*) without adjuvant (this treatment has previously been shown to elicit protective immunity). All groups were challenged with infective G5 theronts (15,000/fish) 8 weeks after the last injection. Seventy-two percent (72%) of fish immunized with the i-antigen and 59.2% of fish immunized with live parasites survived challenge (Fig. 16). All of the negative control animals died. In addition, there were significant differences ($P > 0.001$, Kruskal-Wallis one way ANOVA) between the median days to death of controls and the fish that died following immunization with i-antigen or live theronts.

30

In a separate trial, single i.p. injections of 10 µg of i-antigen mixed with either a CpG oligodeoxynucleotide (19-mer) adjuvant or Freund's complete

adjuvant provided 33% and 40% protection, respectively. Control fish immunized with i-antigen given with a non-CpG oligonucleotide or BSA with a CpG oligodeoxynucleotide all died following challenge.

5 Serum and mucus antibody production in vaccinated fishes corresponded with protection. These results demonstrate the efficacy of purified i-antigen with adjuvant in eliciting protective immunity following vaccination.

Example 7

10 Immune Response of Channel Catfish to Vaccination with *I. multifiliis* (G5 Isolate) 55kD I-antigen Plasmid Vaccine

Truncated versions of the 55kD i-antigen from *I. multifiliis* (G5 isolate) containing N-terminal and C-terminal deletions (Example 5), along with the full-length sequence, were cloned into the eucaryotic expression vector
15 pcDNA3.1 for use fish vaccine trials. Although we have not yet determined how the respective gene products localize in cultured fish cells, an equivalent C-terminal deletion in the gene for the 48 kD i-antigen from serotype A resulted in secretion of the corresponding protein following transformation of *T. thermophila* (Example 9, Fig. 17).

20 Groups of 10 fish were vaccinated by intramuscular injection with either 10, 1 or 0.1 µg of plasmid DNA (pcDNA3.1) containing either the full-length, N-terminal or C-terminal deletion of the synthetic 55 kDa i-antigen gene. A positive control group vaccinated with the purified antigen in Freund's complete adjuvant (see Example 6), and a negative control group injected with the
25 pcDNA3.1 containing the lacZ gene were included in the study. Sera were withdrawn from fish at two week intervals beginning 14 days after injection and antibody levels were determined by Western blotting and ELISA.

SDS-PAGE was carried out under both reducing and non-reducing conditions, and Western blots were probed with pooled antisera from the
30 different groups of fish. The 55 kD i-antigen from parasite isolate G5 was affinity purified and fractionated by SDS-PAGE under non-reducing conditions

(50 ng/lane). Protein was then transferred to PVDF membrane and reacted sequentially with pooled sera from fish vaccinated with pcDNA3.1 DNA vaccine constructs followed by a monoclonal antibody conjugate (alkaline phosphatase) against the heavy chain of channel catfish Ig. The Western blot is shown in Fig. 18. Lanes were probed with sera from fish immunized as follows: Lanes 1-3, 10, 1, and 0.1 µg full length gene construct, respectively; lanes 4-6: 10, 1, and 0.1 µg C-terminal deletion construct, respectively; lanes 7-9: 10, 1, and 0.1 µg N-terminal deletion construct, respectively; lane 10, 10 µg LacZ construct (negative control); lane 11, naive fish serum; lane 12, fish vaccinated with 20 µg affinity purified 55 kDa i-antigen (positive control). Sera from fish vaccinated with constructs harboring the C-terminal deletion (lanes 4-6) reacted positively with the 55 kD protein run under non-reducing conditions, as did sera from fish injected with the purified antigen itself (lane 12). In contrast, only weak signals were seen in equivalent blots of protein separated under reducing conditions, the one exception being with sera from fish injected with 10 µg of the full-length construct. These results suggest that antibodies against the product of the C-terminal deletion (and against the i-antigen itself) are directed primarily towards conformational epitopes, while those against the full-length protein are directed towards linear epitopes. Of further interest was the fact that the antibody response to the vector encoded antigens decreased over time and was not detectable by ELISA 6 weeks after vaccination.

The animals were challenged with lethal numbers of parasites (15,000 theronts per fish) 9 weeks after immunization. The percent survival in all groups injected with the i-antigen constructs was higher than that in the negative control (LacZ). Still, not all fish died in the LacZ control group, and because the number of fish injected was small, the relative differences between groups were statistically significant in only one case (Table 1). This experiment did not include a group of fish injected with PBS alone.

Table 1.

	Immunogen	LacZ	F10	F1	FOA	C10	C1	C0.1	N10	N1	N0.1	GSiAg
5	No- of fish challenged	9	9	10	10	9	10	10	9	10	10	10
	No. of fish survived	4	8	8	9	6	7	8	7	10	8	10
10	Survival %	44.4	88.9	80	90	66.7	70	80	77.8	100	80	100
	RSP	N.A.	50	44.5	50.1	33.4	57.7	44.5	42.9	55.6	44.5	55.6
	*MDD	14.0	17.0	14.5	16.0	20.3	12.3	21.0	10.5		21.0	
	±	±		±	±	±	±	±			±	
15	SD	4.5		13A	1.5	5.5	57	6.4			7.1	

Groups of fish were injected with 10, 1 or 0.1 µg pcDNA3.1 DNA containing the sequence for either the full-length 55 kD i-antigen (F10, F1, F0.1), the C-terminal deletion (C10, C11, C0.1), or the N-terminal deletion (N10, N1, N0.1). Two additional groups of fish were injected with plasmid DNA containing a LacZ insert (LacZ), and 20 µg the affinity purified 55kD protein (i-Ag). Fish were challenged 9 weeks after vaccination with 15,000 theronts per fish.

*Mean days to death + /-Standard Deviation: no significant difference between groups by One Way Anova,

**A significant difference in percent survival was seen between the negative control group (LacZ) and the test groups N I and G5 i-Ag (P<0.5).

Because animals were exposed to what should have been a lethal challenge, the fact that some fish survived in the group injected with the lacZ constructs might be interesting in light of recent evidence that methylated CpG motifs in bacterial DNA can stimulate both cytokine production and B-cell proliferation, and in some cases, can protect animals non-specifically against microbial pathogens.

Example 8**Construction of a Multivalent *I. multifiliis* Vaccine**

A multivalent vaccine vector is constructed based on the i-antigens of *I. multifiliis* serotype A or serotype D. The gene for the 48 kD i-antigen of serotype A has been isolated and the parasite itself is currently available for vaccine trials. If the 48 kD i-antigen is used, a synthetic copy of the gene equivalent to the one made for the 55 kD antigen (Example 5) is constructed. The construction is straightforward and involves the design and synthesis of overlapping oligonucleotides (-100 bp each) that span the coding region of the gene. The oligonucleotides are mixed at equimolar concentrations in a single reaction and allowed to assemble into the full-length sequence using a thermostable DNA polymerase (High Fidelity Expand enzyme, Roche). A fraction of the assembled product is then used as a template for amplification of the gene in a standard PCR reaction using flanking primers to drive the reaction. The resulting full-length product is gel-purified, cloned into pcDNA3.1 and sequenced. Errors in the sequence are corrected by *in vitro* mutagenesis according to the method of Deng et al. (*Anal. Biochem.* 200:81 (1992)) and the final version is tested as a DNA vaccine. A combined vaccine containing plasmid vectors for both the 48 and 55 kD i-antigens is also tested on fish challenged with serotype A and D.

Example 9**Immune Response of Channel Catfish to Live Vaccine:**

Transformed *Tetrahymena* Expressing Full-length or Truncated *I. multifiliis* (Serotype A) 48 kD I-antigen Protein and Heterologous Challenge with *I. multifiliis* (Serotype D)

The *LAG48[G1]* gene of *Ichthyophthirius multifiliis* G1 encodes the GPI anchored 48- kDa i-antigen. The extreme 3' region of the gene encodes a stretch of 14 mostly hydrophobic amino acids separated by a short spacer from three small amino acids (CAS). This sequence encodes the protein's GPI anchor

addition site. *Tetrahymena thermophila* cells transformed with the entire *LAG48[G1]* gene produce an intact i-antigen anchored to the cells' surface. *Tetrahymena* cells transformed with a modified *LAG48[G1]* gene construct lacking the 3' sequence which includes the GPI addition site would be expected to produce a truncated protein lacking the GPI anchor.

Tetrahymena cells were transformed with either the gene encoding the full-length *Ichthyophthirius* G1 48- kDa i-antigen protein, or a truncated version of the gene that encodes the i-antigen protein lacking 19 amino acids at the carboxy terminus. Transformants encoding the intact or C-terminal truncated i-antigen were grown in standard *Tetrahymena* growth medium. Cell pellets and supernatant fluids were collected at the time points indicated. I-antigen was detected in cell cytosol, cell membrane or cell culture supernatants by Western blots using rabbit antisera against affinity purified *Ichthyophthirius* G5 i-antigen (see Fig. 17). It is clearly seen that the truncated protein is secreted into the culture medium.

Groups of channel catfish (6 fish per group) were immunized by bath exposure (10^6 or 10^5 cells/fish) or intraperitoneal injection with *T. thermophila* transformants (10^6 , 10^5 , or 10^4 cells/fish) producing intact or truncated i-antigen. A third group of fish was immunized with membrane protein extracts (1 mg or 0.1 mg/fish) from *T. thermophila* producing the full length protein.

Immunization by bath exposure to Tetrahymena transformants. Two groups of fish (6 fish in each group) were immunized by bath exposure. The fish were exposed to either 10^6 or 10^5 cells /fish for a period of 24 hours. Two immunogens were used: 1) transformed *Tetrahymena* cells expressing the entire *Ichthyophthirius* G1 48-kDa protein, and 2) transformed cells secreting a truncated form of the i-antigen lacking the GPI anchor. Fish in the control group were exposed to *Tetrahymena* transformants expressing the *neoI* gene product. Fish were exposed twice at a 30 day interval and challenged 30-60 days after the last immunization with the G5 *Ichthyophthirius* isolate. There were no significant differences (z test) between test and control groups (see Table 2). Immunized fish were challenged with a heterologous strain (G5 isolate) of

Ichthyophthirius expressing a different i-antigen than that produced by the recombinant *Tetrahymena* used for vaccination. It is expected that challenge with a strain of *Ichthyophthirius* producing an i- antigen homologous to the G1 48 i-antigen would show increased levels of protection.

5

Table 2. Vaccination by bath exposure

Immunogen	Dose (cells/fish)	Number of fish challenged	Number of fish surviving	% survival	RSP ³	MDD ⁴ ± SD ⁵
Neo control	10 ⁶	5	2	40	N.A.	17.0 ± 1.0
TG1 ¹	10 ⁵	5	3	60	33.3	18.5 ± 2.1
TG1	10 ⁶	6	3	50	25.0	13.3 ± 4.9
sTG1 ²	10 ⁵	6	3	50	25.0	21.0 ± 4.6
sTG1	10 ⁶	6	4	66.7	40.0	17.0 ± 1.4

10

15

¹ *Tetrahymena* expressing intact membrane form of *Ichthyophthirius* G1 i-antigen.

² *Tetrahymena* secreting truncated form of G1 i-antigen.

³ Relative Survival Percent = 1 - (number of dead fish in test group/number of dead fish in control group) x 100%

20

⁴ Mean days to death

⁵ Standard deviation

25

Immunization by injection of Tetrahymena transformants. Fish in each group were injected intraperitoneally with 10⁶, 10⁵, or 10⁴ live transformed *Tetrahymena* cells/fish. The same immunogens and controls were tested as in the immersion vaccinations. Fish were injected two times at a 30 day interval, and challenged 21 days after the last immunization with G5 *Ichthyophthirius*. A greater degree of protection was elicited in immunized fish compared to controls (Table 3).

Table 3. Vaccination by injection

Immunogen	Dose (cells/fish)	Number of fish challenged	Number of fish surviving	% survival	RSP ³	MDD ⁴ ± SD ⁵
Neo control	10 ⁵	6	2	33.3	N.A.	15.3 ± 3.6
TG1 ¹	10 ⁶	5	3	60	44.5	19.0 ± 2.8
TG1	10 ⁵	5	4	80	58.4	15.0 ± 0.0
TG1	10 ⁴	6	2	33.3	0	14.0 ± 1.4
sTG1 ²	10 ⁶	6	5	83.3	50.0	21.0 ± 4.6
sTG1	10 ⁵	6	3	50.0	25.0	20.0 ± 5.7

¹ *Tetrahymena* expressing intact membrane form of *Ichthyophthirius* G1 i-antigen.

² *Tetrahymena* secreting truncated form of G1 i-antigen.

³ Relative Survival Percent = 1 - (number of dead fish in test group/number of dead fish in control group) x 100%

⁴ Mean days to death

⁵ Standard deviation

Serum antibody production. Fish serum antibody responses against recombinant G1 *Ichthyophthirius* i-antigen were determined by ELISA at 2, 4, and 6 weeks after immunization. Serum antibodies from immunized fish were detected with a sandwich ELISA technique that used wells coated with a cross-reactive rabbit antibody against *Ichthyophthirius* G5 i-antigen to capture recombinant G1 i- antigen produced in transformed *Tetrahymena*. Sera from test and control fish were added to wells and antibodies that bound to the captured i-antigen were detected using an alkaline phosphatase labeled mouse mAb against the immunoglobulin heavy chain of channel catfish. ELISA

controls consisted of antibody-coated wells reacted with membrane protein from *Tetrahymena* cells transformed with the *neol* gene.

Fish injected with *Tetrahymena* membrane protein produced high levels of serum antibody against the recombinant i-antigen. The antibody response elicited by fish immunized with live cells was almost an order of magnitude lower. The antibody response of fish immunized by bath or i.p. injection with live cells secreting recombinant i-antigen was approximately two-fold greater than the antibody response of fish immunized with *Tetrahymena* producing the membrane-bound, intact i-antigen. In Fig. 19, the differences in antibody production between fish immunized with the (a) membrane associated or (b) secreted form of the i-antigen are shown. These results suggest that live cells secreting antigen are more efficacious in eliciting the production of serum antibodies. The mucosal antibody response was not determined in these experiments.

Example 10

Immune Response of Channel Catfish to Live Vaccine:

Transformed *Tetrahymena* Expressing Full-length or Truncated *I. multifiliis* (Serotype A) 48 kD I-antigen Protein and Homologous Challenge with *I. multifiliis* (Serotype A)

Tetrahymena cells were transformed with either the entire *Ichthyophthirius* G1 48- kDa i-antigen protein, or a truncated gene sequence which encodes the i-antigen protein lacking 19 amino acids at the carboxy terminus as in Example 9.

Groups of channel catfish (70 fish per group) were vaccinated by intraperitoneal injection with 10^6 *T. thermophila* transformants producing intact or truncated i-antigen. A third group of fish (control group) was vaccinated with *T. thermophila* transformants expressing *neo*. No adjuvant was used in any of the vaccinations. The fish were boosted 2 weeks following the initial injection

and bled at 3 weeks following the initial injection. Sera from 3 fish per group were pooled.

A 96 well ELISA plate was seeded with a homologous strain (i.e., serotype A) of *I. multifiliis* (strain NY1, a G1 isolate), 200 cells per well. Fish sera were serially diluted and added to the wells, and the effect on the motility of *I. multifiliis* was observed. Immobilization of *I. multifiliis* was immediately evident at serum dilutions of 1:20, and at higher concentrations the organisms exhibited clumping (Fig. 20). Sera from the control group did not cause any change in motility of *I. multifiliis*.

As another control, additional wells were seeded with a heterologous strain of *I. multifiliis* (a G5 isolate). The motility of these organisms was not affected by sera from any of the groups of vaccinated fish, confirming that the immobilization epitopes on *I. multifiliis* i-antigens are highly specific.

For comparison, two other groups of fish were vaccinated with purified subunit proteins produced from recombinant *Tetrahymena* (either the full-length 48 kD i-antigen protein or the C-terminal truncated version). The subunit proteins were adjuvanted with Freund's Complete Adjuvant. In a plate assay similar to the one described above using the homologous strain of *I. multifiliis*, some immobilization was observed but not to the degree caused by the "live vaccine." This observation lends support to the expectation that the "live vaccine" will prove to be more efficacious than the analogous protein subunit vaccine.

Example 11

Degenerate Primers for Amplification of I-antigen Genes from Other Serotypes

Forward and reverse primers for amplifying i-antigen gene sequences from different parasite isolates were designed based on regions of homology discovered between the 48 kDa (G1 strain) and 55 kDa i-antigens (G5 strain) of *I. multifiliis*. Forward primer P2 was successfully used to amplify sequences

from a variety of different parasite isolates in combination with the reverse primers P3, P4 and P5. Primer sequences are as follows: P2:

CCGAATTCTCTGG(C/T)ACTGCACTTGATGATGGAG (SEQ ID NO:45),

which is 2-fold degenerate and corresponds to all or part of the amino acid

5 sequence GTALDDGV (SEQ ID NO:46); it contains an EcoR I restriction site for cloning purposes; P3: GTGGATCCAGTACATGTTACA(A/G)TACCTGC

(SEQ ID NO:47), which is 2-fold degenerate and corresponds to all or part of

the amino acid sequence AGTDTCT (SEQ ID NO:48); it contains a BamH I restriction site for cloning purposes; P4:

10 GTGGATCC(A/G)CCAGAAGTTAATTTTTTA(T/G)TAC (SEQ ID NO:49),

which is 4-fold degenerate and corresponds to all or part of the amino acid

sequence CTKKLTSGA (SEQ ID NO:50); it contains a BamH I site; and P5:

GTGGATCCAAGGAAAT(C/T)GATAAAAA(T/A)TTAGCG (SEQ ID

NO:51), which is 4-fold degenerate and corresponds to all or part of amino acid

15 sequence FAKFLSISL (SEQ ID NO:52); it contains a BamH I restriction site.

PCR amplification of i-antigen gene sequences was carried out under standard conditions (30 cycles at 94° C for 1 minute, 52° C for 1 minute, 72° C for 1 minute).

Fig. 21 shows PCR amplification of genomic DNA from several
20 serotypic variants using the P2/P4 primer pair. Amplification products were run on 1.5% agarose gel and stained with ethidium bromide. Multiple bands seen in some of the lanes may be due to amplification from more than a single i-antigen gene (serotype A, for example, has two i-antigen genes) or to mispriming from closely related sequences within tandem repeats of the same gene. The major
25 band in the lane containing G5 isolate DNA is precisely the expected size (~800 bp) based on the sequence of the 55 kD i-antigen gene. Among the ten isolates represented in Fig. 21, two belong to serotype A (G1 and G10) and four to serotype D (G3, US, G7, and JI). Isolates G1.1, G2 and 04 correspond to serotypes B, C and E, respectively (the CUI isolate has not yet been typed).

Example 12**Construction of an I-antigen/C3d DNA Vaccine**

Several distinct genes for the third component of trout complement have
5 been identified. Although unique from one another, they share the same coding
region for C3d (J. Sunyer et al., Proc. Natl. Acad. Sci USA 93, 8546 (1996)).
Preparation of the hybrid i-antigen/C3d construct is carried out as follows.
Three separate PCR reactions are performed to synthesize the basic elements of
the construct. The first reaction involves amplification of the 55 kDa i-antigen
10 gene using a forward primer that encodes restriction endonuclease cloning sites
and replaces the existing N-terminal signal peptide of the i-antigen with the
signal peptide of trout Ig. The reverse primer in this case contains restriction
sites as well, and omits the coding sequence for the last 15 amino acids at the C-
terminus of the protein (ordinarily, the C-terminus acts as a GPI-anchor addition
15 site). The second PCR reaction involves synthesis of the C3d fragment
containing appropriate restriction sites at its ends. The forward primer in this
case mutates the first cysteine in the C3d fragment to a serine (thereby assuring
correct disulfide bridging between cysteine residues within C3d.. The final PCR
reaction involves synthesis of a second C3d fragment containing a short linker
20 sequence (GS[G₄S]₂) (SEQ ID NO:101) at its C-terminus along with appropriate
restriction sites that allow cloning between the i-antigen sequence and the first
C3d PCR product. The template for synthesis of the C3d fragments is trout
genomic DNA. The entire construct is assembled by first cloning the PCR
product for the i-antigen gene into pcDNA3.1. The C3d products are inserted at
25 the 3' end of the i-antigen gene using restriction sites built into the fragments.
Following transformation of bacteria with the resulting construct, the vector is
directly sequenced to determine the number of C3d fragments in the hybrid, as
well as the accuracy of the overall sequence. The same basic strategy is
employed in the construction of a HEL (hen egg-white lysozyme)/C3d hybrid
30 control vaccine. The rationale for including the model antigen (HEL) in these
studies relates to the uncertainty associated with correct folding of the i-

antigen/C3d hybrid (and consequently the likelihood that it will induce the expected result). After correcting nucleotide sequence errors, groups of fish (in this case 20-50 g rainbow trout) are injected with varying amounts of either the i-antigen or HEL hybrid constructs and the antibody response is determined in plate ELISAs (as described in other Examples) using secondary antibody conjugates against trout Ig. Trout immunized with the i-antigen/C3d hybrid vaccine are also challenged with parasites of the G5 isolate to determine levels of protection.

Example 13

Oral Delivery of a DNA Vaccine

Oral delivery represents an extremely attractive alternative for administration of DNA vaccines, particularly in aquaculture species. Based on recent experiments in mice (D. Jones et al., Dev. Biol. Stand. 92:149 (1998); K. Roy et al., Nature Med. 3:387 (1999)) it may now be possible to administer genetic vaccines orally using biodegradable polymers. Fish are expected to be capable of developing cutaneous mucosal antibody responses against *Ichthyophthirius* following oral vaccination with vector-encoded antigens.

Juvenile channel catfish are vaccinated orally using i-antigen based DNA vaccines complexed with chitosan. Encapsulation is performed substantially in accordance with the method of K. Leong et al., (J. Controlled Release 53:183 (1998)). Briefly, chitosan (MW 390,000) is dissolved at a concentration of 0.02% in 25 mM sodium acetate, pH 5-7. After prewarming to 55°C, 100 µl aliquots are added to an equivalent volume of vector DNA (1 µg/ml) in sodium sulfate buffer at 55°C, and the mixture is vortexed rapidly for 20 seconds. Nanoparticles formed by complex coacervation are examined by scanning electron microscopy and the resulting preparations stored at room temperature. Preparations are combined with fish food and animals are fed the equivalent of 10- 100 µg plasmid. DNA. Antigen-specific antibody responses are determined

in cutaneous mucus and serum by ELISA, and positive fish are challenged with live theronts.

The complete disclosures of all patents, patent applications, publications,
5 and nucleic acid and protein database entries, including for example GenBank
accession numbers and EMBL accession numbers, that are cited herein are
hereby incorporated by reference as if individually incorporated. Various
modifications and alterations of this invention will become apparent to those
skilled in the art without departing from the scope and spirit of this invention,
10 and it should be understood that this invention is not to be unduly limited to the
illustrative embodiments set forth herein.

WHAT IS CLAIMED IS:

1. A nucleic acid molecule comprising a polynucleotide fragment having a nucleotide sequence that encodes at least a C-terminal portion of an i-antigen polypeptide having amino acid sequence SEQ ID NO:6.
2. The nucleic acid molecule of claim 2 comprising SEQ ID NO:1.
3. A nucleic acid molecule comprising a polynucleotide fragment having a nucleotide sequence that encodes at least an antigenic portion of an i-antigen polypeptide having amino acid sequence SEQ ID NO:7.
4. A nucleic acid molecule comprising a polynucleotide fragment having a nucleotide sequence that encodes at least one terminal portion of an i-antigen polypeptide having amino acid sequence SEQ ID NO:7.
5. The nucleic acid molecule of claim 4 comprising SEQ ID NO:3 or SEQ ID NO:5.
6. The nucleic acid molecule of claims 1, 3 or 4 that is a vector capable of expressing the polypeptide encoded by the nucleic acid sequence in a cell or an organism, wherein the cell or organism is selected from the group consisting of a bacterium, a protozoan, a yeast, an insect and an animal cell or organism.
7. The nucleic acid molecule of claim 6 that is capable of expressing the polypeptide encoded by the nucleic acid sequence in *E. coli*, *Pischia pastoris* or *Tetrahymena*.

8. A nucleic acid molecule encoding an antigenic polypeptide that shares a significant level of primary structure with at least one of a 55 kD i-antigen protein from a G5 isolate of *Ichthyophthirius* and a 48 kD i-antigen protein from a G1 isolate of *Ichthyophthirius*.
9. The nucleic acid molecule of claim 8 encoding an antigenic polypeptide that shares a significant level of primary structure with at least one of SEQ ID NO:6 and SEQ ID NO:7.
10. A nucleic acid molecule that is substantially complementary to the nucleic acid molecule of claims 1, 3, 4, or 8.
11. A nucleic acid molecule comprising a polynucleotide fragment that hybridizes to at least a portion of the complement of at least one of SEQ ID NO:1 or SEQ ID NO:3, under standard hybridization conditions, wherein the polynucleotide fragment encodes a polypeptide comprising at least a membrane targeting portion or an antigenic portion of an i-antigen protein.
12. A polypeptide selected from the group consisting of:
 - an i-antigen polypeptide having SEQ ID NO:6;
 - an i-antigen polypeptide having SEQ ID NO:7;
 - an analog or modification of an i-antigen polypeptide having SEQ ID NO:6;
 - a fragment of an i-antigen polypeptide having SEQ ID NO:6 wherein the fragment comprises at least a C-terminal portion of SEQ ID NO:6;
 - an analog or modification of an i-antigen polypeptide having SEQ ID NO:7;

a fragment of an i-antigen polypeptide having SEQ ID NO:7
wherein the fragment comprises at least at least one terminal portion of
SEQ ID NO:7; and

an antigenic fragment of an i-antigen polypeptide having SEQ ID
NO:7; and

an i-antigen polypeptide that shares a significant level of primary
structure with at least one of SEQ ID NO:6 and SEQ ID NO:7.

13. The polypeptide of claim 12 that is antigenic.
14. A composition for inducing an immune response in a fish comprising at least one component selected from the group consisting of (a) a polypeptide comprising an antigenic portion of an i-antigen polypeptide and (b) a nucleic acid molecule comprising a polynucleotide fragment having a nucleotide sequence encoding an antigenic portion of an i-antigen polypeptide.
15. The composition of claim 14 comprising a polypeptide of claim 13.
16. The composition of claim 14 comprising at least one of the nucleic acid molecules of claims 1, 3, 4, 8 or 10.
17. The composition of claim 14 wherein administration of the composition to fish prevents or controls *I. multifiliis* infection.
18. The composition of claim 14 comprising a nucleic acid molecule comprising a polynucleotide fragment having a nucleotide sequence encoding an antigenic portion of an i-antigen polypeptide linked at its carboxy-terminus to a plurality of molecules of the C3d component of complement.

19. The composition of claim 14 formulated for oral administration.
20. The composition of claim 19 wherein the polypeptide or nucleic acid molecule is encapsulated in a biodegradable polymer.
21. A host cell transformed with the nucleic acid molecule of claim 6.
22. A fish comprising the nucleic acid molecule of any of claims 1, 3 or 4.
23. Transformed *Tetrahymena* comprising the nucleic acid molecule of any of claims 1, 3 or 4.
24. An antibody capable of binding a polypeptide of claim 12.
25. A method for detecting *Ichthyophthirius* in an aquaculture comprising:
obtaining a sample containing nucleic acid from an aquaculture fish or an aquaculture water;
adding at least one primer oligonucleotide having a sequence complementary to at least a portion of SEQ ID NO:1 or SEQ ID NO:3 to the nucleic acid sample;
conducting a polymerase chain reaction amplification with the sample;
and analyzing the reaction mixture for the presence of a product amplified by the at least one oligonucleotide primer.
26. The method of claim 25 wherein the primer is capable of amplifying nucleotide sequences encoding i-antigens derived from least two different *I. multifiliis* serotypes.
27. The method of claim 26 wherein the primer has a nucleic acid sequence that encodes an amino acid sequence selected from the group consisting of MKYNILLT (SEQ ID NO:36), FLSISLLF (SEQ ID NO:38),

GTALDDGV (SEQ ID NO:46), AGTDTCT (SEQ ID NO:48),
CTKKLTSGA (SEQ ID NO:50) and FAKFLSISL (SEQ ID NO:52).

28. The method of claim 25 further comprising making an polynucleotide vaccine comprising at least a portion of the amplified product, wherein the portion of the amplified product encodes an antigenic polypeptide.
29. The method of claim 25 further comprising making a protein subunit vaccine comprising an antigenic polypeptide encoded by at least a portion of the amplified product.
30. The method of claims 28 or 29 further comprising administering the vaccine to fish to treat or prevent *Ichthyophthirius* infection.
31. A method for identifying an *I. multifiliis* serotype comprising:
providing a sample comprising an *I. multifiliis* nucleic acid molecule having a nucleotide sequence encoding an i-antigen;
adding to the sample at least one primer oligonucleotide having a sequence complementary to a unique region of an *I. multifiliis* nucleotide sequence encoding an i-antigen;
subjecting the sample to amplification conditions; and
analyzing the sample to determine the presence of a product amplified by the at least one oligonucleotide primer.
32. A method for inducing an immune response in a fish comprising administering to the fish the immunogenic composition of claim 14.
33. The method of claim 32 performed prophylactically in advance of exposure to *I. multifiliis*.

34. The method of claim 32 performed therapeutically while the fish is infected with *I. multifiliis*.
35. The method of claim 32 wherein administration is performed by injection, immersion, or oral ingestion.

1/27

48 KD G1 l-antigen : protein and nucleic acid sequences

SEQ ID NO: 6	SEQ ID NO: 2
+	
1	1
2	2
3	3
4	4
5	5
6	6
7	7
8	8
9	9
10	10
11	11
12	12
13	13
14	14
15	15
16	16
17	17
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31
32	32
33	33
34	34
35	35
36	36
37	37
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45
46	46
47	47
48	48
49	49
50	50
51	51
52	52
53	53
54	54
55	55
56	56
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66
67	67
68	68
69	69
70	70
71	71
72	72
73	73
74	74
75	75
76	76
77	77
78	78
79	79
80	80
81	81
82	82
83	83
84	84
85	85
86	86
87	87
88	88
89	89
90	90
91	91
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99
100	100
101	101
102	102
103	103
104	104
105	105
106	106
107	107
108	108
109	109
110	110
111	111
112	112
113	113
114	114
115	115
116	116
117	117
118	118
119	119
120	120
121	121
122	122
123	123
124	124
125	125
126	126
127	127
128	128
129	129
130	130
131	131
132	132
133	133
134	134
135	135
136	136
137	137
138	138
139	139
140	140
141	141
142	142
143	143
144	144
145	145
146	146
147	147
148	148
149	149
150	150
151	151
152	152
153	153
154	154
155	155
156	156
157	157
158	158
159	159
160	160
161	161
162	162
163	163
164	164
165	165
166	166
167	167
168	168
169	169
170	170
171	171
172	172
173	173
174	174
175	175
176	176
177	177
178	178
179	179
180	180
181	181
182	182
183	183
184	184
185	185
186	186
187	187
188	188
189	189
190	190
191	191
192	192
193	193
194	194
195	195
196	196
197	197
198	198
199	199
200	200
201	201
202	202
203	203
204	204
205	205
206	206
207	207
208	208
209	209
210	210
211	211
212	212
213	213
214	214
215	215
216	216
217	217
218	218
219	219
220	220
221	221
222	222
223	223
224	224
225	225
226	226
227	227
228	228
229	229
230	230
231	231
232	232
233	233
234	234
235	235
236	236
237	237
238	238
239	239
240	240
241	241
242	242
243	243
244	244
245	245
246	246
247	247
248	248
249	249
250	250
251	251
252	252
253	253
254	254
255	255
256	256
257	257
258	258
259	259
260	260
261	261
262	262
263	263
264	264
265	265
266	266
267	267
268	268
269	269
270	270
271	271
272	272
273	273
274	274
275	275
276	276
277	277
278	278
279	279
280	280
281	281
282	282
283	283
284	284
285	285
286	286
287	287
288	288
289	289
290	290
291	291
292	292
293	293
294	294
295	295
296	296
297	297
298	298
299	299
300	300
301	301
302	302
303	303
304	304
305	305
306	306
307	307
308	308
309	309
310	310
311	311
312	312
313	313
314	314
315	315
316	316
317	317
318	318
319	319
320	320
321	321
322	322
323	323
324	324
325	325
326	326
327	327
328	328
329	329
330	330
331	331
332	332
333	333
334	334
335	335
336	336
337	337
338	338
339	339
340	340
341	341
342	342
343	343
344	344
345	345
346	346
347	347
348	348
349	349
350	350
351	351
352	352
353	353
354	354
355	355
356	356
357	357
358	358
359	359
360	360
361	361
362	362
363	363
364	364
365	365
366	366
367	367
368	368
369	369
370	370
371	371
372	372
373	373
374	374
375	375
376	376
377	377
378	378
379	379
380	380
381	381
382	382
383	383
384	384
385	385
386	386
387	387
388	388
389	389
390	390
391	391
392	392
393	393
394	394
395	395
396	396
397	397
398	398
399	399
400	400
401	401
402	402
403	403
404	404
405	405
406	406
407	407
408	408
409	409
410	410
411	411
412	412
413	413
414	414
415	415
416	416
417	417
418	418
419	419
420	420
421	421
422	422
423	423
424	424
425	425
426	426
427	427
428	428
429	429
430	430
431	431
432	432
433	433
434	434
435	435
436	436
437	437
438	438
439	439
440	440
441	441
442	442
443	443
444	444
445	445
446	446
447	447
448	448
449	449
450	450
451	451
452	452
453	453
454	454
455	455
456	456
457	457
458	458
459	459
460	460
461	461
462	462
463	463
464	464
465	465
466	466
467	467
468	468
469	469
470	470
471	471
472	472
473	473
474	474
475	475
476	476
477	477
478	478
479	479
480	480
481	481
482	482
483	483
484	484
485	485
486	486
487	487
488	488
489	489
490	490
491	491
492	492
493	493
494	494
495	495
496	496
497	497
498	498
499	499
500	500
501	501
502	502
503	503
504	504
505	505
506	506
507	507
508	508
509	509
510	510
511	511
512	512
513	513
514	514
515	515
516	516
517	517
518	518
519	519
520	520
521	521
522	522
523	523
524	524
525	525
526	526
527	527
528	528
529	529
530	530
531	531
532	532
533	533
534	534
535	535
536	536
537	537
538	538
539	539
540	540
541	541
542	542
543	543
544	544
545	545
546	546
547	547
548	548
549	549
550	550
551	551
552	552
553	553
554	554
555	555
556	556
557	557
558	558
559	559
560	560
561	561
562	562

2/27

G5 Wild-type

SEQ ID NO: 44

```

10 20 30 40 50 60 70 80 90 100 110 120
ATGAAAATA ATATTTHGT ATATTGAT ATTTCATT TTATCAATTA AATTAAATCT GCTAATTCTC CTGTTCGAAC TGAAAATTAAC AGAGCCGAT AAGTTTCATCA TCTAAGAACT
130 140 150 160 170 180 190 200 210 220 230 240
CCTGCNAAT GTGTTAATTG TTGAAAAAC TTTTATTATA ATAAATGTC TACTTTGTTT CTTCTATATA GTACATATAC ACTTCTGCA TAAAAAAGAG ATCTCTGCTGC TTAAACAAAT
250 260 270 280 290 300 310 320 330 340 350 360
CAACCTGCTA CTGCTAATTT AGTCACATAA TGTAAAGCTTA AAATXCTTCC TGGTACCGCA ATTCAAGCTC GAGCAACAGA TTATCCAGCA ATAAATCAG AGTGTCTTAA TTGTAGAATT
370 380 390 400 410 420 430 440 450 460 470 480
AATTTTATTA ATGAAAAATGC TCCAAATTTT AATCCAGCTG CTAGTATATG CACAGCTTGT CCGGTAAACA GAGTTATCTG TCTAATTGALT GCTGTAAAG CCGCTAACAT AGTCCGATAA
490 500 510 520 530 540 550 560 570 580 590 600
TTGTAAGTGC CATGTCTTAC TGTACTCTCA CTTCATGATG CAATTAAGTAC TCAATTAATG TCAATCTGCT AAGTAAATG TAAATCTTAA CAGAAATGCT ACTATTAATG TAATTAATGCT
610 620 630 640 650 660 670 680 690 700 710 720
AATACTCTCT TCAATCCAGG TAAAGTTTAA TCCACACCTT GTTATTAAT TAAATCTGCT TAAATCTGCT AAGTAAATG TAAATCTGCT TAAATCTGCT TAAATCTGCT TAAATCTGCT
730 740 750 760 770 780 790 800 810 820 830 840
TCCCTCTGAT GTACTATAAG TGTCTCTGCA GTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT
850 860 870 880 890 900 910 920 930 940 950 960
AGTACATGCC TACTCTGCCC AATTAATAAA GATTATGCTG TTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT TTAAATAAT
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
GGAGCAACTA ATTATGTAAT AATTAATAAA GAATTTCTTA ATCTCTCTTA TAAATTTTAT TTATTAATGATA ATAAATCTGCT GAAATCTGCT CTGCTACTCT ACTAATCTGCT AGCAATCTGCT AGCAATCTGCT
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
GTTTAAGGCG CTGTAGCAAC TCCAGGCTGT ACTGCTACTT TAATTCGATA ATGCTGCTGT GAAATCTGCT CTGCTACTCT ACTAATCTGCT GAAATCTGCT GAAATCTGCT GAAATCTGCT
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320
TCTGAATGTT TTAAATGCTG TCCCACTTTT TATACTACA AATAAACTCA TTGCTGAGCA GGTATGATA CATGCTACTAG TTGTAATAAA AAATTAATCT CTGCTGCTGCA AGCTAATTTA
1330 1340 1350 1360 1370 1380 1390 1400 1410 1420 1430 1440
CCGGAATCTG CTAAAAAAA TATATAATGT GAATTCGCTA ATTTTATATC AATTTCTTAA TTATTTGATTT CTATTAATTT ATTATGATGA .....

```

Coding region: nucleotides 1-1404

Fig. 2a

3/27

G5 SYNTHETIC															
SEQ ID NO: 102		10	20	30	40	50	60	70	80	90	100	110	120		
	ATGAGAGCA	ACATCTTGT	GATCTGTAT	ATCTCTGT	TCTCTAGCA	QATCTGTAT	GCTTACTGT	CTCTGAGCA	ACCTGAGCA	AGCTGAGCA	AGCTGAGCA	AGCTGAGCA	AGCTGAGCA		
	130	140	150	160	170	180	190	200	210	220	230	240			
	CCTGCTACT	GTCTGAGCA	TGAGAGAGC	TTCTTACTA	ACATCTTGT	TCTCTGTAT	CTCTGAGCA	AGCTGAGCA	AGCTGAGCA	AGCTGAGCA	AGCTGAGCA	AGCTGAGCA	AGCTGAGCA		
	250	260	270	280	290	300	310	320	330	340	350	360			
	CCTCTCTCA	CCCTTAACT	CTCTGAGCA	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT		
	370	380	390	400	410	420	430	440	450	460	470	480			
	AACTTCTCA	ACGAGAGCA	TCTCTGTAT	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA		
	490	500	510	520	530	540	550	560	570	580	590	600			
	TGTACTGTC	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA		
	610	620	630	640	650	660	670	680	690	700	710	720			
	AACAGCCCT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT		
	730	740	750	760	770	780	790	800	810	820	830	840			
	TGTCTGAGC	GAATCTTCT	TCTCTGTAT	GAATCTTCT	GAATCTTCT	GAATCTTCT	GAATCTTCT	GAATCTTCT	GAATCTTCT	GAATCTTCT	GAATCTTCT	GAATCTTCT	GAATCTTCT		
	850	860	870	880	890	900	910	920	930	940	950	960			
	TGTACTGTC	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT		
	970	980	990	1000	1010	1020	1030	1040	1050	1060	1070	1080			
	GGAGCTTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA	AACTTCTCA		
	1090	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	1200			
	GTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA		
	1210	1220	1230	1240	1250	1260	1270	1280	1290	1300	1310	1320			
	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT	TCTCTGTAT		
	1330	1340	1350	1360	1370	1380	1390	1400	1410	1420	1430	1440			
	CCTCTGTAT	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA	CTCTGAGCA		

Coding region: nucleotides 1-1404

Fig. 2b




Fig. 3b

6/27

Fig. 3b₁

Sequence Alignment of 48 kD G1 i-antigen
and 55 kD G5 i-antigen nucleotide sequences

```

G1 SEQ ID NO: 1 ATGAAATATAATATTTTATTAAATTTTAAATTTTCTTTATTTTATTAATGAATTAAGAGCT
G5 SEQ ID NO: 3 ATGAAAAATAATATTTTAGTAATATTGATTATTTTCATTATTTATCAATTAAATTAAATCT
.....|.....

G1      GTTCCATGTCCTGATGGTACTTAGACTCA---AGCTGGAT----TGACTGATGTAGGTGC
G5      GCTAATTGTCCTGTTGGAACTGAAACTAACACAGCCGGATAAGTTGA-TGATCTAGGAAC
.....

G1      TGCTGATCTTGGTACTTGTGTTAATTGC-AGACCTAATTTTACTATAATGGTGGTGCTG
G5      TCCT-----GCAAATTGTGTTAATTGTTAGAAA-AACTTTATTATAATAATGCTGCTG
.....

G1      CTTAAGGAGAAGCTAATGGTAATTAACCTTTTCGACGCAAATAATGCTGCTAGAGGTATAT
G5      CTT-----TCGTTCC-----TGGTGCTAG---TACGT
.....

G1      GTGTACCATG-CCA-AATAAACAGA-GTAGGCTCTGTTACCAA-TGCAGGTG--ACTTAG
G5      GTACACCTTGTCCATAAAAAAAGATGCTGGTGCT-TAACCAAATCCACCTGCTACT--G
.....

G1      CTACTTTAGCCACATAATGCAGTACTTAATGTCCTACTGGCACTGCACCTTGATGATGGAG
G5      CTAATTTAGTCACATAATGTAACGTTAAATGCCCTGCTGGTACCGCAATTGCAGGTGGAG
.....

G1      TGACAGATGTTTTTG--ATAGATCAGCCGCATAATGTGTTAAATGCAAACCTAACTTTTA
G5      CAACAGATTATGCAGCAATA-ATCA----CAGAATGTGTTAATTGTAGAATTAATTTTTA
.....

G1      CTATAATGGTGGTTCTCCTTAAGGTGAAGCTCCTGGCGTTTAAGTTTTTGCTGCTGGTGC
G5      ---TAATGA-----AA---ATGCTCC-----AAATTTTAA-----
.....

G1      TGCCGCTGCAGGTGTTGCTGCCGTTACTAGTTAATGTGTACCTTGCCAACTAAACAAAAA
G5      -----TGCAGGTG-----CTAGTACATGCACAGCTTGCCGGTAAACAGAGT
.....

G1      CGATTCTCCTGCCACTGCAGGT---GCCTAAGCTAATTTAGCCACATAATGTAGCAATTA
G5      TGGTGGTGCAATTGACTGCTGGTAATGCC---GCTACCATAGTCGCATAATGTAAACGTGCG
.....

```


7/27

G1 ATGTCCTACTGGCACTGTACTTGATGATGGAGTGACACTTGTTTTAAATACATCAGCCAC
G5 ATGTCCTACTGGTACTGCACTTGATGATGGAGTAACTACTGATTATGTTAGATCATTAC
***** ** * * * * *

G1 ATTATGTGTTAAATGCAGACCTAACTTTTACTATAATGGT-----GGTT---CTCCTTA
G5 AGAATGTGTTAAATGTAGACTTAACTTTTACTATAATGTAATAATGGTAATACTCCTTT
* ***** ** *

G1 -----AGGTGAA-----GCTCCTGGCGTTTA
G5 CAATCCAGGTAAAAGTTAATGCACACCTTGTCCGCAATTAAACCTGCTAATGTTGCTTA
***** ** *

G1 AG---TTT-----TTGC-----TGCTGG
G5 AGCTACTTTAGGTAATGATGCTACAATAACCGCATAATGTAACGTTGCATGCCCTGATGG
** *** ** *

G1 TGCT-----GCCGCTGCAG-----GTGTTGC-----
G5 TACTATAAGTCTGCTGGAGTAAATAATTGGGTAGCACAAAACACTGAATGTACTAATTG
* ** * * * *

G1 -----TGCCGTTACTAGTTAATGTGT
G5 TGCTCCTAACTTTTACAATAATAATGCTCCTAATTCAATCCAGGTAATAGTACATGCCCT
* * * * *

G1 ACCTTGCCAAATAAACAAAAACGATTCTCCTG---CCACTGCAGGTGCCTAAGCTAATTT
G5 ACCTTGCCAGCAATAAAGATTATGGTGTGAAGCCACTGCAGGTGGTGCCGCTACTTT
***** ** *

G1 ACCCACAATAATGCAGTACTTAATGTCCAACCTGGCACTGCAATT-CAAGACGGAGTGACAC
G5 AGCCAAATAATGTAATATTGCATGCCCTGATGGTACTGCAATTGCTAGT-GGAGCAAC--
***** ** *

G1 TTGTTTTAGTAAT-TCATCCACATAATGTTCTTAAT-GCATGTCTAATTACTTTTTTAA
G5 -TAATTAT-GTAATATTATAACAGAATGT-CTAAATTGTGCTGCTAATTTATTTTGA
* * * * *

G1 TGGTAAT---TTCGAAGCAGGTAAAAGTTAATGTTAAAG--TGTCCAGTAAGTAAACT
G5 TGGTAATAATTTCTAGGCAGGAAGTAGTAGATGC--AAAGCATGTCAGCAATAAAGTT
***** ** *

G1 A-----CTCCAGCACATGCTCCAGGTAATACTGCTACTTAAGCCACATAATGT-----TT
G5 TAAGGCGCTGTAGCAA---CTGCAGGTGGTACTGCTACTTTAATTGCATAATGTGCCCTT
** **** * * * * *

G1 GACCACATGTCCTGCTGGTACAGTACTTGATGATGGAACATCAACTAATTTGTAGCTTC
G5 GA---ATGCCCTGCTGGTACTGTACTACCGATGGAACAACATCTACTTATAAATAAGC
** * * * * *

G1 CGCAACTGAATGTACTAAATGTTCTGCTGGCTTTTGTGATCAAAAAACACTGGTTTTAC
G5 AGCATCTGAATGTGTTAAATGTGCTGCCAATTTTATACTACAAAAATAACTGATTGGGT
* * * * *

G1 AGCAGGTACTGATACATGTACTGAATGTACTAAAAAATAACTTCTGGTGCCACAGCTAA
G5 AGCAGGTATTGATACATGTACTAGTTGTAATAAAAAATAACTTCTGGCGCTGAAGCTAA
***** ** *

G1 AGTATATGCTGAAGCTACTCAAAAAG---TATAATGCGCCTCCACTACTTTCGCTAAAT
G5 TTTAC---CTGAATCTGCTAAAAAAATATATAATGTG-----ATTTCGCTAATTT
** ***** *

G1 TTTATCGATTTCCTTATTATTATTCTTTCTATTATTG
G5 TTTATCAATTTCCTTATTATTGATTCTTATTATTATTA

Fig. 3b₂

8/27

55 KD i-antigen protein

SEQ ID NO: 7	10	20	30	40	50	60
	MKNNILVILI	ISLFINQIKS	ANCPVGTEIN	TAGQVDDLGT	PANCVNCQKN	FYYNNAAAFV
	70	80	90	100	110	120
	PGASTCTPCP	QKKDAGAQP	PPATANLVTQ	CNVKCPAGTA	LAGGATDYAA	ITTECVNCRI
	130	140	150	160	170	180
	NFYNNAPNF	NAGASTCTAC	PVNRVGGALT	AGNAATIVAQ	CNVACPTGTA	LDDGVTTDYV
	190	200	210	220	230	240
	RSFTECVKCR	LNFFYYNGNG	NTPFNPQKSQ	CTPCPAIKPA	NVAQATLGND	ATITAQCIVA
	250	260	270	280	290	300
	CPDGTISAAG	VNNWVAQNT	CTNCAPNFYN	NNAPNFNPGN	STCLPCPANK	DYGAEATAGG
	310	320	330	340	350	360
	AATLAKQCNI	ACPDGTALAS	GATNYVILQT	ECLNCAANFY	FDGNNFQAGS	SRCKACPANK
	370	380	390	400	410	420
	VQGAVATAGG	TATLIAQCAL	ECPAGTVLTD	GTTSTYKQAA	SECVKCAANF	YTTKQTDWVA
	430	440	450	460	470	480
	GIDTCTSCNK	KLTSGAEANL	PESAKNIQC	DFANFLSISL	LLISYLL**

Fig. 4

9/27

48 kDa G1 i-antigen repeats

SEQ ID NO:	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	33	34	35	36	37	38	39	40	41	42	43	44	45	46	47	48	49	50	51	52	53	54	55	56	57	58	59	60	61	62	63	64	65	66	67	68	69	70	71	72	73	74	75	76	77	78	79	80	81	82	83	84	85	86	87	88	89	90	91	92	93	94	95	96	97	98	99	100	101	102	103	104	105	106	107	108	109	110	111	112	113	114	115	116	117	118	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	136	137	138	139	140	141	142	143	144	145	146	147	148	149	150	151	152	153	154	155	156	157	158	159	160	161	162	163	164	165	166	167	168	169	170	171	172	173	174	175	176	177	178	179	180	181	182	183	184	185	186	187	188	189	190	191	192	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219	220	221	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246	247	248	249	250	251	252	253	254	255	256	257	258	259	260	261	262	263	264	265	266	267	268	269	270	271	272	273	274	275	276	277	278	279	280	281	282	283	284	285	286	287	288	289	290	291	292	293	294	295	296	297	298	299	300	301	302	303	304	305	306	307	308	309	310	311	312	313	314	315	316	317	318	319	320	321	322	323	324	325	326	327	328	329	330	331	332	333	334	335	336	337	338	339	340	341	342	343	344	345	346	347	348	349	350	351	352	353	354	355	356	357	358	359	360	361	362	363	364	365	366	367	368	369	370	371	372	373	374	375	376	377	378	379	380	381	382	383	384	385	386	387	388	389	390	391	392	393	394	395	396	397	398	399	400	401	402	403	404	405	406	407	408	409	410	411	412	413	414	415	416	417	418	419	420	421	422	423	424	425	426	427	428	429	430	431	432	433	434	435	436	437	438	439	440	441	442	443	444	445	446	447	448	449	450	451	452	453	454	455	456	457	458	459	460	461	462	463	464	465	466	467	468	469	470	471	472	473	474	475	476	477	478	479	480	481	482	483	484	485	486	487	488	489	490	491	492	493	494	495	496	497	498	499	500	501	502	503	504	505	506	507	508	509	510	511	512	513	514	515	516	517	518	519	520	521	522	523	524	525	526	527	528	529	530	531	532	533	534	535	536	537	538	539	540	541	542	543	544	545	546	547	548	549	550	551	552	553	554	555	556	557	558	559	560	561	562	563	564	565	566	567	568	569	570	571	572	573	574	575	576	577	578	579	580	581	582	583	584	585	586	587	588	589	590	591	592	593	594	595	596	597	598	599	600	601	602	603	604	605	606	607	608	609	610	611	612	613	614	615	616	617	618	619	620	621	622	623	624	625	626	627	628	629	630	631	632	633	634	635	636	637	638	639	640	641	642	643	644	645	646	647	648	649	650	651	652	653	654	655	656	657	658	659	660	661	662	663	664	665	666	667	668	669	670	671	672	673	674	675	676	677	678	679	680	681	682	683	684	685	686	687	688	689	690	691	692	693	694	695	696	697	698	699	700	701	702	703	704	705	706	707	708	709	710	711	712	713	714	715	716	717	718	719	720	721	722	723	724	725	726	727	728	729	730	731	732	733	734	735	736	737	738	739	740	741	742	743	744	745	746	747	748	749	750	751	752	753	754	755	756	757	758	759	760	761	762	763	764	765	766	767	768	769	770	771	772	773	774	775	776	777	778	779	780	781	782	783	784	785	786	787	788	789	790	791	792	793	794	795	796	797	798	799	800	801	802	803	804	805	806	807	808	809	810	811	812	813	814	815	816	817	818	819	820	821	822	823	824	825	826	827	828	829	830	831	832	833	834	835	836	837	838	839	840	841	842	843	844	845	846	847	848	849	850	851	852	853	854	855	856	857	858	859	860	861	862	863	864	865	866	867	868	869	870	871	872	873	874	875	876	877	878	879	880	881	882	883	884	885	886	887	888	889	890	891	892	893	894	895	896	897	898	899	900	901	902	903	904	905	906	907	908	909	910	911	912	913	914	915	916	917	918	919	920	921	922	923	924	925	926	927	928	929	930	931	932	933	934	935	936	937	938	939	940	941	942	943	944	945	946	947	948	949	950	951	952	953	954	955	956	957	958	959	960	961	962	963	964	965	966	967	968	969	970	971	972	973	974	975	976	977	978	979	980	981	982	983	984	985	986	987	988	989	990	991	992	993	994	995	996	997	998	999	1000	1001	1002	1003	1004	1005	1006	1007	1008	1009	1010	1011	1012	1013	1014	1015	1016	1017	1018	1019	1020	1021	1022	1023	1024	1025	1026	1027	1028	1029	1030	1031	1032	1033	1034	1035	1036	1037	1038	1039	1040	1041	1042	1043	1044	1045	1046	1047	1048	1049	1050	1051	1052	1053	1054	1055	1056	1057	1058	1059	1060	1061	1062	1063	1064	1065	1066	1067	1068	1069	1070	1071	1072	1073	1074	1075	1076	1077	1078	1079	1080	1081	1082	1083	1084	1085	1086	1087	1088	1089	1090	1091	1092	1093	1094	1095	1096	1097	1098	1099	1100	1101	1102	1103	1104	1105	1106	1107	1108	1109	1110	1111	1112	1113	1114	1115	1116	1117	1118	1119	1120	1121	1122	1123	1124	1125	1126	1127	1128	1129	1130	1131	1132	1133	1134	1135	1136	1137	1138	1139	1140	1141	1142	1143	1144	1145	1146	1147	1148	1149	1150	1151	1152	1153	1154	1155	1156	1157	1158	1159	1160	1161	1162	1163	1164	1165	1166	1167	1168	1169	1170	1171	1172	1173	1174	1175	1176	1177	1178	1179	1180	1181	1182	1183	1184	1185	1186	1187	1188	1189	1190	1191	1192	1193	1194	1195	1196	1197	1198	1199	1200	1201	1202	1203	1204	1205	1206	1207	1208	1209	1210	1211	1212	1213	1214	1215	1216	1217	1218	1219	1220	1221	1222	1223	1224	1225	1226	1227	1228	1229	1230	1231	1232	1233	1234	1235	1236	1237	1238	1239	1240	1241	1242	1243	1244	1245	1246	1247	1248	1249	1250	1251	1252	1253	1254	1255	1256	1257	1258	1259	1260	1261	1262	1263	1264	1265	1266	1267	1268	1269	1270	1271	1272	1273	1274	1275	1276	1277	1278	1279	1280	1281	1282	1283	1284	1285	1286	1287	1288	1289	1290	1291	1292	1293	1294	1295	1296	1297	1298	1299	1300	1301	1302	1303	1304	1305	1306	1307	1308	1309	1310	1311	1312	1313	1314	1315	1316	1317	1318	1319	1320	1321	1322	1323	1324	1325	1326	1327	1328	1329	1330	1331	1332	1333	1334	1335	1336	1337	1338	1339	1340	1341	1342	1343	1344	1345	1346	1347	1348	1349	1350	1351	1352	1353	1354	1355	1356	1357	1358	1359	1360	1361	1362	1363	1364	1365	1366	1367	1368	1369	1370	1371	1372	1373	1374	1375	1376	1377	1378	1379	1380	1381	1382	1383	1384	1385	1386	1387	1388	1389	1390	1391	1392	1393	1394	1395	1396	1397	1398	1399	1400	1401	1402	1403	1404	1405	1406	1407	1408	1409	1410	1411	1412	1413	1414	1415	1416	1417	1418	1419	1420	1421	1422	1423	1424	1425	1426	1427	1428	1429	1430	1431	1432	1433	1434	1435	1436	1437	1438	1439	1440	1441	1442	1443	1444	1445	1446	1447	1448	1449	1450	1451	1452	1453	1454	1455	1456	1457	1458	1459	1460	1461	1462	1463	1464	1465	1466	1467	1468	1469	1470	1471	1472	1473	1474	1475	1476	1477	1478	1479	1480	1481	14
------------	---	---	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	----

10/27




Fig. 6




Fig. 7a

12/27

```

SEQ ID NO: 61      20 AVHCPDGTQAG-LTDVGAADLGTVC-RPNFYNGGAAG---EANGHP-FAANNAAR--GICVP---CQINRVGSVYNAGDLATL
SEQ ID NO: 62      61 AVDCD-----GSAGYTTDDSVSDAKGCKRKNAPCTACAGTADKCTKDANGAAPYLKKTNPBDDPTGCVSAVDCQG--SAGYTT--DDSVSD
                ** * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . .
                * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . .

                ATCCSTQCTGTALDDGVTVDRSAACVTKPN-----FYNGGSPQ--GE-----APGVQVTAAGAAAGVAAVTSQVFCQINKNDSPA
                AKECK-RCAEGQKPNATAGTQCFSCSDANCFERCDONDVCAKRGTCGAPFNGKCPAATPGCHSSCDGCTENANTNQADKCTGCKEGRYLKPE
                * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . .
                * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . .

                TAGAQNATQCSNQCPTGVLDGVTLVFNTSATLCVRCRPNFYNGGSPQGEAPGVQVTAAGAAAGVAAVTSQVFCQINKNDSPAT
                SAAGSGTCLR--AEZCFSDTH--PTEKAGDSKGMCLPCH-----DATHGIAGCKK--CAL---KTLSGEAKSTVVCHEC-TDKWLTPS-
                !* . . . . . !* . . . . . !* . . . . . !* . . . . . !* . . . . . !* . . . . . !* . . . . . !* . . . . .

                AGAQNATQCSQCTPTGTATIQDGVTLVFNSTQCSQCLANFYFNFNFEACKSQCLFCPVSKTTPAHAPGNATATQATCLTICP---AGT
                -G---N---ACLDNCPAGTYPND--NNLCTSDHT--CHFC-----NGN--ADRASCDFAC-----YFGYSLLYGSCCTAGTCVPCCTGAFGA
                * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . .
                * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . .

                VLDDGTSTNFAVASETECTKCSAGP7-----ASKTTGPT-----AGTD--TCTPCTKTLTSGATAKVY--AEATQKVQCASTTFAK 428
                NCADGQCTADVGGAKYCAQCCKDGYAPIDGICTAVAAGRTNVCTAADGTCCTCAAGBYT-LMSGGCTGVAKLPKRSVCTLASNGK 459
                ** * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . .
                * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . . * . . . . .

```

Fig. 8

13/27




Fig. 9

14/27




Fig. 10




Fig. 11

SEQ ID NO: Primers for synthesis of G5 synthetic gene.

- 3201:
70 ATG GGA ATT CAA ATG AAG AAC AAC ATC CTG GTG ATC CTG ATC TCT CTG TTC ATC AAC CAG ATC AAG
TCT GCT AAC TGT CCT GTG GGA ACC GAG ACC AAC ACC GCT GGA CAG GTG
- 3202:
71 CTC CAG GCA CGA AAG CAG CAG CGT TGT TGT AGT AGA AGT TCT TCT GAC AGT TCA CAC AGT TAG CAG GGG
TTC CCA GGT CGT CCA CCT GTC CAG CGG TGT TGG TC
- 3203:
72 CGC TGC TGC TTT CGT GCC TGG AGC TTC TAC CTG TAC CCC TTG TCC TCA GAA GAA GGA CGC TGG AGC TCA
GCC TAA CCC TCC TGC TAC CGC TAA CCT GGT G
- 3204:
73 GAT GAT AGC AGC GTA GTC GGT AGC TCC TCC AGC GAT AGC GGT TCC AGC AGG ACA CTT CAC GTT ACA CTG
GGT CAC CAG GTT AGC GGT AGC AGG AG
- 3205:
74 GCT ACC GAC TAC GCT GCT ATC ATC ACC GAG TGT GTG AAC TGT CGC ATC AAC TTC TAC AAC GAG AAC GCT
CCT AAC TTC AAC GCT GGA GCT TCT ACC TGT ACC GCT TGT CCT GTG AAC CGC GTG GGA GGA GCT CTG ACC
- 3206:
75 GGT GAA AGA GCG CAC GTA GTC GGT GGT CAC TCC GTC GTC CAG AGC GGT TCC GGT AGG ACA AGC CAC GTT
ACA CTG AGC CAC GAT GGT AGC AGC GTT TCC AGC GGT CAG AGC TCC TCC CAC GCG
- 3207:
76 GAC TAC GTG CGC TCT TTC ACC GAG TGT GTG AAG TGT CGC CTG AAC TTC TAC TAC AAC GGA AAC AAC GGA
AAC ACC CCT TTC AAC CCT GGA AAG TCT CAG
- 3208:
77 GTG ATG GTA GCG TCG TTT CCC AGG GTA GCC TGA GCC ACG TTA GCA GGC TTG ATA GCA GGA CAA GGG GTA
CAC TGA GAC TTT CCA GGG TTG AAA GG
- 3209:
78 GGG AAA CGA CGC TAC CAT CAC CGC TCA GTG TAA CGT GGC TTG TCC TGA CGG AAC CAT CTC TGC TGC TGG
AGT GAA CAA CTG GGT GGC TCA GAA C
- 3210:
79 CAG ACA GGT AGA GTT TCC AGG GTT GAA GTT AGG AGC GTT GTT GTT GTA GAA GTT AGG AGC ACA GTT GGT
ACA CTC GGT GTT CTG AGC CAC CCA GTT GTT C
- 3211:
80 CCC TGG AAA CTC TAC CTG TCT GCC TTG TCC TGC TAA CAA GGA CTA CGG AGC TGA GGC TAC CGC TGG AGG
AGC TGC TAC CCT GGC TAA GC
- 3212:
81 GGT CTG CAG GAT CAC GTA GTT GGT AGC TCC AGA AGC GAT AGC GGT TCC GTC AGG ACA AGC GAT GTT ACA
CTG CTT AGC CAG GGT AGC AGC
- 3213:
82 CAA CTA CGT GAT CCT GCA GAC CGA GTG TCT GAA CTG TGC TGC TAA CTT CTA CTT CGA CGG AAA CAA CTT
CCA GGC TGG ATC TTC TCG CTG TAA GG
- 3214:
83 GAG CGA TCA GGG TAG CGG TTC CTC CAG CGG TAG CCA CAG CTC CCT GCA CCT TGT TAG CAG GAC AAG CCT
TAC AGC GAG AAG ATC CAG CCT GG
- 3215:
84 GAA CCG CTA CCC TGA TCG CTC AGT GTG CTC TGG AGT GTC CTG CTG GAA CCG TGC TGA CCG ACG GAA CCA
CCT CTA CCT ACA AGC AGG CTG CTT C
- 3216:
85 GGT GTC GAT TCC AGC CAC CCA GTC GGT CTG CTT GGT GGT GTA GAA GTT AGC AGC ACA CTT CAC ACA CTC
AGA AGC AGC CTG CTT GTA GGT AG
- 3217:
86 GGG TGG CTG GAA TCG ACA CCT GTA CCT CTT GTA ACA AGA AGC TGA CCT CTG GAG CTG AGG CTA ACC TGC
CTG AGT CTG CTA AGA AGA ACA TC
- 3218:
87 GAG GGA TCC TTA TTA CAG CAG GTA GTA AGA GAT CAG CAG CAG AGA GAT AGA CAG GAA GTT AGC GAA GTC
ACA CTG GAT GTT CTT CTT AGC AGA CT

Fig. 12




Fig. 13

G5 proline mutant 18/27

SEQ ID NO: 53 10 ↓ 20 30 40 50 60
 ATGAAGAACA ACATCCCGGT GATCCTGATC ATCTCTCTGT TCATCAACCA GATCAAGTCT
 70 80 90 100 110 120
 GCTAACTGTC CTGTGGGAAC CGAGACCAAC ACCGCTGGAC AGGTGGACGA CCTGGGAACC
 130 140 150 160 170 180
 CCTGCTAACT GTGTGAACTG TCAGAAGAAC TTCTACTACA ACAACGCTGC TGCTTTTCGTG
 190 200 210 220 230 240
 CCTGGAGCTT CTACCTGTAC CCTTGTCTCT CAGAAGAAGG ACGCTGGAGC TCAGCCTAAC
 250 260 270 280 290 300
 CCTCCTGCTA CCGCTAACCT GGTGACCCAG TGTAACGTGA AGTGTCTGTC TGGAACCGCT
 310 320 330 340 350 360
 ATCGCTGGAG GAGCTACCGA CTACGCTGCT ATCATCACCG AGTGTGTGAA CTGTTCGCATC
 370 380 390 400 410 420
 AACTTCTACA ACCGAAACGC TCCTAACTTC AACGCTGGAG CTCTTACCTG TACCGCTTGT
 430 440 450 460 470 480
 CCTGTGAACC GTGTGGGAGG AGCTCTGACC GCTGGAAACG CTGCTACCAT CGTGGCTCAG
 490 500 510 520 530 540
 TGTAACGTGG CTGTCTCTAC CGGAACCGCT CTGGACGACG GAGTGACCAC CGACTACGTG
 550 560 570 580 590 600
 CGCTCTTTCA CCGAGTGTGT GAAGTGTGCG CTGAACTTCT ACTACAACGG AAACAACGGA
 610 620 630 640 650 660
 AACACCCCTT TCAACCCCTG AAAGTCTCAG TGTACCCCTT GTCTCTGCTAT CAAGCCTGCT
 670 680 690 700 710 720
 AACGTGGCTC AGGCTACCCT GGGAAACGAC GCTACCATCA CCGCTCAGTG TAACGTGGCT
 730 740 750 760 770 780
 TGTCCTGACG GAACCATCTC TGCTGCTGGA GTGAACAAC TGGTGGCTCA GAACACCGAG
 790 800 810 820 830 840
 TGTACCAACT GTGCTCCTAA CTTCTACAAC AACAACGCTC CTAACCTCAA CCCTGGAAAC
 850 860 870 880 890 900
 TCTACCTGTC TGCCTTGTCC TGCTAACAA GACTACGGAG CTGAGGCTAC CGCTGGAGGA
 910 920 930 940 950 960
 GCTGCTACCC TGGCTAAGCA GTGTAACATC GCTTGTCTCTG ACGGAACCGC TATCGCTTCT
 970 980 990 1000 1010 1020
 GGAGCTACCA ACTACGTGAT CCTGCAGACC GAGTGTCTGA ACTGTGCTGC TAACTTCTAC
 1030 1040 1050 1060 1070 1080
 TTCGACGGAA ACAACTTCCA GGCTGGATCT TCTCGCTGTA AGGCTTGTCC TGCTAACAAAG
 1090 1100 1110 1120 1130 1140
 GTGCAGGGAG CTGTGGCTAC CGCTGGAGGA ACCGCTACCC TGATCGCTCA GTGTGCTCTG
 1150 1160 1170 1180 1190 1200
 GAGTGTCTCTG CTGGAACCGT GCTGACCGAC GGAACCACCT CTACCTACAA GCAGGCTGCT
 1210 1220 1230 1240 1250 1260
 TCTGAGTGTG TGAAGTGTGC TGCTAACTTC TACACCACCA AGCAGACCGA CTGGGTGGCT

Fig. 13a

19/27

proline mutant

1270	1280	1290	1300	1310	1320
GGAATCGACA	CCTGTACCTC	TTGTAACAAG	AAGCTGACCT	CTGGAGCTGA	GGCTAACCTG
1330	1340	1350	1360	1370	1380
CCTGAGTCTG	CTAAGAAGAA	CATCCAGTGT	GACTTCGCTA	ACTTCCTGTC	TATCTCTCTG
1390	1400	1410	1420	1430	1440
CTGCTGATCT	CTTACTACCT	GCTG.....

Fig. 13b

20/27

G5 proline mutant protein

↓ 10 20 30 40 50 60
SEQ ID NO: 54 MKNNIPVILI ISLFINQIKS ANCPVGTETN TAGQVDDLGT PANCVNCQKN FYNNNAAFV
70 80 90 100 110 120
PGASTCTPCP QKKDAGAQP N PPATANLV TQ CNVKCPAGTA IAGGATDYAA IITECVNCRI
130 140 150 160 170 180
NFYNNAPNF NAGASTCTAC PVNRVGGALT AGNAATTIVAQ CNVACPIGTA LDDGVTTD YV
190 200 210 220 230 240
RSFTECVKCR LNFYNGNNG NTPFNPGKSQ CTPCPA KPA NVAQATLGND ATITAQC NVA
250 260 270 280 290 300
CPDGTISAAG VNNWVAQNT E CTNCAPNFY N NNA PNFPNGN STCLPCPANK DYGA EATAGG
310 320 330 340 350 360
AATLAKQCNI ACPDGTAIAS GATNYVILQT ECLNCAANFY FDGNNFQAGS SRCKAC PANK
370 380 390 400 410 420
VQGAVATAGG TATLIAQCAL ECPAGTVLTD GTTSTYKQAA SECVKCAANF YTTKQTDWVA
430 440 450 460 470 480
GIDTCTSCNK KLTSGAEANL PESAKKNIQC DFANFLSISL LLISYLL... ..

Fig. 14






Fig. 15

22/27

*Fig. 16*

*Fig. 17*






Fig. 18

25/27

*Fig. 19a*

□ Week 2
▨ Week 4
▩ Week 6


*Fig. 19b*

□ Week 2
▨ Week 4
▩ Week 6




Serum: anti-live TG1 (1 : 20)

Fig. 20b



Serum: anti-live Tneo (1 : 20)
(negative control)

Fig. 20a

*Fig. 21*

SEQUENCE LISTING

<110> Dickerson, Harry
Clark, Theodore G.
Lin, Tian-Long
UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

<120> DIAGNOSTIC AND PROTECTIVE ANTIGEN GENE SEQUENCES OF
ICHTHYOPHTHIRIUS

<130> 235.00170201

<140> Unassigned
<141> 2000-02-04

<150> 60/131,121
<151> 1999-04-27

<150> 60/118,634
<151> 1999-02-04

<150> 60/122,372
<151> 1999-03-02

<150> 60/124,905
<151> 1999-03-17

<160> 102

<170> PatentIn Ver. 2.0

<210> 1
<211> 1326
<212> DNA
<213> Ichthyophthirius multifiliis

<400> 1
atgaaatata atatatttatt aattttaatt atttctttat ttattaatga attaagagct 60
gttccatgtc ctgatggtac ttagactcaa gctggattga ctgatgtagg tgctgctgat 120
cttggtactt gtgttaattg cagacctaat ttttactata atgggtggtgc tgcttaagga 180
gaagctaata gtaattaacc ttctgcagca aataatgctg ctagaggat atgtgtacca 240
tgccaaataa acagagtagg ctctgttacc aatgcagggtg acttagctac tttagccaca 300
taatgcagta cttaattgtc tactggcact gcacttgatg atggagtgc agatgttttt 360
gatagatcag ccgcataatg tgttaaatgc aaacctaaact ttactataa tgggtggttct 420
ccttaagggtg aagctcctgg cgtttaagtt tttgctgctg gtgctgccgc tgcaggtgtt 480
gctgccgtta ctagttaatg tgtaccttgc caactaaaca aaaacgatc tcctgccact 540
gcaggtgcct aagctaattt agccacataa tgtagcaatt aatgtcctac tggcactgta 600
cttgatgatg gagtgcact tgtttttaat acatcagcca cattatgtgt taaatgcaga 660

```

cctaactttt actataatgg tgggttcctcct taaggtgaag ctccctggcgt ttaagttttt 720
gctgctggtg ctgccgctgc aggtgttgct gccgttacta gttaatgtgt accttgccaa 780
ataaacaaaa acgattctcc tgccactgca ggtgcctaag ctaatttagc cacataatgc 840
agtacttaat gtccaactgg cactgcaatt caagacggag tgacacttgt ttttagtaat 900
tcatccacat aatgtttctta atgcattgct aattactttt ttaatggtaa tttcgaagca 960
ggtaaaaagt aatgttttaa gtgtccagta agtaaaaacta ctccagcaca tgctccaggt 1020
aatactgcta cttaaagccac ataatgtttg accacatgtc ctgctggtac agtacttgat 1080
gatggaacat caactaattt tgtagcttcc gcaactgaat gtactaaatg ttctgctggc 1140
ttttttgcat caaaaacaac tgggttttaca gcaggtagctg atacatgtac tgaatgtact 1200
aaaaaattaa cttctgggtgc cacagctaaa gtatatgctg aagctactca aaaagtataa 1260
tgcgccctcca ctactttcgc taaattttta tcgatttcct tattatttat ttctttctat 1320
ttattg 1326

```

<210> 2

<211> 2486

<212> DNA

<213> *Ichthyophthirius multifiliis*

<400> 2

```

aaattaaata atgtttttat ttaataatat tttttcacgt gtaattatta ttattttttt 60
tttaataaaa ttataaaaaa taaaaagtag aaaaatatca ataataaaat ataaaaataa 120
tttaaaaatt atttatgatt tgtttttaga aaataagggt ttatttataa taatgaattc 180
ttaaaataat gaatcgatat tatataaatt tttatttttt ataaaatatt gaattaccta 240
aaataatata aatttatgaa atattattta aaataataag ttatagaata aatttatttt 300
tatttctaatt tttttttata attattaaaa aaaaaaaaaa aatctattac tattttgcat 360
ttacaaacga tagaaaaaac taaaatttat aatattatta aaaaaaaaaa tataaataat 420
aataataaaa atatgaaata taatatttta ttaattttta ttatttcttt atttattaat 480
gaattaagag ctgttccatg tcctgatggg acttagactc aagctggatt gactgatgta 540
gggtgctgctg atcttggtac ttgtgttaat tgcagacctc atttttacta taatgggtgt 600
gctgcttaag gagaagctaa tggttaattaa cctttcgtag caaataatgc tgctagaggt 660
atatgtgtac catgccaaat aaacagagta ggctctgtta ccaatgcagg tgacttagct 720
actttagcca cataatgcag tacttaatgt cctactggca ctgcacttga tgatggagt 780
acagatgttt ttgatagatc agccgcataa tgtgttaaat gcaaacctaa cttttactat 840
aatgggtggt ctccttaagg tgaagctcct ggcgtttaag tttttgctgc tgggtgctgcc 900
gctgcagggt ttgctgccgt tactagttaa tgtgtacctt gccactaaa caaaaacgat 960
tctcctgcca ctgcagggtgc ctaagctaatt ttagccacat aatgtagcaa ttaatgtcct 1020
actggcactg tacttgatga tggagtgaac cttgttttta atacatcagc cacattatgt 1080
gttaaatgca gacctaaact ttactataat ggtggttctc cttaagggtga agctcctggc 1140
gtttaagttt ttgctgctgg tgctgccgct gcagggtgtg ctgccgttac tagttaatgt 1200
gtaccttgcc aaataaacia aaacgattct cctgccactg cagggtgccta agctaattta 1260
gccacataat gcagtactta atgtccaaact ggcactgcaa ttcaagacgg agtgacactt 1320
gttttttagta attcatccac ataatgttct taatgcattg ctaattactt ttttaatggt 1380
aatttcgaag caggtaaaag ttaatgttta aagtgtccag taagtaaaac tactocagca 1440
catgctccag gtaatactgc tacttaagcc acataatgtt tgaccacatg tcctgctggg 1500
acagtacttg atgatggaac atcaactaat tttgtagctt ccgcaactga atgtactaaa 1560
tgttctgctg gcttttttgc atcaaaaaca actggtttta cagcaggtag tgatacatgt 1620
actgaatgta ctaaaaaatt aacttctggt gccacagcta aagtatatgc tgaagctact 1680
caaaaagtat aatgcgcctc cactactttc gctaaatttt tctcgatttc cttattattt 1740

```

```

atttctttct atttattgtg atgaataaaa taattcatat tattttattt ttttatttta 1800
tgtttataaa ttaaaaaata gataaaattt aaaatatatt aaaaataatt ttttatataa 1860
attatcaatt aacaactaac taacaaaata caattaaaat ctttatagaa gggttttctt 1920
tataatattt taaggattaa ttacaaaatt ttaattaaag taacatttta tcatttaaaa 1980
tcttattaaa ataaatacat aaattctagt tgattctttt ttaattattaa tttaaaatta 2040
gaataaaaaa atatgtttta agtaaaaaaa agaagaaatt taatttaatt tatttatatt 2100
taatttaata tttatttaatt ttattttcga atattttatt atcaaacttt taaaactaaa 2160
aatttattaa gtctaattta aactatatat attatattat tttgtattct tttttttatt 2220
cataatcata aatacagaat tttttatatt ttgagttgtg catattattt tatgaatgtt 2280
atcacttata tatgcgtatg taattttatt tatctcattc agggcttaag cttgtaaaat 2340
aataatattc aatatatttg ttaagggaaa ggtaggcaa actaaactaa attttttaac 2400
aaaaatatat caattacaaa aatattttatt tataaatgaa tgaataaaaa tagtattttt 2460
atttatttat aactactaaa gaattc 2486

```

<210> 3

<211> 1404

<212> DNA

<213> *Ichthyophthirius multifiliis*

<400> 3

```

atgaaaaata atatttttagt aatattgatt atttcattat ttatcaatta aattaaatct 60
gctaattgtc ctgttggaac tgaaactaac acagccggat aagttgatga tctaggaact 120
cctgcaaatt gtgttaattg ttagaaaaac ttttattata ataatgctgc tgctttcgtt 180
cctggtgcta gtacgtgtac acctgttcca taaaaaaaag atgctggtgc ttaaccaaatt 240
ccacctgcta ctgctaattt agtcacataa tgtaacgtta aatgccctgc tggtagcgca 300
attgcagggtg gagcaacaga ttatgcagca ataactacag aatgtgttaa ttgtagaatt 360
aatttttata atgaaaatgc tccaaatttt aatgcagggtg ctagtacatg cacagcttgt 420
ccggtaaaaca gagttggtgg tgcattgact gctggtaatg ccgctaccat agtcgcataa 480
tgtaacgtcg catgtcctac tggtagtgc cttgatgatg gagtaactac tgattatgtt 540
agatcattca cagaatgtgt taaatgtaga cttaactttt actataatgg taataatggg 600
aatactcctt tcaatccagg taaaagttaa tgcacacctt gtccggcaat taaacctgct 660
aatgttgctt aagctacttt aggtaatgat gctacaataa ccgcataatg taacgttgca 720
tgccctgatg gtactataag tgctgctgga gtaaataatt gggtagcaca aaacactgaa 780
tgtactaatt gtgctcctaa cttttacaat aataatgctc ctaatttcaa tccaggtaat 840
agtacatgcc taccttgccc agcaaataaa gattatgggtg ctgaagccac tgcagggtgt 900
gccgctactt tagccaaata atgtaatat gcatgccctg atggtactgc aattgctagt 960
ggagcaacta attatgtaat attataaaca gaatgtctaa attgtgctgc taacttttat 1020
tttgatggta ataatttcta ggcaggaagt agtagatgca aagcatgtcc agcaaataaa 1080
gtttaaggcg ctgtagcaac tgcagggtgt actgctactt taattgcata atgtgccctt 1140
gaatgccctg ctggtactgt actaccgat ggaacaacat ctacttataa ataagcagca 1200
tctgaatgtg ttaaattgtc tgccaacttt tatactacaa aataaactga ttgggtagca 1260
gggtattgata catgtactag ttgtaataaa aaattaactt ctggcgctga agctaattta 1320
cctgaatctg ctaaaaaaaaa tatataatgt gatttcgcta attttttatt aatttcctta 1380
ttattgattt cttattattt attt 1404

```

<210> 4

<211> 100

<212> DNA

<213> *Ichthyophthirius multifiliis*

<400> 4

taaagtatat gctgaagcta ctcaaaaagt ataatgcgcc tccactactt tcgctaaatt 60
tttatcgatt tccttattat ttatttcttt ctatttattg 100

<210> 5

<211> 1404

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
55kD i-antigen coding region

<400> 5

atgaagaaca acatcctggt gatcctgata atctctctgt tcatcaacca gatcaagtct 60
gctaaactgtc ctgtgggaac cgagaccaac accgctggac aggtggacga cctgggaacc 120
cctgctaact gtgtgaactg tcagaagaac ttctactaca acaacgctgc tgctttcgtg 180
cctggagctt ctacctgtac cccttgctct cagaagaagg acgctggagc tcagcctaac 240
cctcctgcta ccgctaacct ggtgacctag tgtaacgtga agtgtcctgc tggaaccgct 300
atcgctggag gagctaccga ctacgctgct atcatcaccg agtgtgtgaa ctgtcgcatc 360
aacttctaca acgagaacgc tcctaacttc aacgctggag cttctacctg taccgcttgt 420
cctgtgaacc gcgtgggagg agctctgacc gctggaaacg ctgctaaccat cgtggctcag 480
tgtaacgtgg cttgtcctac cggaaaccgct ctggacgacg gagtgaccac cgactacgtg 540
cgctctttca ccgagtgtgt gaagtgtcgc ctgaacttct actacaacgg aaacaacgga 600
aacaccctt tcaaccctgg aaagtctcag tgtaccctt gtctgctat caagcctgct 660
aacgtggctc aggtaccct gggaaacgac gctaccatca ccgctcagt taacgtggct 720
tgtcctgacg gaaccatctc tgctgctgga gtgaacaact ggggtggctca gaacaccgag 780
tgtaccaact gtgtcctaa cttctacaac aacaacgctc ctaacttcaa ccctggaaac 840
tctacctgtc tgcttctcc tgctaacaag gactacggag ctgaggctac cgctggagga 900
gctgctaccc tggttaagca gtgtaacatc gcttgtcctg acggaaccgc tatcgcttct 960
ggagctacca actacgtgat cctgcagacc gagtgtctga actgtgctgc taacttctac 1020
ttcgacggaa acaacttcca ggctggatct tctcgtgta aggttgtcc tgctaacaag 1080
gtgcaggag ctgtggctac cgctggagga accgctaccc tgatcgctca gtgtgctctg 1140
gagtgtcctg ctggaaccgt gctgaccgac ggaaccacct ctacctaaa gcaggctgct 1200
tctgagtgtg tgaagtgtgc tgctaacttc tacaccacca agcagaccga ctgggtggct 1260
ggaatcgaca cctgtacctc ttgtaacaag aagctgacct ctggagctga ggctaacctg 1320
cctgagtctg ctaagaagaa catccagtgt gacttcgcta acttcctgtc tatctctctg 1380
ctgctgatct cttactacct gctg 1404

<210> 6

<211> 442

<212> PRT

<213> *Ichthyophthirius multifiliis*

<400> 6

Met Lys Tyr Asn Ile Leu Leu Ile Leu Ile Ile Ser Leu Phe Ile Asn

1	5	10	15
Glu Leu Arg Ala Val Pro Cys Pro Asp Gly Thr Gln Thr Gln Ala Gly	20	25	30
Leu Thr Asp Val Gly Ala Ala Asp Leu Gly Thr Cys Val Asn Cys Arg	35	40	45
Pro Asn Phe Tyr Tyr Asn Gly Gly Ala Ala Gln Gly Glu Ala Asn Gly	50	55	60
Asn Gln Pro Phe Ala Ala Asn Asn Ala Ala Arg Gly Ile Cys Val Pro	65	70	75
Cys Gln Ile Asn Arg Val Gly Ser Val Thr Asn Ala Gly Asp Leu Ala	85	90	95
Thr Leu Ala Thr Gln Cys Ser Thr Gln Cys Pro Thr Gly Thr Ala Leu	100	105	110
Asp Asp Gly Val Thr Asp Val Phe Asp Arg Ser Ala Ala Gln Cys Val	115	120	125
Lys Cys Lys Pro Asn Phe Tyr Tyr Asn Gly Gly Ser Pro Gln Gly Glu	130	135	140
Ala Pro Gly Val Gln Val Phe Ala Ala Gly Ala Ala Ala Ala Gly Val	145	150	155
Ala Ala Val Thr Ser Gln Cys Val Pro Cys Gln Leu Asn Lys Asn Asp	165	170	175
Ser Pro Ala Thr Ala Gly Ala Gln Ala Asn Leu Ala Thr Gln Cys Ser	180	185	190
Asn Gln Cys Pro Thr Gly Thr Val Leu Asp Asp Gly Val Thr Leu Val	195	200	205
Phe Asn Thr Ser Ala Thr Leu Cys Val Lys Cys Arg Pro Asn Phe Tyr	210	215	220
Tyr Asn Gly Gly Ser Pro Gln Gly Glu Ala Pro Gly Val Gln Val Phe	225	230	235
Ala Ala Gly Ala Ala Ala Ala Gly Val Ala Ala Val Thr Ser Gln Cys	245	250	255
Val Pro Cys Gln Ile Asn Lys Asn Asp Ser Pro Ala Thr Ala Gly Ala			

260	265	270
Gln Ala Asn Leu Ala Thr Gln Cys Ser Thr Gln Cys Pro Thr Gly Thr		
275	280	285
Ala Ile Gln Asp Gly Val Thr Leu Val Phe Ser Asn Ser Ser Thr Gln		
290	295	300
Cys Ser Gln Cys Ile Ala Asn Tyr Phe Phe Asn Gly Asn Phe Glu Ala		
305	310	315 320
Gly Lys Ser Gln Cys Leu Lys Cys Pro Val Ser Lys Thr Thr Pro Ala		
325	330	335
His Ala Pro Gly Asn Thr Ala Thr Gln Ala Thr Gln Cys Leu Thr Thr		
340	345	350
Cys Pro Ala Gly Thr Val Leu Asp Asp Gly Thr Ser Thr Asn Phe Val		
355	360	365
Ala Ser Ala Thr Glu Cys Thr Lys Cys Ser Ala Gly Phe Phe Ala Ser		
370	375	380
Lys Thr Thr Gly Phe Thr Ala Gly Thr Asp Thr Cys Thr Glu Cys Thr		
385	390	395 400
Lys Lys Leu Thr Ser Gly Ala Thr Ala Lys Val Tyr Ala Glu Ala Thr		
405	410	415
Gln Lys Val Gln Cys Ala Ser Thr Thr Phe Ala Lys Phe Leu Ser Ile		
420	425	430
Ser Leu Leu Phe Ile Ser Phe Tyr Leu Leu		
435	440	

<210> 7

<211> 468

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 7

Met Lys Asn Asn Ile Leu Val Ile Leu Ile Ile Ser Leu Phe Ile Asn
1 5 10 15

Gln Ile Lys Ser Ala Asn Cys Pro Val Gly Thr Glu Thr Asn Thr Ala
20 25 30

Gly Gln Val Asp Asp Leu Gly Thr Pro Ala Asn Cys Val Asn Cys Gln
 35 40 45
 Lys Asn Phe Tyr Tyr Asn Asn Ala Ala Ala Phe Val Pro Gly Ala Ser
 50 55 60
 Thr Cys Thr Pro Cys Pro Gln Lys Lys Asp Ala Gly Ala Gln Pro Asn
 65 70 75 80
 Pro Pro Ala Thr Ala Asn Leu Val Thr Gln Cys Asn Val Lys Cys Pro
 85 90 95
 Ala Gly Thr Ala Ile Ala Gly Gly Ala Thr Asp Tyr Ala Ala Ile Ile
 100 105 110
 Thr Glu Cys Val Asn Cys Arg Ile Asn Phe Tyr Asn Glu Asn Ala Pro
 115 120 125
 Asn Phe Asn Ala Gly Ala Ser Thr Cys Thr Ala Cys Pro Val Asn Arg
 130 135 140
 Val Gly Gly Ala Leu Thr Ala Gly Asn Ala Ala Thr Ile Val Ala Gln
 145 150 155 160
 Cys Asn Val Ala Cys Pro Thr Gly Thr Ala Leu Asp Asp Gly Val Thr
 165 170 175
 Thr Asp Tyr Val Arg Ser Phe Thr Glu Cys Val Lys Cys Arg Leu Asn
 180 185 190
 Phe Tyr Tyr Asn Gly Asn Asn Gly Asn Thr Pro Phe Asn Pro Gly Lys
 195 200 205
 Ser Gln Cys Thr Pro Cys Pro Ala Ile Lys Pro Ala Asn Val Ala Gln
 210 215 220
 Ala Thr Leu Gly Asn Asp Ala Thr Ile Thr Ala Gln Cys Asn Val Ala
 225 230 235 240
 Cys Pro Asp Gly Thr Ile Ser Ala Ala Gly Val Asn Asn Trp Val Ala
 245 250 255
 Gln Asn Thr Glu Cys Thr Asn Cys Ala Pro Asn Phe Tyr Asn Asn Asn
 260 265 270
 Ala Pro Asn Phe Asn Pro Gly Asn Ser Thr Cys Leu Pro Cys Pro Ala
 275 280 285

Asn Lys Asp Tyr Gly Ala Glu Ala Thr Ala Gly Gly Ala Ala Thr Leu
 290 295 300

Ala Lys Gln Cys Asn Ile Ala Cys Pro Asp Gly Thr Ala Ile Ala Ser
 305 310 315 320

Gly Ala Thr Asn Tyr Val Ile Leu Gln Thr Glu Cys Leu Asn Cys Ala
 325 330 335

Ala Asn Phe Tyr Phe Asp Gly Asn Asn Phe Gln Ala Gly Ser Ser Arg
 340 345 350

Cys Lys Ala Cys Pro Ala Asn Lys Val Gln Gly Ala Val Ala Thr Ala
 355 360 365

Gly Gly Thr Ala Thr Leu Ile Ala Gln Cys Ala Leu Glu Cys Pro Ala
 370 375 380

Gly Thr Val Leu Thr Asp Gly Thr Thr Ser Thr Tyr Lys Gln Ala Ala
 385 390 395 400

Ser Glu Cys Val Lys Cys Ala Ala Asn Phe Tyr Thr Thr Lys Gln Thr
 405 410 415

Asp Trp Val Ala Gly Ile Asp Thr Cys Thr Ser Cys Asn Lys Lys Leu
 420 425 430

Thr Ser Gly Ala Glu Ala Asn Leu Pro Glu Ser Ala Lys Lys Asn Ile
 435 440 445

Gln Cys Asp Phe Ala Asn Phe Leu Ser Ile Ser Leu Leu Leu Ile Ser
 450 455 460

Tyr Tyr Leu Leu
 465

<210> 8

<211> 83

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 8

Cys Pro Asp Gly Thr Gln Thr Gln Ala Gly Leu Thr Asp Val Gly Ala
 1 5 10 15

Ala Asp Leu Gly Thr Cys Val Asn Cys Arg Pro Asn Phe Tyr Tyr Asn
 20 25 30

Gly Gly Ala Ala Gln Gly Glu Ala Asn Gly Asn Gln Pro Phe Ala Ala
 35 40 45

Asn Asn Ala Ala Arg Gly Ile Cys Val Pro Cys Gln Ile Asn Arg Val
 50 55 60

Gly Ser Val Thr Asn Ala Gly Asp Leu Ala Thr Leu Ala Thr Gln Cys
 65 70 75 80

Ser Thr Gln

<210> 9

<211> 89

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 9

Cys Pro Thr Gly Thr Ala Leu Asp Asp Gly Val Thr Asp Val Phe Asp
 1 5 10 15

Arg Ser Ala Ala Gln Cys Val Lys Cys Lys Pro Asn Phe Tyr Tyr Asn
 20 25 30

Gly Gly Ser Pro Gln Gly Glu Ala Pro Gly Val Gln Val Phe Ala Ala
 35 40 45

Gly Ala Ala Ala Ala Gly Val Ala Ala Val Thr Ser Gln Cys Val Pro
 50 55 60

Cys Gln Leu Asn Lys Asn Asp Ser Pro Ala Thr Ala Gly Ala Gln Ala
 65 70 75 80

Asn Leu Ala Thr Gln Cys Ser Asn Gln
 85

<210> 10

<211> 89

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 10

Cys Pro Thr Gly Thr Val Leu Asp Asp Gly Val Thr Leu Val Phe Asn
 1 5 10 15

Thr Ser Ala Thr Leu Cys Val Lys Cys Arg Pro Asn Phe Tyr Tyr Asn
20 25 30

Gly Gly Ser Pro Gln Gly Glu Ala Pro Gly Val Gln Val Phe Ala Ala
35 40 45

Gly Ala Ala Ala Ala Gly Val Ala Ala Val Thr Ser Gln Cys Val Pro
50 55 60

Cys Gln Ile Asn Lys Asn Asp Ser Pro Ala Thr Ala Gly Ala Gln Ala
65 70 75 80

Asn Leu Ala Thr Gln Cys Ser Thr Gln
85

<210> 11

<211> 69

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 11

Cys Pro Thr Gly Thr Ala Ile Gln Asp Gly Val Thr Leu Val Phe Ser
1 5 10 15

Asn Ser Ser Thr Gln Cys Ser Gln Cys Ile Ala Asn Tyr Phe Phe Asn
20 25 30

Gly Asn Phe Glu Ala Gly Lys Ser Gln Cys Leu Lys Cys Pro Val Ser
35 40 45

Lys Thr Thr Pro Ala His Ala Pro Gly Asn Thr Ala Thr Gln Ala Thr
50 55 60

Gln Cys Leu Thr Thr
65

<210> 12

<211> 72

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 12

Cys Pro Ala Gly Thr Val Leu Asp Asp Gly Thr Ser Thr Asn Phe Val
1 5 10 15

Ala Ser Ala Thr Glu Cys Thr Lys Cys Ser Ala Gly Phe Phe Ala Ser

20 25 30
 Lys Thr Thr Gly Phe Thr Ala Gly Thr Asp Thr Cys Thr Glu Cys Thr
 35 40 45
 Lys Lys Leu Thr Ser Gly Ala Thr Ala Lys Val Tyr Ala Glu Ala Thr
 50 55 60
 Gln Lys Val Gln Cys Ala Ser Thr
 65 70

<210> 13
 <211> 14
 <212> PRT
 <213> *Ichthyophthirius multifiliis*

<400> 13
 Phe Leu Ser Ile Ser Leu Leu Phe Ile Ser Phe Tyr Leu Leu
 1 5 10

<210> 14
 <211> 23
 <212> PRT
 <213> *Ichthyophthirius multifiliis*

<400> 14
 Gln Cys Ala Ser Thr Thr Phe Ala Lys Phe Leu Ser Ile Ser Leu Leu
 1 5 10 15

Phe Ile Ser Phe Tyr Leu Leu
 20

<210> 15
 <211> 20
 <212> PRT
 <213> *Ichthyophthirius multifiliis*

<400> 15
 Met Lys Asn Asn Ile Leu Val Ile Leu Ile Ile Ser Leu Phe Ile Asn
 1 5 10 15

Gln Ile Lys Ser
 20

<210> 16

<211> 14

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 16

Phe Leu Ser Ile Ser Leu Leu Leu Ile Ser Tyr Tyr Leu Leu
1 5 10

<210> 17

<211> 20

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 17

Gln Cys Asp Phe Ala Asn Phe Leu Ser Ile Ser Leu Leu Leu Ile Ser
1 5 10 15

Tyr Tyr Leu Leu
20

<210> 18

<211> 33

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 18

Lys Val Tyr Ala Glu Ala Thr Gln Lys Val Gln Cys Ala Ser Thr Thr
1 5 10 15

Phe Ala Lys Phe Leu Ser Ile Ser Leu Leu Phe Ile Ser Phe Tyr Leu
20 25 30

Leu

<210> 19

<211> 60

<212> DNA

<213> Ichthyophthirius multifiliis

<400> 19

atgaaaaata atatttttagt aatattgatt atttcattat ttatcaatta aattaaatct 60

<210> 20

<211> 60

<212> DNA

<213> *Ichthyophthirius multifiliis*

<400> 20

taatgtgatt tcgctaattt tttatcaatt tccttattat tgatttotta ttatttatta 60

<210> 21

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense
primer

<400> 21

agcagcacct acatcagtca atcc

24

<210> 22

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: universal
primer

<400> 22

gtaaaacgac ggccagt

17

<210> 23

<211> 40

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: EPBdT18
primer

<400> 23

gcgaattctg caggatccaa actttttttt tttttttttt

40

<210> 24

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: forward
primer

<400> 24

gtgtcgacag caggtactga tacatg

26

<210> 25

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: forward
primer

<400> 25

cgaaaacagt ggtgtagta cctt

24

<210> 26

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse
primer

<400> 26

gcgaattctg caggatccaa ac

22

<210> 27

<211> 24

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide probe

<400> 27

agcagcacca acatcagtca aacc

24

<210> 28

<211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: forward
primer

<400> 28

atggaatta accttcgca gcaaataa

28

<210> 29

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse
primer

<400> 29

ggtctgcatt taacacataa

20

<210> 30

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse
primer

<400> 30

agatacatca gtatacgaaa

20

<210> 31

<211> 4

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primary
structure motif

<400> 31

Cys Xaa Xaa Cys

1

<210> 32

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primary
structure motif

<400> 32

Cys Xaa Xaa Xaa Cys
1 5

<210> 33

<211> 53

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: repeating
primary structure motif

<400> 33

Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Xaa Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45

Xaa Cys Xaa Xaa Cys
50

<210> 34

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: i-antigen
P-loop domain

<400> 34

Gly Xaa Xaa Xaa Xaa Gly Lys Ser
1 5

<210> 35
<211> 24
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: sense primer

<400> 35
atgaaataya ayattttatt aatt

24

<210> 36
<211> 8
<212> PRT
<213> Ichthyophthirius multifiliis

<400> 36
Met Lys Tyr Asn Ile Leu Leu Thr
1 5

<210> 37
<211> 24
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense
primer

<400> 37
aaataataar gaaatmgata aaaa

24

<210> 38
<211> 8
<212> PRT
<213> Ichthyophthirius multifiliis

<400> 38
Phe Leu Ser Ile Ser Leu Leu Phe
1 5

<210> 39
<211> 26
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense
primer

<400> 39

tgctcgagaa tctgttgctc cacctg

26

<210> 40

<211> 52

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: forward
primer

<400> 40

ccagtgcagca gactgacgag gactcgagct caagcccccc cccccccccc cc

52

<210> 41

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: forward
primer

<400> 41

gaggactcga gctcaagc

18

<210> 42

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse
primer

<400> 42

aactcgagta ccagcagggc atttaac

27

<210> 43

<211> 23

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: primer

<400> 43

cacaccttgt ccggcaatta aac

23

<210> 44

<211> 1410

<212> DNA

<213> *Ichthyophthirius multifiliis*

<400> 44

atgaaaaata atatttttagt aatattgatt atttcattat ttatcaatta aattaaatct 60
 gctaattgtc ctggttgaac tgaaactaac acagccggat aagttgatga tctaggaact 120
 cctgcaaat gtgttaattg ttagaaaaac ttttattata ataatgctgc tgctttcgtt 180
 cctggtgcta gtacgtgtac accttgtcca taaaaaaaag atgctggtgc ttaaccaa 240
 ccacctgcta ctgctaattt agtcacataa tgtaacgtta aatgccctgc tggtagcgca 300
 attgcagggtg gagcaacaga ttatgcagca ataatcacag aatgtgttaa ttgtagaatt 360
 aatttttata atgaaaatgc tccaaatttt aatgcagggtg ctagtacatg cacagcttgt 420
 ccggtaaaca gagttggtgg tgcattgact gctggtaatg ccgctaccat agtcgcataa 480
 tgtaacgtcg catgtcctac tggtagctga cttgatgatg gagtaactac tgattatgtt 540
 agatcattca cagaatgtgt taaatgtaga cttactttt actataatgg taataatggt 600
 aatactcctt tcaatccagg taaaagttaa tgcacacctt gtccggcaat taaacctgct 660
 aatgttgctt aagctacttt aggtaatgat gctacaataa ccgcataatg taacgttgca 720
 tgccctgatg gtactataag tgctgctgga gtaaataatt gggtagcaca aaacactgaa 780
 tgtaactaatt gtgtcctaa cttttacaat aataatgctc ctaatttcaa tccaggtaat 840
 agtacatgcc taccttgccc agcaaataaa gattatggtg ctgaagccac tgcaggtggt 900
 gccgtactt tagccaaata atgtaattt gcatgccctg atggtactgc aattgctagt 960
 ggagcaacta attatgtaat attataaaca gaatgtctaa attgtgctgc taacttttat 1020
 tttgatggta ataatttcta ggcaggaagt agtagatgca aagcatgtcc agcaaataaa 1080
 gtttaaggcg ctgtagcaac tgcaggtggt actgctactt taattgcata atgtgccctt 1140
 gaatgccctg ctggtactgt actcacgat ggaacaacat ctacttataa ataagcagca 1200
 tctgaatgtg ttaaattgtc tgccaacttt tatactacaa aataaactga ttgggtagca 1260
 ggtattgata catgtactag ttgtaataaa aaattaactt ctggcgctga agctaattta 1320
 cctgaatctg ctaaaaaaaaa tatataatgt gatttcgcta attttttata aatttcctta 1380
 ttattgattt cttattattt attatgatga 1410

<210> 45

<211> 33

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: forward primer

<400> 45

ccgaattctc tgggactgca cttgatgatg gag

33

<210> 46
<211> 8
<212> PRT
<213> Ichthyophthirius multifiliis

<400> 46
Gly Thr Ala Leu Asp Asp Gly Val
1 5

<210> 47
<211> 29
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: reverse
primer

<400> 47
gtggatccag tacatgttac artacctgc

29

<210> 48
<211> 7
<212> PRT
<213> Ichthyophthirius multifiliis

<400> 48
Ala Gly Thr Asp Thr Cys Thr
1 5

<210> 49
<211> 31
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: reverse
primer

<400> 49
gtggatccrc cagaagttaa tttttakta c

0

31

<210> 50
<211> 9
<212> PRT

<213> Ichthyophthirius multifiliis

<400> 50

Cys Thr Lys Lys Leu Thr Ser Gly Ala

1

5

<210> 51

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: reverse
primer

<400> 51

gtggatccaa ggaaatygat aaaaawttag cg

32

<210> 52

<211> 9

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 52

Phe Ala Lys Phe Leu Ser Ile Ser Leu

1

5

<210> 53

<211> 1404

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic G5
proline mutant i-antigen

<400> 53

atgaagaaca acatcccggg gatcctgata atctctctgt tcatcaacca gatcaagtct 60
gctaactgtc ctgtgggaac cgagaccaac accgctggac aggtggacga cctgggaacc 120
cctgctaact gtgtgaactg tcagaagaac ttctactaca acaacgctgc tgctttcgtg 180
cctggagctt ctacctgtac cccttgctcct cagaagaagg acgctggagc tcagcctaac 240
cctcctgcta ccgctaacct ggtgaccag tgtaacgtga agtgtcctgc tggaaaccgct 300
atcgtctggag gagctaccga ctacgctgct atcatcaccg agtgtgtgaa ctgtcgcatac 360
aacttctaca acgagaacgc tcctaacttc aacgctggag cttctacctg taccgcttgt 420
cctgtgaacc gtgtgggagg agctctgacc gctggaaacg ctgctaccat cgtggctcag 480
tgtaacgtgg cttgtcctac cggaaccgct ctggacgacg gagtgaccac cgactacgtg 540

cgctctttca ccgagtgtgt gaagtgtcgc ctgaacttct actacaacgg aaacaacgga 600
 aacacccctt tcaaccctgg aaagtctcag tgtaccctt gtcctgctat caagcctgct 660
 aacgtggctc aggctaccct gggaaacgac gctaccatca ccgctcagt taacgtggct 720
 tgtcctgacg gaaccatctc tgctgctgga gtgaacaact ggggtggtca gaacaccgag 780
 tgtaccaact gtgctcctaa cttctacaac aacaacgctc ctaacttcaa ccctggaaac 840
 tctacctgtc tgccttgtcc tgctaacaag gactacggag ctgaggctac cgctggagga 900
 gctgctaccc tggctaagca gtgtaacatc gcttgctctg acggaaccgc tatcgcttct 960
 ggagctacca actacgtgat cctgcagacc gagtgtctga actgtgctgc taacttctac 1020
 ttcgacggaa acaacttcca ggctggatct tctcgctgta aggcttgtcc tgctaacaag 1080
 gtgcagggag ctgtggctac cgctggagga accgctaccc tgatcgctca gtgtgctctg 1140
 gagtgtctctg ctggaaccgt gctgaccgac ggaaccacct ctacctaca gcaggctgct 1200
 tctgagtgtg tgaagtgtgc tgctaacttc tacaccacca agcagaccga ctgggtggct 1260
 ggaatcgaca cctgtacctc ttgtaacaag aagctgacct ctggagctga ggctaacctg 1320
 cctgagctctg ctaagaagaa catccagtgt gacttcgcta acttctgtc tatctctctg 1380
 ctgctgatct cttactacct gctg 1404

<210> 54

<211> 468

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic G5
proline mutant antigen protein

<400> 54

Met Lys Asn Asn Ile Pro Val Ile Leu Ile Ile Ser Leu Phe Ile Asn
1 5 10 15

Gln Ile Lys Ser Ala Asn Cys Pro Val Gly Thr Glu Thr Asn Thr Ala
20 25 30

Gly Gln Val Asp Asp Leu Gly Thr Pro Ala Asn Cys Val Asn Cys Gln
35 40 45

Lys Asn Phe Tyr Tyr Asn Asn Ala Ala Ala Phe Val Pro Gly Ala Ser
50 55 60

Thr Cys Thr Pro Cys Pro Gln Lys Lys Asp Ala Gly Ala Gln Pro Asn
65 70 75 80

Pro Pro Ala Thr Ala Asn Leu Val Thr Gln Cys Asn Val Lys Cys Pro
85 90 95

Ala Gly Thr Ala Ile Ala Gly Gly Ala Thr Asp Tyr Ala Ala Ile Ile
100 105 110

Thr Glu Cys Val Asn Cys Arg Ile Asn Phe Tyr Asn Glu Asn Ala Pro

115	120	125
Asn Phe Asn Ala Gly Ala Ser Thr Cys Thr Ala Cys Pro Val Asn Arg		
130	135	140
Val Gly Gly Ala Leu Thr Ala Gly Asn Ala Ala Thr Ile Val Ala Gln		
145	150	155
Cys Asn Val Ala Cys Pro Thr Gly Thr Ala Leu Asp Asp Gly Val Thr		
165	170	175
Thr Asp Tyr Val Arg Ser Phe Thr Glu Cys Val Lys Cys Arg Leu Asn		
180	185	190
Phe Tyr Tyr Asn Gly Asn Asn Gly Asn Thr Pro Phe Asn Pro Gly Lys		
195	200	205
Ser Gln Cys Thr Pro Cys Pro Ala Ile Lys Pro Ala Asn Val Ala Gln		
210	215	220
Ala Thr Leu Gly Asn Asp Ala Thr Ile Thr Ala Gln Cys Asn Val Ala		
225	230	235
Cys Pro Asp Gly Thr Ile Ser Ala Ala Gly Val Asn Asn Trp Val Ala		
245	250	255
Gln Asn Thr Glu Cys Thr Asn Cys Ala Pro Asn Phe Tyr Asn Asn Asn		
260	265	270
Ala Pro Asn Phe Asn Pro Gly Asn Ser Thr Cys Leu Pro Cys Pro Ala		
275	280	285
Asn Lys Asp Tyr Gly Ala Glu Ala Thr Ala Gly Gly Ala Ala Thr Leu		
290	295	300
Ala Lys Gln Cys Asn Ile Ala Cys Pro Asp Gly Thr Ala Ile Ala Ser		
305	310	315
Gly Ala Thr Asn Tyr Val Ile Leu Gln Thr Glu Cys Leu Asn Cys Ala		
325	330	335
Ala Asn Phe Tyr Phe Asp Gly Asn Asn Phe Gln Ala Gly Ser Ser Arg		
340	345	350
Cys Lys Ala Cys Pro Ala Asn Lys Val Gln Gly Ala Val Ala Thr Ala		
355	360	365
Gly Gly Thr Ala Thr Leu Ile Ala Gln Cys Ala Leu Glu Cys Pro Ala		

370 375 380
 Gly Thr Val Leu Thr Asp Gly Thr Thr Ser Thr Tyr Lys Gln Ala Ala
 385 390 395 400
 Ser Glu Cys Val Lys Cys Ala Ala Asn Phe Tyr Thr Thr Lys Gln Thr
 405 410 415
 Asp Trp Val Ala Gly Ile Asp Thr Cys Thr Ser Cys Asn Lys Lys Leu
 420 425 430
 Thr Ser Gly Ala Glu Ala Asn Leu Pro Glu Ser Ala Lys Lys Asn Ile
 435 440 445
 Gln Cys Asp Phe Ala Asn Phe Leu Ser Ile Ser Leu Leu Leu Ile Ser
 450 455 460
 Tyr Tyr Leu Leu
 465

<210> 55
 <211> 72
 <212> PRT
 <213> Ichthyophthirius multifiliis

<400> 55
 Cys Pro Val Gly Thr Glu Thr Asn Thr Ala Gly Gln Val Asp Asp Leu
 1 5 10 15
 Gly Thr Pro Ala Asn Cys Val Asn Cys Gln Lys Asn Phe Tyr Tyr Asn
 20 25 30
 Asn Ala Ala Ala Phe Val Pro Gly Ala Ser Thr Cys Thr Pro Cys Pro
 35 40 45
 Gln Lys Lys Asp Ala Gly Ala Gln Pro Asn Pro Pro Ala Thr Ala Asn
 50 55 60
 Leu Val Thr Gln Cys Asn Val Lys
 65 70

<210> 56
 <211> 70
 <212> PRT
 <213> Ichthyophthirius multifiliis

<400> 56

Cys Pro Ala Gly Thr Ala Ile Ala Gly Gly Ala Thr Asp Tyr Ala Ala
 1 5 10 15

Ile Ile Thr Glu Cys Val Asn Cys Arg Ile Asn Phe Tyr Asn Glu Asn
 20 25 30

Ala Pro Asn Phe Asn Ala Gly Ala Ser Thr Cys Thr Ala Cys Pro Val
 35 40 45

Asn Arg Val Gly Gly Ala Leu Thr Ala Gly Asn Ala Ala Thr Ile Val
 50 55 60

Ala Gln Cys Asn Val Ala
 65 70

<210> 57

<211> 76

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 57

Cys Pro Thr Gly Thr Ala Leu Asp Asp Gly Val Thr Thr Asp Tyr Val
 1 5 10 15

Arg Ser Phe Thr Glu Cys Val Lys Cys Arg Leu Asn Phe Tyr Tyr Asn
 20 25 30

Gly Asn Asn Gly Asn Thr Pro Phe Asn Pro Gly Lys Ser Gln Cys Thr
 35 40 45

Pro Cys Pro Ala Ile Lys Pro Ala Asn Val Ala Gln Ala Thr Leu Gly
 50 55 60

Asn Asp Ala Thr Ile Thr Ala Gln Cys Asn Val Ala
 65 70 75

<210> 58

<211> 71

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 58

Cys Pro Asp Gly Thr Ile Ser Ala Ala Gly Val Asn Asn Trp Val Ala
 1 5 10 15

Gln Asn Thr Glu Cys Thr Asn Cys Ala Pro Asn Phe Tyr Asn Asn Asn
 20 25 30

Ala Pro Asn Phe Asn Pro Gly Asn Ser Thr Cys Leu Pro Cys Pro Ala
 35 40 45

Asn Lys Asp Tyr Gly Ala Glu Ala Thr Ala Gly Gly Ala Ala Thr Leu
 50 55 60

Ala Lys Gln Cys Asn Ile Ala
 65 70

<210> 59

<211> 70

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 59

Cys Pro Asp Gly Thr Ala Ile Ala Ser Gly Ala Thr Asn Tyr Val Ile
 1 5 10 15

Leu Gln Thr Glu Cys Leu Asn Cys Ala Ala Asn Phe Tyr Phe Asp Gly
 20 25 30

Asn Asn Phe Gln Ala Gly Ser Ser Arg Cys Lys Ala Cys Pro Ala Asn
 35 40 45

Lys Val Gln Gly Ala Val Ala Thr Ala Gly Gly Thr Ala Thr Leu Ile
 50 55 60

Ala Gln Cys Ala Leu Glu
 65 70

<210> 60

<211> 72

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 60

Cys Pro Ala Gly Thr Val Leu Thr Asp Gly Thr Thr Ser Thr Tyr Lys
 1 5 10 15

Gln Ala Ala Ser Glu Cys Val Lys Cys Ala Ala Asn Phe Tyr Thr Thr
 20 25 30

Lys Gln Thr Asp Trp Val Ala Gly Ile Asp Thr Cys Thr Ser Cys Asn

35

40

45

Lys Lys Leu Thr Ser Gly Ala Glu Ala Asn Leu Pro Glu Ser Ala Lys
 50 55 60

Lys Asn Ile Gln Cys Asp Phe Ala
 65 70

<210> 61

<211> 409

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 61

Ala Val Pro Cys Pro Asp Gly Thr Gln Thr Gln Ala Gly Leu Thr Asp
 1 5 10 15

Val Gly Ala Ala Asp Leu Gly Thr Cys Val Asn Cys Arg Pro Asn Phe
 20 25 30

Tyr Tyr Asn Gly Gly Ala Ala Gln Gly Glu Ala Asn Gly Asn Gln Pro
 35 40 45

Phe Ala Ala Asn Asn Ala Ala Arg Gly Ile Cys Val Pro Cys Gln Ile
 50 55 60

Asn Arg Val Gly Ser Val Thr Asn Ala Gly Asp Leu Ala Thr Leu Ala
 65 70 75 80

Thr Gln Cys Ser Thr Gln Cys Pro Thr Gly Thr Ala Leu Asp Asp Gly
 85 90 95

Val Thr Asp Val Phe Asp Arg Ser Ala Ala Gln Cys Val Lys Cys Lys
 100 105 110

Pro Asn Phe Tyr Tyr Asn Gly Gly Ser Pro Gln Gly Glu Ala Pro Gly
 115 120 125

Val Gln Val Phe Ala Ala Gly Ala Ala Ala Ala Gly Val Ala Ala Val
 130 135 140

Thr Ser Gln Cys Val Pro Cys Gln Leu Asn Lys Asn Asp Ser Pro Ala
 145 150 155 160

Thr Ala Gly Ala Gln Ala Asn Leu Ala Thr Gln Cys Ser Asn Gln Cys
 165 170 175

Pro Thr Gly Thr Val Leu Asp Asp Gly Val Thr Leu Val Phe Asn Thr
 180 185 190

Ser Ala Thr Leu Cys Val Lys Cys Arg Pro Asn Phe Tyr Tyr Asn Gly
 195 200 205

Gly Ser Pro Gln Gly Glu Ala Pro Gly Val Gln Val Phe Ala Ala Gly
 210 215 220

Ala Ala Ala Ala Gly Val Ala Ala Val Thr Ser Gln Cys Val Pro Cys
 225 230 235 240

Gln Ile Asn Lys Asn Asp Ser Pro Ala Thr Ala Gly Ala Gln Ala Asn
 245 250 255

Leu Ala Thr Gln Cys Ser Thr Gln Cys Pro Thr Gly Thr Ala Ile Gln
 260 265 270

Asp Gly Val Thr Leu Val Phe Ser Asn Ser Ser Thr Gln Cys Ser Gln
 275 280 285

Cys Ile Ala Asn Tyr Phe Phe Asn Gly Asn Phe Glu Ala Gly Lys Ser
 290 295 300

Gln Cys Leu Lys Cys Pro Val Ser Lys Thr Thr Pro Ala His Ala Pro
 305 310 315 320

Gly Asn Thr Ala Thr Gln Ala Thr Gln Cys Leu Thr Thr Cys Pro Ala
 325 330 335

Gly Thr Val Leu Asp Asp Gly Thr Ser Thr Asn Phe Val Ala Ser Ala
 340 345 350

Thr Glu Cys Thr Lys Cys Ser Ala Gly Phe Phe Ala Ser Lys Thr Thr
 355 360 365

Gly Phe Thr Ala Gly Thr Asp Thr Cys Thr Glu Cys Thr Lys Lys Leu
 370 375 380

Thr Ser Gly Ala Thr Ala Lys Val Tyr Ala Glu Ala Thr Gln Lys Val
 385 390 395 400

Gln Cys Ala Ser Thr Thr Phe Ala Lys
 405

<210> 62

<211> 399

<212> PRT

<213> Giardia lamblia virus

<400> 62

Ala Val Asp Cys Gln Gly Ser Ala Gly Tyr Tyr Thr Asp Asp Ser Val
 1 5 10 15

Ser Asp Ala Lys Glu Cys Lys Lys Cys Asn Ala Pro Cys Thr Ala Cys
 20 25 30

Ala Gly Thr Ala Asp Lys Cys Thr Lys Cys Asp Ala Asn Gly Ala Ala
 35 40 45

Pro Tyr Leu Lys Lys Thr Asn Pro Ser Asp Pro Thr Gly Thr Cys Val
 50 55 60

Ser Ala Val Asp Cys Gln Gly Ser Ala Gly Tyr Tyr Thr Asp Asp Ser
 65 70 75 80

Val Ser Asp Ala Lys Glu Cys Lys Lys Cys Ala Glu Gly Gln Lys Pro
 85 90 95

Asn Thr Ala Gly Thr Gln Cys Phe Ser Cys Ser Asp Ala Asn Cys Glu
 100 105 110

Arg Cys Asp Gln Asn Asp Val Cys Ala Arg Cys Ser Thr Gly Ala Pro
 115 120 125

Pro Glu Asn Gly Lys Cys Pro Ala Ala Thr Pro Gly Cys His Ser Ser
 130 135 140

Cys Asp Gly Cys Thr Glu Asn Ala Met Thr Asn Gln Ala Asp Lys Cys
 145 150 155 160

Thr Gly Cys Lys Glu Gly Arg Tyr Leu Lys Pro Glu Ser Ala Ala Gly
 165 170 175

Gln Ser Gly Thr Cys Leu Thr Ala Glu Glu Cys Thr Ser Asp Thr Thr
 180 185 190

His Phe Thr Lys Glu Lys Ala Gly Asp Ser Lys Gly Met Cys Leu Pro
 195 200 205

Cys Ser Asp Ala Thr His Gly Ile Ala Gly Cys Lys Lys Cys Ala Leu
 210 215 220

Lys Thr Leu Ser Gly Glu Ala Glu Ser Thr Val Val Cys Ser Glu Cys
 225 230 235 240

Thr Asp Lys Trp Leu Thr Pro Ser Gly Asn Ala Cys Leu Asp Asn Cys
 245 250 255

Pro Ala Gly Thr Tyr Pro Asn Asp Asn Asn Leu Cys Thr Ser Cys His
 260 265 270

Asp Thr Cys Ala Glu Cys Asn Gly Asn Ala Asp Arg Ala Ser Cys Thr
 275 280 285

Ala Cys Tyr Pro Gly Tyr Ser Leu Leu Tyr Gly Ser Cys Thr Ala Gly
 290 295 300

Thr Cys Val Lys Glu Cys Thr Gly Ala Phe Gly Ala Asn Cys Ala Asp
 305 310 315 320

Gly Gln Cys Thr Ala Asp Val Gly Gly Ala Lys Tyr Cys Ala Gln Cys
 325 330 335

Lys Asp Gly Tyr Ala Pro Ile Asp Gly Ile Cys Thr Ala Val Ala Ala
 340 345 350

Ala Gly Arg Thr Asn Val Cys Thr Ala Ala Asp Gly Thr Cys Thr Lys
 355 360 365

Cys Ala Gly Glu Tyr Thr Leu Met Ser Gly Gly Cys Tyr Gly Val Ala
 370 375 380

Lys Leu Pro Gly Lys Ser Val Cys Thr Leu Ala Ser Asn Gly Lys
 385 390 395

<210> 63

<211> 5

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 63

Val Asn Ile His Gln

1

5

<210> 64

<211> 77

<212> DNA

<213> Ichthyophthirius multifiliis

<400> 64

gtaaatatcc attaatgaag cttcgaaaac agtgggtgga gtaccttatt catgcttgaa 60
gtatttagaa tcaagag 77

<210> 65

<211> 33

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 65

Lys Val Tyr Ala Glu Ala Thr Gln Lys Val Gln Cys Ala Ser Thr Thr
1 5 10 15

Phe Ala Lys Phe Leu Ser Ile Ser Leu Leu Phe Ile Ser Phe Tyr Leu
20 25 30

Leu

<210> 66

<211> 202

<212> DNA

<213> Ichthyophthirius multifiliis

<400> 66

aaagtatatg ctgaagctac tcaaaaagta taatgcgcct ccactacttt cgctaaattt 60
ttatcgattt ccttattatt tttttctttc tttttattgt gatgaataaa ataattcata 120
ttatttttatt tttttatttt atgtttataa attaaaaaat agataaaaatt taaaatatat 180
taaaaataat tttttatata aa 202

<210> 67

<211> 199

<212> DNA

<213> Ichthyophthirius multifiliis

<400> 67

aaagtatatg ctgaagctac tcaaaaagta taatgcgcct ccactacttt cgctaaattt 60
ttatcgattt ccttattatt tttttctttc tttttattgt gattaataaa ataattcata 120
ttatttttatt tttttatttt atgtttataa attaaaaaat agataaaaatt taaaatatat 180
taaaaaaaaa aaaaaaaaaa 199

<210> 68

<211> 162

<212> DNA

<213> Ichthyophthirius multifiliis

<400> 68

aaagtatatg ctgaagctac tcaaaaagta taatgcgcct ccactacttt cgctaaattt 60

ttatcgattt ccttattatt tatttctttc tatttattgt gatgaataaa ataattcata 120
ttattttatt tttttatttt atgtttataa attaaaaaat ag 162

<210> 69

<211> 119

<212> DNA

<213> Ichthyophthirius multifiliis

<400> 69

aaagtatatg ctgaagctac tcaaaaagta taatgcgcct ccactacttt cgctaaattt 60
ttatcgattt ccttattatt tatttctttc tatttattgt gatgaataaa ataattcat 119

<210> 70

<211> 117

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 70

atgggaattc aatgaagaa caacatcctg gtgatcctga tcattctctt gttcatcaac 60
cagatcaagt ctgctaactg tcctgtggga accgagacca acaccgctgg acagggtg 117

<210> 71

<211> 104

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 71

ctccaggcac gaaagcagca gcgttggtgt agtagaagtt cttctgacag ttcacacagt 60
tagcaggggt tcccaggctg tccacctgct cagcgggtgt ggctc 104

<210> 72

<211> 100

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 72

cgctgctgct ttcgtgcctg gagcttctac ctgtaccctc tgccttcaga agaaggacgc 60
tggagctcag cctaaccctc ctgctaccgc taacctggtg 100

<210> 73

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 73

gatgatagca gcgtagtcgg tagctcctcc agcgatagcg gttccagcag gacacttcac 60
gttacactgg gtcaccaggt tagcggtagc aggag 95

<210> 74

<211> 138

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 74

gctaccgact acgctgctat catcaccgag tgtgtgaact gtgcgcatcaa ctcttacaac 60
gagaacgctc ctaacttcaa cgctggagct tctacctgta ccgcttgtcc tgtgaaccgc 120
gtgggaggag ctctgacc 138

<210> 75

<211> 123

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 75

ggtgaaagag cgcacgtagt cgggtggcac tccgtcgtcc agagcggttc cggtaggaca 60
agccacgtta cactgagcca cgatggtagc agcgtttcca gcggtcagag ctctccccc 120
gcg 123

<210> 76

<211> 99

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 76

gactacgtgc gctctttcac cgagtgtgtg aagtgtcgcc tgaacttcta ctacaacgga 60
aacaacggaa acacccttt caaccctgga aagtctcag 99

<210> 77

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 77

gtgatggtag cgtcgtttcc cagggtagcc tgagccacgt tagcaggctt gatagcagga 60
caaggggtac actgagactt tccagggttg aaagg 95

<210> 78

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 78

gggaaacgac gctaccatca ccgctcagtg taacgtggct tgcctgaçg gaaccatctc 60
tgctgctgga gtgaacaact ggtggtctca gaac 94

<210> 79

<211> 100

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 79

cagacaggta gaggttccag ggtgaagtt aggagcgttg ttgtttaga agttaggagc 60
acagttggta cactcgggtg tctgagccac ccagttgttc 100

<210> 80

<211> 89

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 80

ccctggaaac tctacctgtc tgccttgtcc tgctaacaag gactacggag ctgaggctac 60
cgctggagga gctgctaccc tggctaagc 89

<210> 81

<211> 90

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 81

ggtctgcagg atcacgtagt tggtagctcc agaagcgata gcggttccgt caggacaagc 60
gatgttacac tgcttagcca gggtagcagc 90

<210> 82

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 82

caactacgtg atcctgcaga ccgagtgtct gaactgtgct gctaacttct acttcgacgg 60
aaacaacttc caggctggat cttctcgctg taagg 95

<210> 83

<211> 92

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 83

gagcgatcag ggtagcgggt cctccagcgg tagccacagc tccctgcacc ttgttagcag 60
gacaagcctt acagcgagaa gatccagcct gg 92

<210> 84

<211> 94

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 84

gaaccgctac cctgatcgt cagtgtgtctc tggagtgtcc tgctggaacc gtgctgaccg 60
acggaaccac ctctacctac aagcaggctg cttc 94

<210> 85

<211> 92

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 85

ggtgtcgatt ccagccaccc agtcggtctg cttggtggtg tagaagttag cagcacactt 60
cacacactca gaagcagcct gctttaggt ag 92

<210> 86

<211> 92

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 86

gggtggctgg aatcgacacc tgtacctctt gtaacaagaa gctgacctct ggagctgagg 60
ctaacctgcc tgagtctgct aagaagaaca tc 92

<210> 87

<211> 95

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:
oligonucleotide primers

<400> 87

gagggatcct tattacagca ggtagtaaga gatcagcagc agagagatag acaggaagtt 60
agcgaagtca cactggatgt tcttcttagc agact 95

<210> 88

<211> 52

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: repeating
primary structure motif

<400> 88

Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Cys Pro Xaa Xaa
20 25 30

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45

Cys Xaa Xaa Cys
50

<210> 89

<211> 58

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: repeating
primary structure motif

<400> 89

Cys Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gln Cys Xaa Xaa Xaa Cys Pro Xaa
20 25 30

Gly Thr Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
35 40 45

35

40

45

Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Cys
50 55

<210> 90

<211> 16

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 90

Met Lys Tyr Asn Ile Leu Leu Ile Leu Ile Ile Ser Leu Phe Ile Asn
1 5 10 15

<210> 91

<211> 16

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 91

Met Lys Asn Asn Ile Leu Val Ile Leu Ile Ile Ser Leu Phe Ile Asn
1 5 10 15

<210> 92

<211> 12

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 92

Cys Pro Thr Gly Thr Ala Leu Asp Asp Gly Val Thr
1 5 10

<210> 93

<211> 13

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 93

Cys Val Lys Cys Lys Pro Asn Phe Tyr Tyr Asn Gly Gly
1 5 10

<210> 94

<211> 12

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 94

Cys Val Lys Cys Arg Leu Asn Phe Tyr Tyr Asn Gly

1 5 10

<210> 95

<211> 11

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 95

Cys Pro Ala Gly Thr Val Leu Asp Asp Gly Thr

1 5 10

<210> 96

<211> 11

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 96

Cys Pro Ala Gly Thr Val Leu Thr Asp Gly Thr

1 5 10

<210> 97

<211> 19

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 97

Ala Gly Thr Asp Thr Cys Thr Glu Cys Thr Lys Lys Leu Thr Ser Gly

1 5 10 15

Ala Thr Ala

<210> 98

<211> 19

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 98

Ala Gly Ile Asp Thr Cys Thr Ser Cys Asn Lys Lys Leu Thr Ser Gly

1 5 10 15

Ala Glu Ala

<210> 99

<211> 17

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 99

Phe Ala Lys Phe Leu Ser Ile Ser Leu Leu Phe Ile Ser Phe Tyr Leu
1 5 10 15

Leu

<210> 100

<211> 17

<212> PRT

<213> Ichthyophthirius multifiliis

<400> 100

Phe Ala Asn Phe Leu Ser Ile Ser Leu Leu Leu Ile Ser Tyr Tyr Leu
1 5 10 15

Leu

<210> 101

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: short linker
sequence

<400> 101

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser
1 5 10

<210> 102

<211> 1410

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic
55kD i-antigen coding region

<400> 102

```

atgaagaaca acatcctggt gatcctgata atctctctgt tcatcaacca gatcaagtct 60
gctaaactgtc ctgtgggaac cgagaccaac accgctggac aggtggacga cctgggaacc 120
cctgctaact gtgtgaactg tcagaagaac ttctactaca acaacgctgc tgctttcgtg 180
cctggagctt ctacctgtac cccttgctcct cagaagaagg acgctggagc tcagcctaac 240
cctcctgcta ccgctaacct ggtgacccag tgtaacgtga agtgctctgc tggaaccgct 300
atcgctggag gagctaccga ctacgctgct atcatcaccg agtggtgtgaa ctgtcgcatac 360
aacttctaca acgagaacgc tcctaacttc aacgctggag cttctacctg taccgcttct 420
cctgtgaacc gcgtgggagg agctctgacc gctggaaacg ctgctaccat cgtggctcag 480
tgtaacgtgg ctgtcctac cggaaccgct ctggacgacg gagtgaccac cgactacgtg 540
cgctctttca ccgagtgtgt gaagtgtcgc ctgaacttct actacaacgg aaacaacgga 600
aacacccctt tcaaccctgg aaagtctcag tgtacccctt gtctgtctat caagcctgct 660
aacgtggctc aggtaccctt gggaaaacgac gctaccatca ccgtcagtg taacgtggct 720
tgtcctgacg gaaccatctc tgctgtctga gtgaacaact ggggtggctca gaacaccgag 780
tgtaccaact gtgtccttaa cttctacaac aacaacgctc ctaacttcaa ccctggaaac 840
tctacctgtc tgccttgctc tgctaacaag gactacggag ctgaggctac cgtggagga 900
gctgtacccc tggctaagca gtgtaacatc gcttgtcctg acggaaccgc tatcgttct 960
ggagctacca actacgtgat cctgcagacc gagtgtctga actgtgctgc taacttctac 1020
ttcgacggaa acaacttcca ggctggatct tctcgtctga aggttgtcc tgctaacaag 1080
gtgcaggagg ctgtggctac cgctggagga accgctaccc tgatcgctca gtgtgctctg 1140
gagtgctctg ctggaaccgt gctgaccgac ggaaccacct ctacctaaa gcaggctgct 1200
tctgagtgtg tgaagtgtgc tgctaacttc tacaccacca agcagaccga ctgggtggct 1260
ggaatcgaca cctgtacctc ttgtaacaag aagctgacct ctggagctga ggctaacctg 1320
cctgagtctg ctaagaagaa catccagtgt gacttcgcta acttctgtc tatctctctg 1380
ctgctgatct cttactacct gctgtaataa 1410

```

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 00/02962

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/30 C07K14/44 A61K39/002 A61K48/00 C12N15/62
 C07K19/00 C12N1/11 C07K16/20 C12Q1/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, MEDLINE, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>HE ET AL: "Protection of goldfish against Ichthyophthirius multifiliis by immunization with a recombinant vaccine" AQUACULTURE, vol. 158, no. 1, 1 December 1997 (1997-12-01), pages 1-10, XP000915477</p> <p>the whole article especially figure 1</p> <p style="text-align: center;">— -/-</p>	<p>3,6-17, 21,22, 24,32-35</p>

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

13 July 2000

Date of mailing of the international search report

26/07/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Cupido, M

INTERNATIONAL SEARCH REPORT

national Application No

PCT/US 00/02962

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CLARK ET AL: "Developmental expression of surface antigen genes in the parasitic ciliate <i>Ichthyophthirius multifiliis</i> " PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, US, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, vol. 89, no. 89, July 1992 (1992-07), pages 6363-6367-7, XP002098111 ISSN: 0027-8424 the whole article especially figure 1	3-5, 8-13
X	CLARK ET AL: "Surface antigen cross-linking triggers forced exit of a protozoan parasite from its host" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 93, no. 13, 25 June 1996 (1996-06-25), pages 6825-6829, XP002142533 NATIONAL ACADEMY OF SCIENCE. WASHINGTON., US ISSN: 0027-8424 the whole document	24
A	EP 0 773 295 A (OTTAWA CIVIC HOSPITAL) 14 May 1997 (1997-05-14) claims 1-4	1-11, 14-22
X,P	GAERTIG ET AL: "Surface display of a parasite antigen in the ciliate <i>Tetrahymena thermophila</i> " NATURE BIOTECHNOLOGY., vol. 17, no. 5, 17 May 1999 (1999-05-17), pages 462-465, XP002141865 NATURE PUBLISHING., US ISSN: 1087-0156 the whole document	1-23
X,P	CLARK T G ET AL: "The gene for an abundant parasite coat protein predicts tandemly repetitive metal binding domains" GENE, NL, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, vol. 229, no. 1-2, 18 March 1999 (1999-03-18), pages 91-100, XP004161162 ISSN: 0378-1119 figure 2	1-5, 8-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/02962

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0773295 A	14-05-1997	US 5780448 A	14-07-1998
		CA 2189831 A	08-05-1997
		JP 9285291 A	04-11-1997
		NO 964713 A	09-05-1997
		EP 0839913 A	06-05-1998



SCIENCE @ DIRECT

Register or Login: Password:
[Home](#) [Search](#) [Journals](#) [Abstract Databases](#) [Books](#) [Reference Works](#) [My Profile](#) [Alerts](#)
Quick Search: within [All Full-text Sources](#) [? Search Tips](#)
[← results list](#) [← previous](#) **15 of 18** [next →](#)
Annual Review of Fish Diseases

Volume 5 , 1995, Pages 113-131

doi:10.1016/0959-8030(95)00005-4 [? Cite or Link Using DOI](#)
Copyright © 1996 Published by Elsevier Science Ltd.**This Document****▶ Abstract****Actions**

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

Surface immobilization antigens of *Ichthyophthirius multifiliis*: Their role in protective immunity

Theodore G. Clark, Tian-Long Lin and Harry W. Dickerson

Department of Medical Microbiology, College of Veterinary Medicine, University of Georgia, Athens, Georgia 30602, USA


Available online 29 March 2000.

Abstract

In response to infection with the pathogenic ciliate *Ichthyophthirius multifiliis*, fish produce serum and mucus antibodies that immobilize the parasite *in vitro*. The antigens responsible for this phenomenon (referred to as **immobilization antigens**, or i-antigens) are thought to be involved in protective immunity and are being studied in connection with efforts to develop subunit vaccines. Using mammalian antibodies, the i-antigens of *Ichthyophthirius* have been identified as a family of related surface proteins with M_r 's in the 40–60 kDA range. The amino acid sequence deduced from a 1.2 kb cDNA encoding a member of this family predicts a protein with a highly periodic structure characteristic of the i-antigens of the free-living ciliates, *Paramecium* and *Tetrahymena*. To date, four distinct immobilization serotypes of *I. multifiliis* have been identified. Northern hybridization studies indicate that i-antigen genes of *Ichthyophthirius* are developmentally regulated during the parasite life cycle and are expressed at extraordinarily high levels in the infective stage. Synthesis of i-antigen mRNA transcripts may also be accompanied by novel RNA processing events. A role for the i-antigens in protective immunity is strongly suggested by the results of passive immunization studies with immobilizing monoclonal antibodies (i-mAbs). Following intraperitoneal injection of naïve channel catfish, i-mAbs confer complete protection against an otherwise lethal parasite challenge. In conjunction with ELISA and *in vitro* immobilization assays, passive immunization experiments indicate that protection requires the presence of antibody at the site of infection (that is, at the surface of fish). The results of

these studies are discussed in the light of current knowledge about mechanisms of protection against *I. multifiliis*, and a model of surface immunity is presented.

Author Keywords: Fish; Immunoparasitology; Ciliate genes

 Corresponding author. To whom correspondence should be addressed.

Annual Review of Fish Diseases

Volume 5 , 1995, Pages 113-131

This Document

► **Abstract**

Actions

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

◀ results list ◀ previous 15 of 18 next ▶

[Home](#) [Search](#) [Journals](#) [Abstract Databases](#) [Books](#) [Reference Works](#) [My Profile](#) [Alerts](#)

[Feedback](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2004 [Elsevier B.V.](#) All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.



SCIENCE @ DIRECT

Register or Login: Password:
[Home](#) [Search](#) [Journals](#) [Abstract Databases](#) [Books](#) [Reference Works](#) [My Profile](#) [Alerts](#)
Quick Search: within [All Full-text Sources](#) [? Search Tips](#)
[◀ results list](#) [◀ previous](#) **1 of 18** [next ▶](#)
Fish & Shellfish Immunology

Volume 13, Issue 5, November 2002, Pages 337-350

doi:10.1006/fsim.2001.0410 [? Cite or Link Using DOI](#)
Copyright © 2002 Elsevier Science Ltd. All rights reserved.**This Document****▶ Abstract****Actions**

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

Regular Articles

Immunisation of channel catfish, *Ictalurus punctatus*, with *Ichthyophthirius multifiliis* immobilisation antigens elicits serotype-specific protection

Xuting Wang^a, Theodore G. Clark^b, Jane Noe^a and Harry W. Dickerson^{a, [fl](#)}^a Departments of Medical Microbiology and Parasitology, University of Georgia, Athens, GA 30602-7371, U.S.A.^b Department of Microbiology and Immunology, Cornell University, Ithaca, NY, U.S.A.

Received 16 November 2001; accepted 14 January 2002. Available online 3 October 2002.

Abstract

Surface immobilisation antigens (i-antigens) were purified from two strains of *Ichthyophthirius multifiliis* (NY1 and G5) that represent different i-antigen serotypes, namely A and D, respectively. The efficacy of the purified antigens as subunit vaccines was then tested in challenge studies using parasites of the homologous or heterologous serotype. Three groups of juvenile channel catfish (70 animals per group) were immunised with i-antigens from either the G5 or NY1 isolates, or with bovine serum albumin (BSA) as a control. Proteins were injected intraperitoneally (i.p.) at a dose of 10 µg/fish with complete Freund's adjuvant on day 1, followed by a second injection in incomplete Freund's adjuvant on day 15. Fish immunised with the purified i-antigens developed high titres of serum immobilising antibodies whereas sera from BSA-injected control fish did not. Fish antisera immobilised parasites of the homologous, but not the heterologous strain, and recognised the corresponding i-antigens on Western blots run under non-reducing conditions. On day 36, each group was divided into two subgroups (n=30). One subgroup was challenged with G5 parasites, and the other was challenged with NY1 parasites. When challenged with G5 parasites, 70% of fish immunised with the G5 i-antigens survived. When challenged with NY1 parasites, 33.3% of fish immunised with the NY1 i-antigens survived. All BSA-injected

control fish died, as did all fish injected with the purified antigens and challenged with the non-homologous parasite strain. Statistical analyses indicated significant differences among test and control groups with regard to the mean days to death (MDD). While the results of these studies clearly support a role for i-antigens in protection, active immunity in response to natural infection is not serotype-specific. The utility of i-antigens, as well as the existence of other potential vaccine candidates for the prevention of 'white-spot' disease, are discussed.

Author Keywords: *Ichthyophthirius multifiliis*, channel catfish (*Ictalurus punctatus*), immobilisation antigen, immunisation, serotype cross protection, subunit vaccine

^{fl} Corresponding author: E-mail: hwd@vet.uga.edu

Fish & Shellfish Immunology

Volume 13, Issue 5 , November 2002, Pages 337-350

This Document

► Abstract

Actions

- [Cited By](#)
- [Save as Citation Alert](#)
- [E-mail Article](#)
- [Export Citation](#)

◀ results list ◀ previous 1 of 18 next ▶

[Home](#) [Search](#) [Journals](#) [Abstract Databases](#) [Books](#) [Reference Works](#) [My Profile](#) [Alerts](#)

[Feedback](#) | [Terms & Conditions](#) | [Privacy Policy](#)

Copyright © 2004 Elsevier B.V. All rights reserved. ScienceDirect® is a registered trademark of Elsevier B.V.

Variation in primary sequence and tandem repeat copy number among i-antigens of *Ichthyophthirius multifiliis*[☆]

Yuankai Lin^a, Tian Long Lin^b, Chia-Cheng Wang^a, Xuting Wang^c, Knut Stieger^d, Robert Klopfleisch^d, Theodore G. Clark^{a,*}

^a Department of Microbiology and Immunology, College of Veterinary Medicine, NYSCVM, Cornell University, Ithaca, NY 14853, USA

^b Institute of Veterinary Medicine and Animal Husbandry, Fujian Academy of Agricultural Science, Fuzhou, Fujian, People's Republic of China

^c Department of Medical Microbiology and Parasitology, College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA

^d School of Veterinary Medicine, University of Leipzig, Leipzig, Germany

Received 29 March 2001; accepted in revised form 20 November 2001

Abstract

The immobilization antigens (i-antigens) of *Ichthyophthirius multifiliis* are potential vaccine candidates for the prevention of 'white spot' disease in freshwater fish. These antigens vary with respect to antigenicity and molecular mass, and at least five i-antigen serotypes have been identified among parasite isolates thus far. In previous studies, the gene and corresponding cDNA encoding a ~48 kDa i-antigen from parasite isolate G1 (serotype A), had been cloned and sequenced. We now report on the isolation of two new genes, designated *IAG52A[G5]* and *IAG52B[G5]*, encoding ~52/55 kDa i-antigens from a parasite isolate representing a different serotype, namely, D. Based on their deduced sequences, the ~52/55 kDa gene products have the same structural features as the 48 kDa protein including hydrophobic N- and C-termini, periodic cysteine residues with the potential for metal binding, and tandemly repetitive amino acid sequence domains that span their length. Nevertheless, the products of these genes vary in their tandem repeat copy number, and share only ~50% homology overall. When expressed in heterologous systems, the products of the newly described genes react strongly with monospecific polyclonal antisera against the i-antigens of serotype D and are clearly i-antigens. It would nevertheless appear that mRNA transcripts from the two genes are present at widely different levels within parasites themselves. Analysis at the protein level using 2-D SDS-PAGE would further suggest that multiple i-antigens are expressed within the same serotype at any given time. © 2002 Elsevier Science B.V. All rights reserved.

Keywords: GPI-anchored protein; Surface antigen gene; Ciliate; *Ichthyophthirius multifiliis*

1. Introduction

As the etiologic agent of 'white spot' disease in freshwater fish, the parasitic ciliate, *Ichthyophthirius multifiliis*, is a major problem in commercial aquaculture worldwide [1,2]. The parasite is highly virulent and readily kills fish. Nevertheless, animals that recover from infection develop acquired immunity, and recent work has identified a family of abundant GPI-anchored membrane proteins (referred to as immobilization antigens, or i-antigens) as important targets of the host immune response [3–6]. Based on passive immunization experiments, monoclonal antibodies against these proteins confer strong protection against an otherwise lethal parasite challenge [4,5]. Furthermore, the proteins themselves induce active immunity when ad-

Abbreviations: BCIP, 5-bromo-4-chloro-indolylphosphate; CHAPS, 3-[3-cholamidopropyl]dimethylammonio]-1-propanesulfonate; Da, dalton; FAM6-carboxy-fluorescein; i-antigen, immobilization antigen; kb, kilobase; kDa, kilodalton; NBT, nitroblue tetrazolium; nt, nucleotide; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; RACE, rapid amplification of cDNA ends; SDS, sodium dodecylsulfate; SSC, standard saline citrate.

[☆] Note: Nucleotide sequence data reported in this paper are available in the GenBank™ database under the accession numbers: AF324424; AF405431.

* Corresponding author. Tel.: +1-607-253-4042; fax: +1-607-253-3384.

E-mail address: tgc3@cornell.edu (T.G. Clark).

ministered directly to naive fish (Wang and Dickerson, unpublished).

While the i-antigens constitute important vaccine candidates, serotypic variation among these proteins exists within natural populations. Using antisera that immobilize *Ichthyophthirius* in a strain-specific manner, five i-antigen serotypes (referred to as A–E) have been now identified [7,8]. Antisera against a given strain cross-react on Western blots with i-antigens of all serotypes indicating that the proteins share linear epitopes in common [3,7]. The determinants responsible for immobilization are nevertheless distinct for each serotype and are conformational in nature. Passive immunization studies have suggested that these epitopes are essential for the development of protective immunity [4,5]. Along with differences in antigenicity, the proteins vary in size and number. Depending on serotype, i-antigens migrate on one-dimensional SDS-PAGE as either one or two polypeptides with apparent molecular mass in the range of ~40–60 kDa [3].

Since differences among these proteins may be of critical importance in the development of effective vaccines, efforts to clone and characterize i-antigen genes of different parasite strains are currently underway. In this regard, the gene encoding a ~48 kDa i-antigen of parasite isolate G1 (serotype A) has recently been isolated [9,10]. Based on its deduced sequence, the product of this gene (*IAG48[G1]*) contains hydrophobic signal peptides at its N- and C-termini, as well as a series of tandem repeats of about 80 amino acids each that span its length [10]. The repeats themselves are characterized by periodic cysteine residues that fall into register when the homologous segments are aligned. The spacing of these cysteines, namely, C–X_{2,3}–C, within the higher order framework, C–X₂–C–X₂₀–C–X₃–C–X₂₀–C–X₂–C, has suggested that the i-antigens may be metal-binding proteins [10]. This type of structure is common to the i-antigens of free-living ciliates [11,12], and is reminiscent of surface coat proteins of more distantly related parasitic protozoa (most notably the variant-specific proteins (VSPs) of *Giardia lamblia* [13–15]).

Although the gene for the ~48 kDa i-antigen of serotype A offers useful information regarding the overall structure of these proteins, little is known about the features that distinguish i-antigens of different serotypes from one another. Furthermore, serotype A occurs relatively infrequently in nature, and the gene for the 48 kDa protein may be of limited use in vaccine development. We report here on the isolation of genes encoding two ~52/55 kDa i-antigens from a member of what appears to be the most common serotype, namely D [8]. Isolation of these new genes provides a basis for the first comparison between i-antigens of different serotypes, and suggests that multiple i-antigens are coordinately expressed within the same

serotype during at least one stage of the parasite life cycle.

2. Materials and methods

2.1. Parasite strains

I. multifiliis strains G1 and G5 were maintained on juvenile channel catfish as previously described [10]. These strains are representative of i-antigen serotypes A and D, respectively [8]. Based on one-dimensional SDS-PAGE and Western blotting analysis, serotype A antigens migrate as two polypeptides of apparent M_r of 48- and 60-kDa, while serotype D proteins run as a single, relatively broad band estimated previously as ~52/55 kDa [3,4,6].

2.2. Library construction and isolation of a partial *IAG52A[G5]* cDNA

A size-selected cDNA library in λ ZAPII (Stratagene, La Jolla, CA) was prepared from *I. multifiliis* G5 trophont mRNA, and screened with a ³²P-labelled probe that hybridized with the gene for the 48 kDa i-antigen of parasite isolate G1 (*IAG48[G1]*) [10]. The probe itself was generated as follows: N-terminal amino acid sequence derived by Edman degradation from affinity purified i-antigens of *I. multifiliis* serotype D (Lin, Wang, and Dickerson, unpublished) was used to design a forward PCR primer with the sequence: 5'CCTAATGGTGCWGCWATTGCWAATGG3'.

This primer was paired with a reverse primer (5'-TT-TAGCRAAAGTAGTDGAKGCRC-3') corresponding to a stretch of eight amino acids (CASTTFAK) near the C-terminus of the 48 kDa i-antigen of parasite strain G1. We reasoned that the latter sequence might be conserved among i-antigen genes by virtue of its proximity to the GPI-anchor cleavage and addition site in the protein. When combined in a standard PCR reaction with genomic DNA of G5 parasites, the two primers generated a complex array of fragments. These were then probed on a Southern blot with the radiolabelled gene for the 48 kDa antigen under conditions of reduced stringency (2 × SSC at 55 °C [1 × SSC contains 0.15 M NaCl, 0.015 M sodium citrate, pH 7.0]). A single band of ~1.1 kb was recognized by the probe. DNA from this region of the gel was purified, labeled with α^{32} P(dCTP) [16], and used to screen the cDNA library under conditions of high stringency (0.1 M SSC at 65 °C). A positive clone containing a 1.2 kb insert (corresponding to *IAG52A[G5]*) was isolated and then sequenced off both strands with a Perkin-Elmer/Applied Biosystems Division 377 automated DNA sequencer using dye terminator chemistry and AmpliTaq-FS DNA polymerase (Applied Biosystems, Foster City, CA).

2.3. PCR amplification of an *IAG52B*[G5] gene fragment

Initial characterization of *IAG52B*[G5] began with amplification of a gene fragment using a degenerate forward primer corresponding to the N-terminal sequence of affinity purified G5 i-antigens (G5NTD-5: 5'-GTWAAAYTGYCCWAAAYGGWGC-3'), and a reverse primer corresponding to a conserved region near the 3'-end of the coding sequences of *IAG48*[G1] and *IAG52A*[G5] (PAN4: 5'-GTGGATCCRCCA-GAAGTTAATTTTTTAKTAC-3'). Amplification of G5 genomic DNA with the degenerate primers gave rise to a 1169 bp PCR product that contained the preponderance of the coding sequence of *IAG52B*[G5].

2.4. Rapid amplification of cDNA ends (RACE)

Total RNA from theronts of the G5 strain was isolated and used as a template for 5'- and 3'-RACE with the SMART™ RACE cDNA amplification kit (CLONTECH, Palo Alto, CA) [17]. First-strand synthesis was carried out with SuperScript™ RNase H⁻ reverse transcriptase (Gibco Life Technologies) using a modified oligodT primer (3'-CDS: 5'-AAGCAGTG-GTAACAACGCAGAGTAC (T)₃₀NV-3'). The resulting cDNA was then amplified in PCR reactions using the following primer pairs. For *IAG52A*[G5], 5'-RACE was carried out with the forward primer, UPM (5'-CTAATACGACTCACTATAGGGCAAGC-AGTGGTAACAACGCAGAGT-3'), and the gene-specific reverse primer, G5-29 (5'-CGGTGGATCCT-CATAATAAATAAAGAAATCAATAATAAGG-3'). For *IAG52B*[G5], 5'-RACE was carried out with UPM as the forward primer, and the gene-specific reverse primer G5-II-9 (5'-CAAGTATTTATATCT-GCAGCTCC-3'). For 3'-RACE with *IAG52B*[G5], we utilized the gene-specific forward primer G5-II-7 (5'-GAATCCTGGTAATGGATAATTCAGTCC-3'), and a reverse primer (NUP) complimentary to a region within 3'-CDS (NUP: 5'-AAGCAGTGGTAACAA-CGCAGAGT-3'). Unless otherwise stated, all PCR reactions were carried out under standard conditions using a proof-reading thermostable DNA polymerase (Expand High Fidelity; Roche Molecular Biochemicals, Indianapolis, IN). RACE products were fractionated on 1.2% agarose gels in TAE buffer (40 mM Tris acetate, 1 mM ethylenediaminetetracetic acid (EDTA), pH 8.0). Following excision from the gel, respective fragments were cloned into the plasmid vector pCR®2.1-TOPO (Invitrogen, Carlsbad, CA) and sequenced.

2.5. Amplification of full-length coding regions

Genomic DNA from G5 parasites was amplified with primers flanking the coding regions of *IAG52A*[G5] and *IAG52B*[G5] cDNAs in order to determine whether introns were present in the corresponding genes. Flanking primers in each case were: G5-28 and G5-29 for *IAG52A*[G5] (G5-28: 5'-TGGCAAGCTTGAAAAATAATATTTTAGTAAT-ATTGATTATTTCC-3'; G5-29: 5'-CGGTGGATCCTC-ATAATAAATAAATAAGAAATCAATAATAAGG-3'); and G5-II-1 and G5-II-2 for *IAG52B*[G5] (G5-II-1: 5'-AGGCAAGCTTGAAATTTAATATTTTAATA-ATTTTGATTATTTCC-3'; G5-II-2: 5'-CGGTGGAT-CACAACAAATAGAAAGAAATAAATATTAAGG-3'). The resulting PCR products were introduced into standard plasmid cloning vectors and sequenced.

2.6. Inverse PCR

Total genomic DNA from G5 tophonts (1 µg per 10 µl reaction) was cleaved with either *Afl* II or *Swa* I for 6 h (5 U enzyme per µg DNA) (Roche Molecular Biochemicals). Reaction mixtures were then diluted to a volume of 160 µl with H₂O and enzyme activity was destroyed by heating to 75 °C for 15 min. Reactions were brought to 200 µl with 5 × ligation buffer (250 mM Tris-HCl pH 7.6, 50 mM MgCl₂, 5 mM ATP, 5 mM dithiothreitol, 25% w/v polyethylene glycol 8000), and extracted once with an equal volume of chloroform. T4 DNA ligase (Gibco Life Technologies) was then added to a final concentration of 0.2 U µl⁻¹ and the samples were incubated overnight at room temperature. DNA was concentrated by ethanol precipitation and redissolved in 5 µl H₂O. Circular fragments were then amplified with the Expand Long Template thermostable DNA polymerase (Roche Molecular Biochemicals) in 50 µl PCR reactions containing 1 µl concentrated DNA and 20 pg each of the oppositely oriented primers G5-11 (5'-TGCTCGAGAATCTGTTGCTCCACCTG-3') and G5-4 (5'-CACACCTTGTCCGGCAATTAAAC-3'). Cycling conditions for PCR were 95 °C for 2 min; ten cycles of 94 °C for 10 s, 60 °C for 30 s and 68 °C for 4 min; then 20 cycles of 94 °C for 10 s, 60 °C for 30 s and 68 °C for 4 min with a 20 s increase in elongation time at each cycle; and finally 68 °C for 7 min. Fragments generated from each of the original restriction digests were purified using the QIAquick gel extraction kit (QIAGEN, Valencia, CA) and directly sequenced off both strands.

2.7. Southern hybridization analysis

Probes were generated by PCR amplification of *IAG52A*[G5] and *IAG52B*[G5] using primer sets G5-28

and G5-29 (for *IAG52A*), and G5-II-1 and G5-II-2 (for *IAG52B[G5]*). Following gel purification, probes were labeled with digoxigenin-tagged dUTP using random primers (DIG DNA labeling kit; Roche Molecular Biochemicals). Genomic DNA from G5 trophonts (4 µg) was digested overnight in separate reactions with a variety of restriction endonucleases. Additional enzyme was added the following day and digestions were continued 1–2 h. Restriction fragments were separated on 0.8% agarose gels and transferred to Zeta-Probe nylon filters (BIO-RAD, Hercules, CA) as described by Rigaud et al. [18]. DNA was fixed to membranes by cross-linking with ultraviolet light and then hybridized with the digoxigenin-labeled probe at high stringency ($0.1 \times \text{SSC}$, 65 °C). Probe detection was carried out using an alkaline phosphatase-tagged anti-digoxigenin monoclonal antibody (Roche Molecular Biochemicals), and the chemiluminescent substrate CSPD (Tropix, Bedford, MA). The size of restriction fragments was estimated using an unlabelled standard (1 kb ladder; Gibco Life Technologies).

2.8. Computer-based sequence analysis

Results of sequencing reactions were compiled and analyzed using DNASIS software (version 2.0; Hitachi Software Engineering). Predictions of potential signal peptides and their cleavage sites were made using the Signalp World Wide Web server (<http://www.cbs.dtu.dk/services/SignalP/>) version 1.0. Peptide mass was determined using the PEPTIDE MASS tool accessed through the ExPASy molecular biology World Wide Web server of the Swiss Institute of Bioinformatics (<http://expasy.hcuge.ch/sprot/peptide-mass.html>). Amino acid sequence alignment was carried out using the CLUSTALW (1.74) multiple sequence alignment program accessed through the ExPASy web server.

2.9. Quantitative RT-PCR

Standards were prepared by in vitro transcription of sense strand RNA from *IAG52A[G5]* and *IAG52B[G5]* in pCR®2.1-TOPO following linearization of the vector. Transcription was driven by T7 RNA polymerase using a Riboprobe® in vitro transcription kit (Promega, Madison, WI). Plasmid DNA was removed by treatment with RQ1 RNase-free DNase for 15 min at 37 °C, and RNA extracted with phenol:chloroform:isoamylalcohol (25:24:1). After precipitation with ethanol, RNA was dissolved in H₂O. Total RNA from G5 theronts was isolated as previously described [9] and treated with RNase-free DNase I to remove traces of residual DNA (Ambion, Austin, TX). RNA concentra-

tions were determined spectrophotometrically, and samples were run on 1.5% agarose–formaldehyde gels to verify their quality. RT-PCR was then carried out using TaqMan® Real Time PCR with FAM labeled probes (Applied Biosystems). Primer/probe combinations for amplification of *IAG52A[G5]* and *IAG52B[G5]* cDNAs were as follows: for *IAG52A[G5]*, the forward primer was 5'-AATTGTCCTGTTG-GAACTGAACTAA-3', the reverse primer was 5'-AGGAACGAAAGCGCAGCAT-3', and the probe was 5'-GGAGTTCCTAGATCATCAACTTATCCG-GCTGT-3'; for *IAG52B[G5]*, the forward primer was 5'-TGCAATAAGTGTGCAGTAAGTAAACTG-3', the reverse primer was 5'-TAAAGCTACAAA-TTAGTTGATGT-3', and the probe was 5'-TTCAG-CATCTGTTCCAGGTAATAGTGCT ACTTCAG-3'. Reactions were carried out in 96-well plates using a one-step PCR reagent master mix supplied by the manufacturer (Applied Biosystems). Amplification was measured as an increase in fluorescence in real time with a laser-driven ABI Prism® 7700 Sequence Detection System (Applied Biosystems). A threshold cycle (the cycle at which a statistically significant increase in fluorescence occurred for a given reaction, abbreviated C_T) was established for each well, and the absolute levels of target sequence in the parasite samples calculated by reference to a standard curve. Controls for the amplification of residual DNA in the different RNA samples (PCR reactions carried out in the absence of reverse transcriptase) were negative.

2.10. Analysis of membrane proteins by one- and two-dimensional SDS-PAGE

Membrane protein from G5 theronts was isolated by extraction in Triton X-114 as previously described [6]. For 2-dimensional gels, protein was concentrated by precipitation in acetone and dissolved in rehydration buffer containing 9 M urea, 10 mM dithiothreitol, 0.2% ampholytes (3/10), 0.5% CHAPS, and 0.005% bromphenol blue. Protein (1–10 µg) was loaded onto 17 cm immobilized pH (4–7) gradient strips by active rehydration, and subjected to isoelectric focusing for 45 000 V h using a PROTEAN IEF power supply (BIO-RAD Laboratories). Gel strips were equilibrated in buffer containing 6 M urea, 20% glycerol, 130 mM dithiothreitol, 2% SDS, and 0.375 M Tris–HCl (pH 8.8), and then loaded onto 10% SDS-polyacrylamide gels where proteins were fractionated by size. For one-dimensional gels, protein was concentrated as above, and then dissolved by boiling in SDS sample buffer (2% SDS, 100 mM dithiothreitol, 10% glycerol, 0.1% bromphenol blue, 50 mM Tris–HCl, pH 6.8) prior to separation on 10% SDS-polyacrylamide gels. I-antigens were visualized by Western blotting after transfer onto

nitrocellulose paper. Filters were blocked overnight in TBST buffer (150 mM NaCl, 5% Tween, 10 mM Tris–HCl pH 8.0) containing 3% (w/v) dry milk and reacted sequentially with 1:500 dilutions of monospecific rabbit polyclonal antisera against affinity purified G5 i-antigens [6], followed by 1:8000 dilutions of goat anti-rabbit IgG coupled to alkaline phosphatase (Sigma, St. Louis, MO). Cross-reacting proteins were visualized with the colorimetric substrates NBT and BCIP.

3. Results

3.1. Isolation of a ~52/55 kDa i-antigen gene from serotype D (*IAG52A[G5]*)

To obtain i-antigen gene sequences from serotype D, a cDNA library from the G5 parasite strain was screened with a radiolabelled probe that hybridized with the gene encoding the 48 kDa i-antigen of parasite isolate G1 (serotype A). Of roughly 2×10^4 phage clones screened, only three scored positive, and one was subjected to further analysis. This clone was found to contain a 1.2 kb insert with an open-reading frame extending 1052 nt from its 5' end. The coding region ended in consecutive TGA stop codons followed by a short untranslated region at its 3' end. The cDNA was nevertheless truncated at its 5' end and lacked coding sequence for the N-terminus of the corresponding protein. To obtain that sequence, we performed RACE and extended the cDNA an additional 397 nt in the 5' direction. When translated in-frame with the 1.2 kb insert, the RACE product and its downstream sequence predicted a full-length protein that bore all the hallmarks of an i-antigen (see below).

To characterize the gene corresponding to this cDNA, PCR was carried out with genomic DNA from the G5 parasite strain as template. Primers that flanked the coding region of the cDNA (G5-28 and G5-29) produced a 1426 bp fragment having the identical sequence as the cDNA with no introns. Inverse PCR was then used to extend the sequences outside the coding region by several hundred bp in either direction. As shown in Fig. 1, genomic DNA cleaved with the restriction enzymes *Afl* II and *Swa* I gave rise to single bands of 1.6 and 2.0 kb, respectively, following inverse PCR. Fig. 2 shows the relationship between the genomic fragments obtained using this approach and the corresponding cDNA described above. The complete nucleotide and deduced amino acid sequence of the gene (designated *IAG52A[G5]*) is shown in Fig. 3.

3.2. Isolation of a second ~52/55 kDa i-antigen gene (*IAG52B[G5]*)

While its deduced amino acid sequence clearly indicated that the product of *IAG52A[G5]* was an i-antigen,




Fig. 1. DNA fragments generated by inverse PCR. Genomic DNA was cut with either *Afl* II or *Swa* I, then self-ligated and subjected to inverse PCR using gene-specific primers oriented in opposite directions. The reactions yielded single bands of slightly more than 1.6 and 2.0 kb for the *Afl* II and *Swa* I digests, respectively, after fractionation on a 1% agarose gels and staining with ethidium bromide. The lane on the extreme left contains a ~1 kb size standard.




Fig. 2. Mapped region of the gene. A restriction map of genomic DNA in the region of *IAG52A[G5]* is on the top line (coding region in bold). Endonuclease cleavage sites are denoted as follows: A, *Afl* II; S, *Swa* I; E, *Eco* R V; P, *Pst* I; N, *Nde* I. The second line diagrams the region spanned by the cloned cDNA and corresponding 5'-RACE product. The last two lines show the regions covered by the *Swa* I and *Afl* II inverse PCR products, respectively. G5-11 and G5-4 are the primers used in the amplification reactions.




Fig. 4. Amplification of an *IAG52B*[G5] gene fragment. Genomic DNA from the G5 parasite strain was amplified with degenerate primers G5NTD-5 and PAN4, and the resulting products fractionated on a 1% agarose gel. After staining with ethidium bromide, two major fragments of ~1.2 and 0.8 kb were detected (right-hand lane). On sequencing, the larger of the two fragments was found to correspond to most of the coding region of *IAG52B*[G5], while the smaller one arose from an irrelevant gene. The left-hand lane contains a DNA size standard.

the region immediately downstream of its predicted N-terminal signal peptide differed markedly from the N-terminal sequence derived by Edman degradation from affinity purified i-antigens of the G5 parasite strain (VN-PNGAAIANGQSDTGAAD; Wang and Dickerson, unpublished). Since this suggested the existence of at least one additional i-antigen gene in this serotype, G5 genomic DNA was amplified with a pair of degenerate primers (G5NTD-5 and PAN4) based on the N-terminal sequence derived from the protein, and a C-terminal sequence that appears highly conserved in the product of *IAG52A*[G5], and the 48 kDa i-antigen of serotype A [10]. As shown in Fig. 4, the degenerate primers gave rise to two major products of ~1.2 and 0.8 kb. On sequencing, it was clear that the larger (1169 bp) fragment arose from an i-antigen gene that was substantially different from either *IAG52A*[G5] or *IAG48*[G1]. RACE was then carried out to obtain the full-length coding sequence of the new gene. The nucleotide and deduced amino acid sequence of this gene (designated *IAG52B*[G5]) are shown in Fig. 5.

3.3. Nucleotide sequence and gene organization

IAG52A[G5] and *IAG52B*[G5] are highly AT-rich and show marked asymmetry in the ratio of AT/GC in coding versus non-coding regions (89 vs. 66%, respectively). In addition, a strong bias toward either A or T

in the third position of codons is present in both genes. As is true of other hymenostome ciliates, *Ichthyophthirius* utilizes a non-standard genetic code in which the normal TAA and TAG 'stop' codons encode glutamine instead [9,10]. A total of 18 and 25 UAA/UAG triplets are present within the coding regions of *IAG52A*[G5] and *IAG52B*[G5], respectively. RACE analysis suggests that the 5'-untranslated regions of these genes are short, and predict tentative transcriptional start sites 45- and 40-nt upstream of the start codons in each case (Figs. 3 and 5). The 3'-untranslated regions also appear rather short. From the location of the polyA tracts associated with the cDNA and RACE products, the 3' untranslated regions extend 85–86 nt and 82 nt from the distal ends of the coding sequences of *IAG52A*[G5] and *IAG52B*[G5], respectively (Figs. 3 and 5). Southern blotting analysis indicates that the two genes are present at single loci within the macronuclear genome of this strain (Fig. 6).

3.4. Deduced amino acid sequences

Both *IAG52A*[G5] and *IAG52B*[G5] predict proteins with features that are highly reminiscent of the 48 kDa i-antigen of parasite isolate G1. Immediately downstream of their putative initiator methionine residues are regions containing 19 mostly hydrophobic amino acids. Using neural network algorithms [18], these regions were judged to be signal peptides for ER-translocation, with predicted cleavage sites between residues 20 and 21 in each case. The signal peptides are then followed by tandemly repetitive amino acid sequence domains that extend nearly the entire length of each protein. As shown in Fig. 7A, the repeats contain six cysteines that fall into register when the homologous segments are aligned. The spacing of these cysteines is on the order: C-X_{19,20}-C-X₂-C-X_{17,21}-C-X₂-C-X_{20,22}-C-X₃ for *IAG52A*[G5]; and, C-X_{20,21}-C-X₂-C-X_{16,47}-C-X₂-C-X_{20,21}-C-X₃ for *IAG52B*[G5]. Finally, the deduced proteins contain hydrophobic amino acid stretches at their C-termini that are characteristic of signal peptides for GPI-anchor addition [19,20]. Overall, *IAG52A*[G5] specifies a proprotein of 468 amino acids with a predicted molecular mass of 48,281 Da, while *IAG52B*[G5] predicts a proprotein of 460 amino acids with a predicted mass of 47,583 Da.

3.5. Sequence comparisons

A comparison of the deduced amino acid sequences predicted by the three i-antigen genes characterized to date (two from serotype D, and one from serotype A) is shown in Fig. 7B. As indicated in Fig. 8, the three proteins share only ~50% identity relative to one

another. They are most similar at their hydrophobic N- and C-termini, although a number of other regions appear to be highly conserved, most notably, the C-X_{2,3}-C motifs, the CP-X-G(T/A) motifs at the start of each repeat, and the KKLTSGA domains that lie just upstream of the C-termini. Overall, the proteins differ most in their central repeats, particularly in the regions that separate adjacent C-X₂-C motifs. There is also an obvious difference in tandem repeat copy num-

ber among the proteins, with the *IAG52A*[G5] gene product having six, and the *IAG48*[G1] and *IAG52B*[G5] gene products having five repeats each (Fig. 7).

3.6. *I*-antigen gene expression in serotype D

Although it was clear from routine RT-PCR that the two G5 *i*-antigen genes (that is, *IAG52A*[G5] and *IAG52B*[G5]) were actively transcribed, their relative levels of expression were unknown. To determine actual transcript levels from each gene, quantitative RT-PCR was carried out using total RNA from G5 theronts (Fig. 9). Based on standard curves generated from known amounts of gene-specific template RNA, steady-state transcript levels from *IAG52B*[G5] were found to be substantially higher (> 100 fold) than those from *IAG52A*[G5]. In absolute terms, expression from *IAG52B*[G5] was extraordinarily high (estimated at ~ 2% of polyA⁺ RNA), and suggested that the corresponding gene product is the predominant *i*-antigen expressed in serotype D. To examine *i*-antigen expression at the protein level, 2-dimensional SDS-PAGE and Western blotting was carried out on total membrane protein from G5 theronts. As shown in Fig. 10, at least four *i*-antigen variants in the ~ 52/55 kDa size range were recognized by monospecific polyclonal antisera against G5 *i*-antigens. This would clearly suggest that the *IAG52A* and *B* gene products are modified, or that additional *i*-antigen genes are expressed in this strain.

4. Discussion

Initial attempts to isolate and characterize *i*-antigen genes from serotype D met with limited success. Although not described here, these efforts began with screens of G5 genomic DNA libraries using *IAG48*[G1] as a probe. A few weakly hybridizing clones were identified in such screens, but none showed homology to the *IAG48*[G1] gene itself. As indicated in this report, attempts to amplify *i*-antigen coding sequences from G5 genomic DNA using degenerate primers were also unsuccessful, giving rise to complex patterns of fragments rather than single bands. Nonetheless, when amplification products generated by these reactions were hybridized under conditions of reduced stringency with *IAG48*[G1], a band of roughly the expected size was detected in Southern blots. This provided a homologous probe for additional library screens and led to the identification of a partial cDNA encoding a polypeptide with all the hallmarks of an *i*-antigen. Amplification of a full-length cDNA (and corresponding *IAG52A*[G5] gene) was then possible using sequence-specific primers. Retrospectively, we found that the degenerate primers that gave rise to the PCR-gener-




Fig. 6. Southern hybridization analysis. Total genomic DNA from the G5 parasite strain was digested with a variety of restriction endonucleases, fractionated on 0.8% agarose gels, and transferred to nylon. Filters were then screened with digoxigenin-labeled probes for either *IAG52A*[G5] (panel A), or *IAG52B*[G5] (panel B). A single major band was present in virtually all restriction digests. Lanes 2–9 contain the following restriction digests: 2. Sma I; 3. Hind III; 4. EcoR I; 5. Dra I; 6. Nde I; 7. Nsi I; 8. Sfu I; and 9. Xba I. Lane 1 in panel (A) contains unlabelled probe, and in panel (B) a DNA size standard (the 1.6 kb fragment in the size standard hybridizes with *i*-antigen probes and serves as a convenient marker on the gel).

A**LAG52A[G5]**

CPVGTETNTA GQVDDLTPA NCVNCQKNFY YN-NAA--AF VPGASTCTPC POKADAGAPQ NPPATAN-LV TQCNVK
 CPAGTALAGS AT-DYAAIIT ECVNCRINFY NE-NAPN--F NAGASTCTAC PVNRVGGALT --AGNAATIV AQCNVA
 CPTGTALDDG VTIDYVRSFT ECVKCRINFY YNGNNGTTPF NPGKSQCTPC PAIKPANVAQ ATLGNDATIT AQCNVA
 CPDGTISAAG VNNWVAQN-T ECTNCAPNFY NN-NAPN--F NPGNSTCLPC PANKDYGAEA -TAGGAATIA KQCNIA
 CPDGTAIASG ATNYVILQ-T ECLNCAANFY FDGN--N--F QAGSSRCAC PANKVQSAVA -TAGGTATLI AQCALE
 CPAGTVLTDG TISTYKQAS ECVKCAANFY TTKQ---TDW VAGIDTCTSC NKKLTSGAEA NLPESAKKNI -QCDEFA
 NFLSISLLLI SYLL**

LAG52B[G5]

CPNGAAIANG QSDTGAADIN TCTHCQKHFY F--NGGNPAG QAPGAVQFN- -----PGVS- ---QCIACQV HKA-DSQHRQ GGDANLAAQC SNL
 CPAGTAVEEG -SPFTQSLT QCVNCKPNFY F--NGGNPTG: QAPGAGQFDP TOLIANPELA NNPEVFNVS PNCQVACQV NKS-DSQLRP QAQANLATQC NNE
 CPTGTALDDG ALFIYTQSLT QCTECKVDFY F--NGGNPSA QNPGNGQFTP QGLIANPDAA TAAQIMVVG PMSKCVACES KKT-NSQSRG GLEANLAAQC GTE
 CPAGTVLTDG VTPTTYVSLG QCVNCKAGFY Q--NSNFEAG KS----- ---QCNKCAV SKT-GSASVP GNSATSATQC QND
 CPAGTVVDEG TSTNEVALAS ECTKQANFY ASKTSQFAAG TD----- ---TCTECSK KLTSGATAKV YAEATQKQCA ASS
 TFAKFLMSL IFISFYLL**

B

LAG52A[G5]	CPVGTETNTA GQVDDLTPA NCVNCQKNFY YN----- --AAAEVPG- --ASTCTPCP QKKDAGAPQ: PPATANLVQ: CNVK	94
LAG52B[G5]	CPNGAAIANG QSDTGAADIN TCTHCQKHFY FNGGNPAGQA PGAVQFNPG- --VSQCIACQ VHK-ADSQHR QGGDANLAAQ CSNL	102
LAG48 [G1]	CPDGTQTAG LTDVGAADLG TCVNCRPNFY YNGGAAQGEA NGNQFPANN AARGICVPCQ INR-VGSVTN AGDLATLATQ CSTQ	105
	** *:	
LAG52A[G5]	CPAGTAVEEG AT-DYAAIIT ECVNCRINFY NEN-----A F--NENAGA S----- -TCTACPVNR VGGALTAGNA ATIVAQCNVA	164
LAG52B[G5]	CPAGTAVEEG SP-TFTQSLT QCVNCKPNFY FNGGNPTGQA PGAGQFDPQT LIANPDANN PEVFNVSPPN GQCVACQVNR SDSQLRPGAQ ANLATQCNNE	201
LAG48 [G1]	CPTGTALDDG VTIDYVRSFT ECVKCRINFY YNGNNGTTPF NPGKSQCTPC PAIKPANVAQ ATLGNDATIT AQCNVA	240
	*****:	
LAG52A[G5]	CPDGTISAAG VNNWVAQNTE CTNCAPNFY: NNAFNPNPGN STCLPCPANK DYGAETAGG AATIAKQCN A	311
LAG52B[G5]	----- --IEMVPGPN SKCVACESKK TN-SQSRSL EANLAAQCGT E	301
LAG48 [G1]	----- --VAAVT--- SQCVPCQINK ND-SPATAGA QANLATQCST Q	283
	
LAG52A[G5]	CPDGTAIASG ATN-YVILQT ECLNCAANFY FDGNFEAGS SRCKACPANK VQAVATAGG TATLIAQCAL E	381
LAG52B[G5]	CPAGTVLTDG VTPTTYVSLG QCVNCKAGFY QNSN-FAAGK SQCNKCAVSK TG-SASVPGN SATSATQCON D	370
LAG48 [G1]	CPTGTALDDG VTIDYVRSFT ECVKCRINFY YNGNNGTTPF NPGKSQCTPC PAIKPANVAQ ATLGNDATIT AQCNVA	240
	*****:	
LAG52A[G5]	CPAGTVLTDG TISTYKQAS ECVKCAANFY TTKQTDWVAG IDTCTSCNKK LTSGAEANLP ESAKKNICCD --	451
LAG52B[G5]	CPAGTVVDEG TSTNEVALAS ECTKQANFY ASKTSQFAAG TDTCTECSKK LTSGATAKVY AEATQKQCA SS	442
LAG48 [G1]	CPAGTVLDDG TSTNEVASAT ECTKCSAGFF ASKTTGFTAG TDTCTECTKK LTSGATAKVY AEATQKQCA ST	424
	*****:	
LAG52A[G5]	-FNFLSISL LLSYFYLL**	468
LAG52B[G5]	TFAKFLMSL IFISFYLL**	460
LAG48 [G1]	TFAKFLSISL LLSYFYLL**	442
	*****:	

Fig. 7. Gene alignments. In (A), the deduced amino acid sequences of *LAG52A[G5]* and *LAG52B[G5]* are shown with their tandem repeats aligned. Hydrophobic signal peptides are at the top and bottom in each case. Cysteine residues are shown in green. Amino acids that are present in three or more repeats are shown in red. Along with the six cysteine residues, there are seven additional amino acids in each protein that are conserved in each of the repeats (five of these are the same in both proteins). In (B), the deduced sequences of all three *Icthyophthirius* i-antigens were aligned using the CLUSTALW sequence alignment tool. Asterisks (*) denote identical amino acids; colons (:) denote conservative amino acid substitutions; and, periods (.) semi-conservative substitutions. Amino acids that are present in all three proteins are shown in red. Cysteines are shown in green.




Fig. 8. Relative homologies. The relative identity of each of the pairs of i-antigen gene products is shown (in %). Note that the products of *IAG52B[G5]* and *IAG48[G1]*, are more similar than the products of *IAG52* and *B* (although the latter are from the same serotype).

ated probe had no matching sequences within *IAG52A[G5]*. Thus, the probe itself arose either by mispriming from *IAG52A[G5]*, or by correct priming from a related gene. While the identification of *IAG52A[G5]* was, in some respects, serendipitous, a comparison of its sequence with *IAG48[G1]* revealed a conserved C-terminal domain that permitted the design of a degenerate primer which made amplification of *IAG52B[G5]* possible. When expressed in heterologous systems, the products of *IAG52A[G5]* and *IAG52B[G5]* react strongly with polyclonal antisera that immobilize the G5 strain indicating that they are, in fact, i-antigens (Lin and Clark, unpublished).

With the isolation of these new genes, sequence comparisons between i-antigens from serologically distinct *I. multifiliis* strains become possible. In general, the i-antigens of serotypes A and D share the same basic structure which is characterized by repetitive amino acid sequence domains of ~70–80 residues each that contain periodic cysteine residues with the spacing C–X_{2,3}–C. Aside from the hydrophobic signal peptides at their N- and C-termini, the sequence elements that are most conserved within these proteins are the first 10 amino acids at the beginning of each repeat (Fig. 7). With only a one exception, the repeats begin with a CP–X–GT motif (the exception being CP–X–GA in the first repeat of *IAG52B[G5]*). A sequence of seven invariant amino acids (KKLTSGA) near the carboxy terminus of each protein is also noteworthy. The i-antigens of *Ichthyophthirius* are linked to the plasma membrane through a GPI-anchor [6], and the proximity of the KKLTSGA motifs to the C-termini of the respective gene products suggests their possible

involvement in addition of the glycolipid moiety. Specifically, the three small amino acids, SGA, could serve as a transamidation site at which cleavage and anchor addition occurs [19,20]. The coding sequence in this region appears to be broadly conserved among *Ichthyophthirius* i-antigen genes, since PCR primers based on this sequence amplify what appear to be




Fig. 9. Quantitative RT-PCR. Standard curves were derived by amplification of known amounts of *IAG52A[G5]* and *IAG52B[G5]* RNA prepared by in vitro transcription from the cloned genes. The signals generated from 50 ng total RNA from G5 theronts were then compared with the standard curve to determine steady-state transcript levels in vivo. Sequences were amplified with gene-specific primers, and the fluorescence generated by FAM-labeled (TaqMan®) probes detected in real time using an ABI Prism® 7700 Sequence Detection System.




Fig. 10. Fractionation of G5 membrane proteins. Total membrane protein from G5 theronts was isolated and subjected to either 1-(left panel) or 2-dimensional (right) polyacrylamide gel electrophoresis. After blotting onto nitrocellulose paper, protein were reacted sequentially with monospecific polyclonal rabbit antiserum against the G5 i-antigens, followed by goat anti-rabbit IgG coupled to alkaline phosphatase. Note the presence of four polypeptides (spots) with pIs in the range of 5–6 in the membrane protein fraction separated by 2-D PAGE.

i-antigen gene fragments from all parasite isolates obtained thus far (Clark, unpublished).

Although conserved elements clearly exist among these proteins, we were surprised that the products of *IAG52B[G5]* and *IAG48[G1]* were more closely related than were the products of *IAG52A[G5]* and *IAG52B[G5]*, which are from the same serotype. Indeed, the existence of multiple i-antigen genes in the G5 parasite strain was somewhat unexpected given that only a single band of ~52/55 kDa had been detected in Western blots conducted with this isolate (3). This raised obvious questions regarding the total number of i-antigen genes expressed in any given serotype, as well as the nature of the epitopes responsible for immobilization. With regard to the latter, preliminary studies have indicated that while the product of *IAG52A[G5]* reacts with the serotype D-specific immobilizing mAb, G3-61, the product of *IAG52B[G5]* does not (despite the fact that *IAG52B[G5]* appears to be the dominant gene expressed in this serotype) (Clark, unpublished). This would suggest that proteins with different specificities (in terms of their immobilizing epitopes) are coordinately expressed in the same parasite strain. In this regard, it should be noted that several monoclonal antibodies that bind epitopes distinct from those recognized by G3-61, can also immobilize parasites of the G5 strain (5). While the precise nature of the epitopes responsible for immobilization are unknown, a comparison of the deduced sequences for the i-antigens currently in-hand would indicate that the proteins themselves differ most in the regions between adjacent C–X₂–C motifs, particularly in the central repeats (Fig. 7B). Hydrophobicity plots indicate that these regions are relatively polar (Clark, unpublished), and it is tempting to speculate that the central repeats contribute

to the antigenic differences between proteins. Indeed, this appears to be the case for the i-antigens of *Paramoecium primaurelia* [11].

While the discovery of two i-antigen genes in the G5 parasite strain was unexpected, two-dimensional SDS-PAGE would suggest that as many as four isoelectric variants of these proteins are expressed in serotype D at any one time. It remains to be determined whether these spot variants represent posttranslational modifications of the *IAG52A* and *B* gene products, or whether they are the products of separate genes. Efforts to amplify additional i-antigen sequences from serotype D using newly designed primers based on conserved elements within the *IAG52A[G5]* and *IAG52B[G5]* sequences have, so far, proven unsuccessful (Clark, unpublished). Regardless of the number of genes that are actually present in this serotype, quantitative RT-PCR would suggest that the *IAG52A* and *B* genes are expressed at widely different levels, with *IAG52B[G5]* transcripts comprising as much as 2% percent of polyA⁺ RNA of the cell. This extraordinarily high level of expression is consistent with previous estimates of i-antigen expression in serotype A [9], as well as data from randomly selected clones taken from the G5 cDNA library in which nine of 384 inserts matched the *IAG52B[G5]* sequence (Clark and Pratt, unpublished). Conversely, the relatively low level of expression of *IAG52A[G5]* determined by real-time RT-PCR (estimated at <0.01% of polyA⁺ RNA) is consistent with the presence of only three potentially positive clones among a total of ~2 × 10⁴ screened in the cDNA library. Assuming mRNA abundance is reflected at the protein level, the *IAG52B[G5]* gene product would be expected to be the predominant i-antigen in this case. Indeed, this could account for the fact that the N-terminal sequence derived by Edman degradation from total i-antigen of the G5 strain corresponded to the product of this gene. While other explanations are possible, Western blotting of G5 proteins fractionated by 2-dimensional SDS-PAGE clearly indicates the i-antigens themselves are present at different levels of abundance within the cell.

The existence of variant serotypes expressing multiple i-antigen genes suggests that the i-antigens have evolved through a process of gene duplication and genetic drift. In addition to point mutations, it is likely that intra-/intergenic recombination has played a role in the evolution of the i-antigen genes. Although direct evidence for recombination is lacking, *CLUSTALW* comparisons of the *IAG52A[G5]* and *IAG48[G1]* gene products split the first repeat of the 48 kDa protein in two, and align the first half with the first repeat, and the second half with the second repeat of the 52 kDa antigen, respectively (Fig. 7B). This would suggest that at some point in their evolution either an insertion in the G1 gene, or a deletion from the G5 gene may have occurred.

I-antigens are common to hymenostome ciliates and have been well-studied in free-living species (most notably, *Paramecium* and *Tetrahymena*) where their expression undergoes marked variation in response to environmental stimuli [11,21]. As might be expected given their taxonomic relationship [22,23], the i-antigens of *Ichthyophthirius* most closely resemble those in *Tetrahymena*. A BLAST search of the SwissProt + Trembl database using the product of *IAG52A[G5]* as the query sequence showed the strongest similarity with a group of *T. thermophila* proteins collectively referred to as SerL (smallest sum probabilities on the order of 5.7e – 20). The SerL paralogs (A–D) are expressed in cells grown below 20 °C, and contain variable numbers of tandem repeats with six cysteines per repeat. As is true of the *IAG52A[G5]* gene product, conserved CP–X–G(T/S) motifs are also present in the SerL paralogs. An important difference between the proteins is the interval between adjacent cysteine residues, with their spacing in the *SerL* gene products being C–X_{1,2}–C, as compared with C–X_{2,3}–C in the *I. multifiliis* antigens. The arrangement of cysteine residues within the ciliate i-antigens is presumed to be of critical importance in the structure and function of these proteins. As noted for the *Ichthyophthirius IAG48[G1]* gene product, the presence of closely spaced cysteines (C–X_{2,3}–C motifs) within a framework of higher order repeats is reminiscent of the variant specific proteins (VSPs) of *Giardia lamblia* [13–15]. The VSPs have been shown to bind zinc in vitro [24,25], and it remains possible that the i-antigens are metal-binding proteins as well. It is nevertheless clear that the periodic cysteines that are characteristic of these proteins could just as easily participate in disulfide bridging [12]. Indeed, the conformational epitopes responsible for immobilization and protective immunity (in the case of the *Ichthyophthirius* i-antigens) have been shown to be highly sensitive to treatment with reducing agents (Wang and Dickerson, unpublished).

Finally, in addition to their basic properties, the genes described here may provide practical tools in the development of a recombinant *I. multifiliis* vaccine. We have recently described methods for the expression of i-antigen genes from *Ichthyophthirius* in *T. thermophila* [26]. Moreover, synthetic alleles with optimized codon usage have been designed that should permit large-scale expression of the corresponding proteins in conventional systems such as *E. coli* and yeast, and attempts to genetically immunize fish with the vector-encoded G5 antigens are now underway.

Acknowledgements

We thank Annemieke Jansens for her contributions during cDNA library construction. We also thank

Georgina Cheng, Yelena Bisharyan and Jane Noe for their excellent technical assistance, along with Dr James Casey, Rebecca Murcek, and Carrie Markowski for their helpful suggestions in the use of TaqMan® Real Time PCR. This work was supported by USDA NRICGP grants # 97-35204-4481 and # 98-35204-6812.

References

- [1] Dickerson HW, Dawe DL. *Ichthyophthirius multifiliis* and *Cryptocaryon irritans* (Phylum Ciliophora). In: Woo PTK, editor. Fish diseases and disorders. Wallingford Oxon: CAB International, 1995:181–227.
- [2] Matthews RA. *Ichthyophthirius multifiliis* Fouquet, 1876: infection and protective response within the fish host. In: Pike AW, Lewis JW, editors. Parasitic diseases of fish. Dyfed: Samara, 1994:17–42.
- [3] Clark TG, Lin TL, Dickerson HW. Surface immobilization antigens of *Ichthyophthirius multifiliis*: their role in protective immunity. Annu Rev Fish Dis 1995;5:113–31.
- [4] Clark TG, Lin TL, Dickerson HW. Surface antigen cross-linking triggers forced exit of a protozoan parasite from its host. Proc Natl Acad Sci USA 1996;93:6825–9.
- [5] Lin TL, Clark TG, Dickerson HW. Passive immunization of channel catfish (*Ictalurus punctatus*) against the ciliated protozoan parasite *Ichthyophthirius multifiliis* by use of murine monoclonal antibodies. Infect Immun 1996;6:4085–90.
- [6] Clark TG, Gao Y, Gaertig J, Cheng G. The i-antigens of *Ichthyophthirius multifiliis* are GPI-anchored proteins. J Euk Microbiol 2001;48:332–7.
- [7] Dickerson HW, Clark TG, Leff AA. Serotypic variation among isolates of *Ichthyophthirius multifiliis* based on immobilization. J Euk Microbiol 1993;40:816–20.
- [8] Dickerson HW, Clark TG. Immune response of fishes to ciliates. Annu Rev Fish Dis 1996;6:107–20.
- [9] Clark TG, McGraw RA, Dickerson HW. Developmental expression of surface antigen genes in the parasitic ciliate, *Ichthyophthirius multifiliis*. Proc Natl Acad Sci USA 1992;89:6363–7.
- [10] Clark TG, Lin TL, Jackwood DA, Sherrill J, Lin Y, Dickerson HW. The gene for an abundant parasite coat protein predicts tandemly repetitive metal binding domains. Gene 1999;229:91–100.
- [11] Caron F, Meyer E. Molecular basis of surface antigen variation in *Paramecia*. Annu Rev Microbiol 1989;43:23–42.
- [12] Doerder FP, Gerber CA. Molecular characterization of the *SerL* paralogs of *Tetrahymena thermophila*. Biochem Biophys Res Commun 2000;278:621–6.
- [13] Chen N, Upcroft JA, Upcroft P. A *Giardia duodenalis* gene encoding a protein with multiple repeats of a toxin homologue. Parasitology 1995;111:423–31.
- [14] Yang YM, Adam RD. Analysis of a repeat-containing family of *Giardia lamblia* variant-specific surface protein genes: diversity through gene duplication and divergence. J Euk Microbiol 1995;42:439–44.
- [15] Nash TE, Conrad JT, Mowatt MR. *Giardia lamblia*: identification and characterization of a variant-specific surface protein gene family. J Euk Microbiol 1995;42:604–9.
- [16] Feinberg AP, Vogelstein B. A technique for radiolabeling of DNA restriction endonuclease fragments to high specific activity. Anal Biochem 1983;132:6–13.
- [17] Chenchik A, Shu Y, Diatchenko L, Li R, Hill J, Siebert P. Generation and use of high-quality cDNA from small amounts of total RNA by SMART PCR. In: Siebert P, Larrick J, editors.

- RT-PCR methods for gene cloning and analysis. BioTechniques Books, 1998:305–19.
- [18] Nielsen H, Engelbrecht J, Brunak S, von Heijne G. Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. *Prot Eng* 1997;10:1–6.
- [19] Englund P. The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. *Annu Rev Biochem* 1993;62:121–38.
- [20] Udenfriend S, Kodukula K. Prediction of omega site in nascent precursor of glycosylphosphatidylinositol protein. *Methods Enzymol* 1995;250:571–82.
- [21] Smith DL, Berkowitz MS, Potoczak D, Krause M, Raab C, Quinn F, Doerder FP. Characterization of the T, L, I, S, M and P cell surface (immobilization) antigens of *Tetrahymena thermophila*: molecular weights, isoforms, and cross-reactivity of antisera. *J Protozool* 1992;39:420–8.
- [22] Wright AD, Lynn DH. Phylogeny of the fish parasite *Ichthyophthirius* and its relatives *Ophryoglena* and *Tetrahymena* (Ciliophora, hymenostomatia) inferred from 18S ribosomal RNA sequences. *Mol Biol Evol* 1995;12:285–90.
- [23] Van Den Bussche RA, Hofer SR, Drew CP, Ewing MS. Characterization of histone H3/H4 gene region and phylogenetic affinity of *Ichthyophthirius multifiliis* based on H4 DNA sequence variation. *Mol Phylogenet Evol* 2000;14:461–8.
- [24] Nash TE, Mowatt MR. Variant-specific surface proteins of *Giardia lamblia* are zinc-binding proteins. *Proc Natl Acad Sci USA* 1993;90:5489–93.
- [25] Zhang YY, Aley SB, Stanley SL Jr, Gillin FD. Cysteine-dependent zinc binding by membrane proteins of *Giardia lamblia*. *Infect Immun* 1993;61:520–4.
- [26] Gaertig J, Gao Y, Tishgarten T, Clark TG, Dickerson HW. Surface display of a parasite antigen in the ciliate *Tetrahymena thermophila*. *Nature Biotechnol* 1999;17:462–5.

Organization IC-1600 Bldg./Room REIMSEN
U. S. DEPARTMENT OF COMMERCE
COMMISSIONER FOR PATENTS

P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

IF UNDELIVERABLE RETURN IN TEN DAYS

OFFICIAL BUSINESS

AN EQUAL OPPO

RECEIVED

SEP 10 2004

TECH CENTER 1600/2900